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UNIVERSITY OF SOUTHAMPTON 
 
ABTRACT 
 
Breast cancer survival rates have risen dramatically over recent years with many women expected 
to survive their diagnosis and live long and fruitful lives.  As a result ‘cancer survivorship’ has 
become of interest to health care providers who state that future services must be developed that 
better meet the long term health needs and expectations of this group. 
 
  To this end, the role of health behaviour change in the secondary prevention of breast cancer is a 
popular area of research.  To date, however, there are no published investigations into what the 
likely uptake in health promotion activities would be; an important consideration when developing 
health services. 
 
  Over a period of six months between April 2007 and September 2007, all eligible newly diagnosed 
postmenopausal women with breast cancer from the participating NHS trust were invited to 
participate in a clinical trial to assess uptake and response in a group healthy eating programme.  
 
  The primary outcome measures were to assess the proportion of women who enrolled on the 
healthy eating programme and to identify health behaviours that predicted enrolment.  Secondary 
outcome measures were to assess the change in diet quality; change in weight and to identify 
health behaviours that predicted attendance at classes.   
 
  Twenty one percent (21%) of women invited agreed to attend the healthy eating programme and 
were subsequently randomly assigned to either the healthy eating programme (n=5) or the usual 
care group (n=6).   
 
  The results suggest that women newly diagnosed with breast cancer were not interested in 
attending healthy eating classes at the time of their diagnosis.  However, screening rates fell 
significantly short of the target and therefore these results cannot be generalised to all newly 
diagnosed postmenopausal women with breast cancer.  Further, due to poor recruitment, 
secondary outcomes could not be assessed. 
 
  In summary, the study was unable to provide information regarding the likely interest and 
response to a group health eating programme for newly diagnosed postmenopausal women with 
breast cancer.  The reasons the study was unable to meet its aims was objectives were twofold; 
firstly the study failed to engage both NHS trusts for which approval was granted and secondly, 
screening procedures were not carried out as planned in the single remaining NHS trust.   
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1.0  Introduction 
With a risk of more than one in three people receiving a cancer diagnosis during their lifetime, 
cancer is one of the most serious and widespread diseases in today’s society.
1 Over the last 25 
years, the number of new cases diagnosed has increased by 24%.
2 The incidence of cancer is set 
to continue its rise and by 2020 it is estimated that, globally, 15,000,000 new cases will be 
diagnosed each year.
3 
 
In contrast to these figures, cancer mortality rates fell by 11% over the last ten years.
4  Extensive 
resources and research efforts have gone into understanding the causes of cancer which have 
resulted in major improvements in cancer treatments.  This, combined with better screening 
programmes leading to early detection of cancers, has contributed to improvements in survival for 
many cancer patients.  Where cancer was once considered a death sentence, today it is, in some 
cases, curable and for many others has become a chronic disease.
2 3 5 
 
Breast cancer (the most common cancer accounting for 30% of all female cancers) has seen 
dramatic improvements in survival in recent times.   Despite a continued rise in the incidence of 
breast cancer in the UK of 45% over the past 20 years, during the same period mortality rates have 
fallen by 31%.
4 6  This trend continues with survival rates for early breast cancer now around 90%.
3 
The most recent estimate for breast cancer survivors in the UK is around 550,000 making this the 
largest group of all female cancer survivors.
7 
 
The progress made in terms of survival from breast cancer, whilst extremely welcome, has led to 
more and more women surviving their diagnosis and expecting to live long and fruitful lives.  It has 
been argued that a struggle now exists between the “medical agenda” and the “personal agenda” 
as the medical model continues its treatment focus on removal of the cancer, whilst breast cancer 
patients deal with a broader agenda that may not be adequately met by the current medical model 
of care.
8  Understandably, breast cancer patients are asking health care providers what steps they 
can take to reduce their chance of a cancer recurrence and how they can improve their overall 
health and wellbeing.
5   
 
The scientific literature reports that many breast cancer patients have made changes to their lives 
after their diagnosis that often includes changes of a dietary nature, as these patients are believed 
to view nutrition as an important part of their cancer therapy.
9 10   Further, these patients are 
concerned with the lack of support offered by their health care providers to achieve this.  As a 
consequence health providers are encouraged to assess whether the services they offer meet the 
changing needs and expectations of breast cancer survivors.
11 
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This scientific evidence is supported anecdotally within my own clinical practice.  Prior to 
commencing this PhD I worked as a research dietitian for the UK Women’s Intervention Nutrition 
Study (WINS UK).  The study was a feasibility study to determine if postmenopausal women with 
breast cancer could adopt a low fat diet and maintain this diet for two years.  Once feasibility was 
established the study would support a larger efficacy study for a low fat dietary intervention and 
subsequent breast cancer outcomes.  My role within the study was to conduct the nutrition 
education classes for both the control group who received healthy eating advice and the 
intervention group who received low fat dietary advice.   
 
Over the 18 month period I worked in this role I was surprised by the positive feedback from both 
groups about how helpful the dietary advice was, with the majority of women stating they felt 
nutrition education should be offered as part of the standard care package after diagnosis.  
 
In summary, both the scientific literature and anecdotal evidence supported the notion that women, 
newly diagnosed with breast cancer were interested in receiving nutrition counselling as part of 
their care package offered by health providers.  At the time of this study breast cancer patients in 
the NHS had no routine access to nutrition advice and therefore a unique opportunity existed to 
develop services that better met the needs and expectations of cancer patients; a philosophy at the 
heart of NHS policy.
11 
 
However, patient desire for service development does not alone provide sufficient basis for the 
introduction of a new service and therefore scientific evidence demonstrating health benefits was 
considered. 
 
When developing the rationale for this study, it was known at the time, that the scientific evidence 
for the proposed benefits (both physiological and/or psychological) following a change in dietary 
behaviour after a breast cancer diagnosis remained unclear. Two large randomised controlled trials 
were being conducted in the United States to investigate these relationships, the Women’s 
Intervention Nutrition Study (WINS) and the Women’s Healthy Eating and Living Study (WHEL).   
The breast cancer research community were hopeful that the results of these trials would provide 
the necessary evidence to support the expansion of routine services for this group of patients to 
include nutrition counselling. In the absence of this evidence, a change in dietary behaviour had 
been shown to improve general health and well-being and this outcome was considered sufficient 
to support the present study.   
 
In either scenario outlined above, a gap in the evidence base for providing nutrition counselling 
after a breast cancer diagnosis still remained.  Specifically, if such a service was offered by health 
providers, would it be well attended and therefore a viable option given the current economic 
climate?   This gap in the evidence provided a unique opportunity to pilot a group “healthy eating” 
programme for newly diagnosed postmenopausal women with breast cancer.  The purpose of the Chapter One: Introduction 
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study was to investigate the feasibility of nutrition counselling embedded within the current routine 
care services offered by the NHS.  
 
The study offered a group “healthy eating” programme at the time of diagnosis, providing four x 120 
minute classes over a six month period. As a pragmatic study, all newly diagnosed 
postmenopausal women with breast cancer were to be invited to join the programme.  The study’s 
primary objective was to assess uptake in the group nutrition education classes. 
 
It was hoped that the results of this study would make an important contribution by providing 
practical, real world information regarding the likely uptake and participation in health promotion 
activities aimed at newly diagnosed postmenopausal women with breast cancer and hence inform 
future cancer services planning. 
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1.1.  Project summary 
 
 
Overall Aims 
 
1. To develop a group healthy eating programme for 
postmenopausal women newly diagnosed with breast cancer 
in partnership with breast cancer patients 
 
2. To understand the factors that influenced enrolment and 
subsequent participation in a group “healthy eating” 
programme for newly diagnosed postmenopausal women with 
breast cancer. 
 
3. To assess if a group “healthy eating” programme improved 
the diets of newly diagnosed postmenopausal women with 
breast cancer 
 
 
Purpose 
 
 
 
To inform cancer service development initiatives 
 
Study design 
 
Mixed methods – embedded experimental model 
 
Study One: Focus Groups QUALITATIVE (QUAL) 
 
Study Two:  
 
1.  Cross-sectional study (Qual + Quantitative (Quan)) 
2.  RCT (QUAN) 
3.  Cross-sectional study (Qual + Quan) 
 
 
 
Table 1-1 Project Aims  Chapter One: Introduction 
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Study One          AIMS 
Focus group     
QUAL  
 
  1.  To develop a group healthy eating programme for postmenopausal  
women newly diagnosed with breast cancer in partnership with breast 
cancer patients 
           
Study Two           AIMS 
1. X-sectional           
       
Qual 
baseline 
1.  To understand the factors that 
influenced enrolment in a group 
healthy eating programme      Quan 
baseline 
1.  To estimate the proportion of newly diagnosed 
postmenopausal women with breast cancer who 
enrolled on a group healthy eating programme 
           
2. RCT           
 
 
 
QUAN 
Premeasure 
       
 
 
QUAN 
Postmeasure 
1.  To assess if a group healthy eating programme 
improved the diets of newly diagnosed 
postmenopausal women with breast cancer compared to 
usual care 
2.  To determine the impact of participating in a group 
healthy eating programme on self reported quality of life 
scores compared to usual care 
           
3. X-sectional           
           
 
Qual  
end of study 
1.  To understand the factors that 
influenced participation in a 
group healthy eating programme 
     
Quan  
end of study 
1.  To estimate the proportion of newly diagnosed 
postmenopausal women with breast cancer who 
completed a group healthy eating programme 
 
 
 
Figure 1-1 Proposed study design Interpretation based on QUAN(qual) results 
Intervention 
T
I
M
E
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1.2.  Thesis summary 
 
Chapter  Topic 
One  Introduction and Project Summary 
Two  Breast cancer 
Three  Nutrition services in the NHS 
Four  Methods 
Five  Results 
Six  Discussion 
Seven  Conclusions 
Eight  References 
Nine  Appendices 
 
Table 1-2 Thesis summaryChapter Two: Breast Cancer 
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2.0  Breast Cancer 
2.1.  Chapter Introduction 
The following chapter provides an overview of the latest breast cancer statistics.  It goes on to 
discuss how breast cancer develops and the known causes of breast cancer.  Finally, the chapter 
concludes with a section on breast cancer prevention, individually addressing primary, secondary 
and tertiary prevention.  The main literature review is focussed on the role of diet in the secondary 
prevention of breast cancer as the present study offers postmenopausal women previously 
diagnosed with breast cancer a group healthy eating programme. 
2.2.  Prevalence of breast cancer in the UK 
At the end of 2008 it was estimated that there were two million cancer survivors or approximately 
3.3% of the UK population.  Of those, breast cancer patients accounted for around 28% or 550,000 
of all UK cancer survivors making them the largest group of all site specific breast cancers.
12   
 
With extensive resources and research efforts directed at understanding the causes of breast 
cancer, many advances have been made enabling major improvements in the treatment of breast 
cancer.  This, in addition to more effective screening programmes has contributed to improved 
survival for many breast cancer patients. In 2001-2003, five year survival rates were 80% 
compared to 52% in 1971-1975 representing a change of around 30%.
13 
 
2.3.  Incidence of breast cancer in the UK 
Breast cancer accounts for around 30% of all female cancers making it the most common cancer in 
women.  It is a major health burden within our society affecting one in eight UK women over a 
lifetime.  The incidence of breast cancer has risen steadily over recent years with around 45,500 
new cases diagnosed each year of which more than 80% occur in women over 50 years of age. 
14 
2.4.  How does breast cancer develop?   
Hormones play a central role in the development of breast cancer as they modulate the structure 
and growth of breast tissue.  Breast tissue develops under the influence of hormones such as 
oestrogen, progesterone, insulin and growth factors.  The main periods of breast tissue 
development occur during puberty, pregnancy and lactation.
15 
 Chapter Two: Breast cancer  
 
  10 
During adulthood most cells, including breast cells, do not undergo cell division (outside periods of 
pregnancy and lactation) but rather enter an inactive period or become ‘quiescent’.  However, 
under the influence of certain growth signalling factors cells can be induced to leave their inactive 
state and re-enter the cell cycle leading to cell division and ultimately growth.
16  
 
Breast cancer is categorised as a hormone dependent cancer and as such must be initiated under 
the influence of a hormone.  In the case of breast cancer, oestrogen is believed to play a central 
role in both the initiation and progression of breast cancer.  Two predominant models for the 
mechanisms by which oestrogen exerts its effect have been proposed and it is likely that both 
mechanisms contribute to the development of both primary and secondary breast cancer.
15 
2.4.1.  Oestrogen acting in the initiation of breast cancer 
Oestrogen and its metabolites can act directly as genotoxic agents damaging DNA in turn initiating 
breast cancer development.  This model explains the mechanisms in which breast cancer develops 
from exposure to chemicals, viruses and radiation.
15  
2.4.2. Oestrogen acting in the progression of breast cancer 
Oestrogen can act indirectly through its action as a mitogen in breast tissue promoting cell 
proliferation.  This higher cell division rate allows less time for DNA repair resulting in increasing 
mutations that can lead to carcinogenesis.  This mechanism differs from the first model in that no 
specific initiator other than errors in replication is required for breast cancer development.
15 
2.4.3. Windows of opportunity for breast cancer development 
Three windows of exposure for breast cancer development have been described by Russo et al 
(1990); pre puberty, post puberty/pre pregnancy and post pregnancy (see table 2-1).  These 
windows of exposure are discussed below. 
2.4.3.1.  Pre puberty 
The first occurs from hormonal exposure to pre-menopausal breast tissue prior to differentiation as 
seen in early menarche.
15  
2.4.3.2.  Post puberty/pre pregnancy 
In the second window of exposure, It is generally agreed that the longer the period of oestrogen 
exposure to Type 2 ducts, as would occur in women who have longer periods of nulliparity, the 
greater the risk of breast cancer development.  The earlier the development of type 3 ducts due to 
full term pregnancy, the greater the risk reduction. This period is seen as one of the most important 
exposure periods in breast cancer development.
15  Chapter Two: Breast cancer  
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2.4.3.3.  Exposure to oestrogen post differentiation 
The last period refers to prolonged or excessive exposure to hormones post-differentiation (when 
under normal conditions breast tissue becomes inactive), as seen in later onset menopause.  
Although this period is regarded as less significant, it is still classed as a measurable risk factor
15.  
 
   
Duct 
Type 
 
Degree of 
proliferation 
 
Degree of 
differentiation 
 
Predominant period in 
lifetime 
 
Window 1 
 
Type 1 
**** 
   
Before and after puberty 
 
Window 2 
 
Type 2  *** 
 
* 
 
After puberty and 
nulliparous women 
   
Type 3 
** 
 
*** 
 
Develop in pregnancy 
   
Type 4 
* 
 
**** 
 
Requires completed 
pregnancy.  Disappears 
after lactation 
 
Window 3 
 
Prolonged or excessive exposure post differentiation 
 
Table 2-1 Model of duct types in the female breast 
15  
 
2.5.  What causes breast cancer? 
Extensive research has been conducted over the last three decades into the causes of breast 
cancer.  Over that time, many risk factors have been identified. However few of these have become 
widely accepted as the causal link in the aetiology of breast cancer. 
 
The following section discusses only those risks which are currently accepted within the scientific 
community as those known to cause breast cancer. The method to categorise breast cancer risks 
vary depending on the source of information.  For the purposes of the following discussion, the 
sections are arbitrary and compiled by the author in a way that best represents the synthesis of the 
information reviewed.   Chapter Two: Breast cancer  
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2.5.1. Breast cancer risk factors 
The following section describes risk factors associated with breast cancer.  These are categorised 
as either demographic, environmental, genetic, medication, reproductive and menstrual and finally 
lifestyle factors. 
2.5.1.1.  Demographics 
2.5.1.1.1.  Age 
The risk of developing breast cancer increases with age.  Very few cases occur in young women in 
their teens or early 20’s. However, breast cancer is the most commonly diagnosed cancer in 
women under 35 with an estimated 1,500 cases each year.  Incidence rates continue to rise with 
age with more than 80% of cases occurring in women over 50 years, with the most diagnoses 
observed in the 50-69 age group.
17-19 
2.5.1.1.2.  Sex 
Breast cancer occurs in both men and women however for every 100 cases diagnosed in women, 
one man will receive a breast cancer diagnosis.  Thus, female sex is considered a risk factor for 
breast cancer supporting the link between the female hormone oestrogen in the aetiology of the 
disease.
17 18 
2.5.1.1.3.  Residence 
Breast cancer rates vary considerably around the world, with the highest rates observed in 
developed countries and the lowest in less developed countries such as Africa and Asia.
17 
 
Interestingly, this variability cannot be adequately explained by genetic factors, as when people 
move from low to high incidence areas, their risk of developing breast cancer changes, reflecting 
that of the adopted country, providing strong evidence that breast cancer is largely an 
environmental disease.  Much of the variation observed can be explained as women in high 
incidence countries have fewer children and breastfeed for shorter durations when compared to 
women in low incidence countries. 
17-19 
2.5.1.2.  Environmental exposures 
2.5.1.2.1.  Radiation 
Exposure from ionising radiation such as x-rays, particularly during puberty, increases risk even at 
low levels.  The mechanism is believed to due to direct DNA damage.
17-19 
2.5.1.3.  Genetics 
Despite popular belief, genetic causes of breast cancer are relatively low when compared to those 
attributable to sporadic causes.  About 5-10% of all breast cancers are of an inherited nature, of Chapter Two: Breast cancer  
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which 85% occur from the two most common high risk breast cancer susceptibility genes, the 
BRCA1 and BRCA2 genes.  For those women who carry the BRCA1 or BRCA2 gene, there is an 
increased risk of ovarian cancer, secondary primary in the contralateral breast and a local 
recurrence after conservative treatment when compared to non carriers.
15 18 19  In the future it is 
likely more breast cancer cases will be attributed to genetic causes as more susceptibility genes 
are identified.  
2.5.1.4.  Medication 
Oral contraceptives containing both oestrogen and progesterone cause a small, transient, 
increased risk of breast cancer; the increased risk disappears after cessation.
17-19   
 
Hormone replacement therapy is a cause of breast cancer.  The effect is greater for oestrogen-
progesterone combinations and risk increases with duration used.  The increased risk appears to 
disappear a few years after cessation.
17-19   
2.5.1.5.  Reproductive and menstrual history 
As the risk of developing breast cancer is related to an individual’s lifetime exposure to oestrogen, 
reproductive and menstrual factors that influence the duration of exposure to oestrogen have a 
significant impact on risk.   These include age at menarche, parity, age at first pregnancy, 
breastfeeding and finally age at menopause. 
 
As risk clearly increases with exposure, women who experience an early menarche, are nulliparous 
and experience late onset of menopause will be at the highest risk, whereas those women who had 
a late menarche, had children early, breastfed their children and experienced early menopause will 
be at the lower risk.
17-19   
2.5.1.6.  Lifestyle  
Undesirable lifestyle behaviours are believed to substantially increase the risk of developing breast 
cancer.  A recent publication states that the population attributable risk
20 (PAR
1) for these 
potentially modifiable risk factors including postmenopausal hormone use, alcohol consumption, 
adult weight gain and level of recreational activity is 40.7%. 
21 
 
The review which follows is largely derived from the 2007 World Cancer Research Fund 2
nd Expert 
Report Food, Nutrition, Physical Activity and the Prevention of Cancer.
19  This report is considered 
the most comprehensive report on the association between lifestyle and cancer risk.  Due to the 
thoroughness of the scientific process involved in judging the evidence for the report, the panel’s 
                                                    
1 Population attributable risk is defined as the proportion of breast cancer incidence in the total population (both exposed 
and unexposed) that can be attributed to a specific exposure Chapter Two: Breast cancer  
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decision has been taken as the view of the scientific community. As such, risks described in the 
following section that are reported by the WCRF panel are stated rather than discussed.   
 
Breast cancer risk factors are presented separately for postmenopausal and premenopausal breast 
cancer. 
 Chapter Two: Breast cancer  
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POSTMENOPAUSAL BREAST CANCER 
 
 
Risk factor 
 
 
Judgement 
 
Proposed mechanism 
Body fatness  There is abundant and consistent epidemiological 
evidence and a clear dose response, with robust 
evidence for mechanisms operating in humans.  The 
evidence that greater body fatness is a cause of 
postmenopausal breast cancer is convincing.  
 
Body fat directly affects levels of many circulating hormones, 
such as insulin, insulin-like growth factors, and oestrogens, 
creating an environment that encourages carcinogenesis 
and discourages apoptosis.   
Abdominal fatness  There is a substantial amount of epidemiological 
evidence, but some inconsistency.  There is robust 
evidence for mechanisms that operate in humans.  
Abdominal fatness is a probable cause of 
postmenopausal breast cancer. 
 
Abdominal fatness is particularly associated with increased 
circulating oestrogens and decreased insulin sensitivity. 
Adult weight gain  There is ample, consistent epidemiological evidence from 
both cohort and case-control studies.  A dose response 
was apparent from case-control and cohort studies.  Adult 
weight gain is a probable cause of postmenopausal 
breast cancer. 
See body fatness 
Table 2-2 Risk factors, panel judgement and proposed mechanisms for postmenopausal breast cancer 
19Chapter Two: Breast cancer  
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POSTMENOPAUSAL BREAST CANCER 
 
 
Risk factor 
 
 
Judgement 
 
Proposed mechanism 
Adult attained height  There is abundant prospective epidemiological evidence, 
which is generally consistent, with a clear dose response, 
and evidence for plausible mechanisms operating in 
humans.  The evidence that factors that lead to greater 
adult attained height, or its consequences, are a cause of 
postmenopausal breast cancer is convincing.  The causal 
factor is unlikely to be tallness itself, but factors that 
promote linear growth in childhood. 
 
Adult attained height is an important nutritional marker for 
early life experiences.  These early life exposures impact on 
several hormones that directly influence breast cancer risk. 
Physical activity  There is ample evidence from prospective studies 
showing lower risk of postmenopausal breast cancer with 
higher levels of physical activity, with a dose-response 
relationship, although there is some heterogeneity.  There 
is little evidence on frequency, duration or intensity of 
activity.  There is robust evidence for mechanisms 
operating in humans.  Physical activity probably protects 
against postmenopausal breast cancer. 
 
Physical activity has a beneficial effect on body fat and is 
therefore protective against hormonal changes that occur 
with weight gain.  In addition, physical activity may directly 
reduce levels of circulating oestrogens and androgens  
Table 2.2 ContChapter Two: Breast cancer  
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POSTMENOPAUSAL BREAST CANCER 
 
 
Risk factor 
 
 
Judgement 
 
Proposed mechanism 
Alcoholic drinks  There is ample, generally consistent evidence from case-
control and cohort studies.  A dose-response relationship 
is apparent.  There is robust evidence for mechanisms 
operating in humans.  The evidence that alcoholic drinks 
are a cause of premenopausal and postmenopausal 
breast cancer is convincing.  No threshold was identified. 
Alcohol interferes with oestrogen pathways in multiple ways 
to influence hormone levels and oestrogen receptors.    
Table 2.2 Cont 
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PREMENOPAUSAL BREAST CANCER 
 
 
Risk factor 
 
 
Judgement 
 
Proposed mechanism 
Body fatness  There is a substantial amount of consistent 
epidemiological evidence, with a dose response, but the 
mechanistic evidence is speculative.  Greater body 
fatness probably protects against premenopausal breast 
cancer 
 
See above as in postmenopausal breast cancer 
Adult attained height  There are fewer data for premenopausal than for 
postmenopausal breast cancer.  The epidemiological 
evidence is generally consistent with a dose response and 
evidence for plausible mechanisms.  Greater adult 
attained height or factors that lead to it are probably a 
cause of premenopausal breast cancer.  The causal factor 
is unlikely to be tallness itself, but factors that promote 
linear growth in children 
 
See above as in postmenopausal breast cancer 
Greater birth weight  There is general consistency amongst the relatively few 
epidemiological studies, with some evidence for a dose 
response.  
 
The mechanistic evidence is speculative.  Greater birth weight 
or factors that lead to greater birth weight are probably a cause 
of premenopausal breast cancer. 
Alcohol  See postmenopausal breast cancer  See postmenopausal breast cancer 
Table 2-3 Risk factors, panel judgement and proposed mechanisms for premenopausal breast cancer 
19Chapter Two: Breast cancer  
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Summary of evidence for lifestyle risk factors of breast cancer
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Figure 2-1 Summary of evidence for lifestyle risk factors for breast cancer 
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2.6.  Risk factor summary  
Risk Factor category  Risk factor  Relative Risk
2  Comparison group 
Demographic  Age 
 
 
 
 
 
Residence 
4+ 
 
 
1.25 – 1.99 
 
 
1.25 – 1.99 
Increasing age 
(50+ vs <50) 
 
Increasing age 
(50-59 vs 40-49)  
 
Affluent country 
Environmental exposures  Radiation  1.25 – 1.99  Especially < 20 yrs, high dose vs low dose 
Genetic  Family history 
 
 
4+ 
 
2 – 3.99 
 
 
1.25 – 1.99 
 
BRCA1, BRCA2 vs those without mutations 
 
Two or more first-degree relatives with breast cancer vs no 
family history 
 
One first degree relative or multiple second degree relatives with 
breast cancer vs no family history 
Reproductive and menstrual history  Age at menarche 
 
Age at first pregnancy 
 
Parity 
 
Lactation 
 
Age at menopause 
<0.8 
 
1.25 – 1.99 
 
1.25 – 1.99 
 
<0.8 
 
1.25 – 1.99 
 
Age at first period >14 vs <12 yrs 
 
First full term pregnancy >29 vs < 20 
 
Nullparity vs any childbirth 
 
Breastfeeding > 12 months vs none  
 
Age at menopause >50 vs <50 yrs 
Table 2-4 Breast cancer risk factor summary 
18 
                                                    
2 Relative risk is the ratio of the risk of developing breast cancer in exposed individuals compared to the risk in the unexposed 
17  Chapter Two: Breast cancer  
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Risk factor summary cont. 
 
Risk Factor category  Risk factor  Relative Risk
3  Comparison group 
Lifestyle  Adult attained height 
 
BMI 
 
 
 
Alcohol 
 
Levels of physical activity 
 
1.25 – 1.99 
 
1.25 – 1.99 
 
<0.8 
 
1.25 – 1.99 
 
<0.8 
Height >174 vs <160cm  
 
BMI > 25 kg/m
2 (postmenopausal breast cancer) 
 
BMI >30 vs <21 (premenopausal breast cancer) 
 
Daily intake of two alcoholic drinks or more vs never drinkers 
 
Increased physical activity vs no activity 
 
Table 2.4 Cont 
                                                    
3 Relative risk is the ratio of the risk of developing breast cancer in exposed individuals compared to the risk in the unexposed. Chapter Two: Breast cancer  
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2.7.  Breast Cancer Prevention  
2.7.1. Primary Prevention
4  
As the causes of both pre and post menopausal breast cancer have been extensively researched 
and as such are well established within the scientific community, opportunities for breast cancer 
prevention are understandably based on reducing exposure to the known and identified risks.   
 
Whilst many of these risks such as reproductive and menstrual factors are not amenable to 
modification, many are and cancer is considered largely a preventable disease.  For many years, 
researchers and other agencies have tried to quantify estimates of preventability.  The general 
consensus from these sources conclude that around two-thirds of all cancers could be prevented, 
one-third through the adoption of healthy diets and exercise patterns and a further one-third 
through the avoidance of smoking.
19 
 
Recently, new estimates for both overall cancer and specific cancer prevention have been 
published based on 2007 WCRF/AICR Diet and cancer report.
22  The latest figures suggest for the 
UK, around 42% of all breast cancers could be prevented through maintenance of appropriate 
food, nutrition, physical activity, and body fatness.  The report goes on to state that these estimates 
are likely to underestimate the true level of preventability, clearly demonstrating that much can be 
done to prevent cancer, and in particular, breast cancer.  Current public health goals for breast 
cancer prevention are as follows: 
 
Recommendation 
Be as lean as possible within the normal range of body weight. 
Be physically active as part of everyday life 
Limit consumption of energy-dense foods 
Limit alcoholic drinks 
Mothers to breastfeed; children to be breastfed 
 
Table 2-5 Recommendations for the prevention of cancer 
19 
 
                                                    
4 Primary prevention is defined as preventing the development of breast cancer. 
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2.7.2. Secondary prevention
5  
As the primary focus of this thesis was to assess the likely interest in a group nutrition education 
programme for newly diagnosed postmenopausal women with breast cancer, the following section 
discusses in detail the literature relating to issues around nutrition for breast cancer patients.   
 
Whilst a large body of scientific evidence exists investigating the proposed benefits of nutrition on 
both physiological and/or psychological factors, the focus of this literature review is limited to the 
role of nutrition in the secondary prevention of breast cancer for several reasons.   
 
Firstly, as a state registered dietitian, our professional body supports the concept that healthy 
eating patterns are best studied and benefits assessed using a whole diet approach as opposed to 
a specific nutrient approach.  For this reason, the literature relating to individual food or nutrient 
components, such as phytoestrogens or dietary supplements has not been addressed in this 
review.   
 
Secondly, although nutritional epidemiology has a long standing research history, enormous 
challenges still remain in accurately determining cause and effect relationships between food and 
health outcomes.  For this reason a food versus a nutrient approach was adopted by the World 
Cancer Research Fund/American Institute for Cancer Research 2007 report on food, nutrition, 
physical activity and the prevention of cancer. 
19 The expert panel justify this approach on the basis 
that identifying a true causal factor from a single nutrient carries unacceptable uncertainty and that 
any relationship found may reflect a marker for a particular food in which it is found, or for other 
dietary components found in that food.   
2.7.2.1.  Search strategy 
A variety of sources were searched to identify all relevant articles.  As the role for nutrition in breast 
cancer survivors was a relatively new area of study, broad search terms were used to ensure the 
search was inclusive. 
 
Keywords: Breast cancer and Diet 
                                                    
5 Secondary prevention is defined at preventing a recurrence of breast cancer 
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2.7.2.2.  Electronic databases 
2.7.2.2.1.  AMED  
 1. Diet, Reducing/ or Diet, Macrobiotic/ or Diet, Atherogenic/ or Diet/ or Diabetic Diet/ or diet.mp. or 
Diet Surveys/ or Diet, Fat-Restricted/ or Diet, Carbohydrate-Restricted/ or Diet, Protein-Restricted/ 
or Diet, Sodium-Restricted/ or Diet Therapy/ or Diet, Vegetarian/ or Diet, Mediterranean/ or Diet, 
Cariogenic/ or Diet Records/ or Diet Fads/ 
2. limit 1 to humans 
3. breast cancer.mp. or Breast Neoplasms/ 
4. limit 3 to humans 
5. 2 and 4 
2.7.2.2.2.  BNI   
 1. Diet, Reducing/ or Diet, Macrobiotic/ or Diet, Atherogenic/ or "Diet"/ or Diabetic Diet/ or diet.mp. 
or Diet Surveys/ or Diet, Fat-Restricted/ or Diet, Carbohydrate-Restricted/ or Diet, Protein-
Restricted/ or Diet, Sodium-Restricted/ or Diet Therapy/ or Diet, Vegetarian/ or Diet, Mediterranean/ 
or Diet, Cariogenic/ or Diet Records/ or Diet Fads/ 
2. limit 1 to humans 
3. breast cancer.mp. or Breast Neoplasms/ 
4. limit 3 to humans 
5. 2 and 4 
2.7.2.2.3.  CAB  
 1. Diet, Reducing/ or Diet, Macrobiotic/ or Diet, Atherogenic/ or "Diet"/ or Diabetic Diet/ or diet.mp. 
or Diet Surveys/ or Diet, Fat-Restricted/ or Diet, Carbohydrate-Restricted/ or Diet, Protein-
Restricted/ or Diet, Sodium-Restricted/ or Diet Therapy/ or Diet, Vegetarian/ or Diet, Mediterranean/ 
or Diet, Cariogenic/ or Diet Records/ or Diet Fads/ 
2. limit 1 to humans 
3. breast cancer.mp. or Breast Neoplasms/ 
4. limit 3 to humans 
5. 2 and 4 Chapter Two: Breast cancer  
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2.7.2.2.4.  CINAHL  
 1. Diet, Reducing/ or Diet, Macrobiotic/ or Diet, Atherogenic/ or "Diet"/ or Diabetic Diet/ or diet.mp. 
or Diet Surveys/ or Diet, Fat-Restricted/ or Diet, Carbohydrate-Restricted/ or Diet, Protein-
Restricted/ or Diet, Sodium-Restricted/ or Diet Therapy/ or Diet, Vegetarian/ or Diet, Mediterranean/ 
or Diet, Cariogenic/ or Diet Records/ or Diet Fads/ 
2. limit 1 to humans 
3. breast cancer.mp. or Breast Neoplasms/ 
4. limit 3 to humans 
5. 2 and 4 
2.7.2.2.5.  EMBASE  
 1. Diet, Reducing/ or Diet, Macrobiotic/ or Diet, Atherogenic/ or "Diet"/ or Diabetic Diet/ or diet.mp. 
or Diet Surveys/ or Diet, Fat-Restricted/ or Diet, Carbohydrate-Restricted/ or Diet, Protein-
Restricted/ or Diet, Sodium-Restricted/ or Diet Therapy/ or Diet, Vegetarian/ or Diet, Mediterranean/ 
or Diet, Cariogenic/ or Diet Records/ or Diet Fads/ 
2. limit 1 to humans 
3. breast cancer.mp. or Breast Neoplasms/ 
4. limit 3 to humans 
5. 2 and 4 
2.7.2.2.6.  HMIC  
 1. Diet, Reducing/ or Diet, Macrobiotic/ or Diet, Atherogenic/ or "Diet"/ or Diabetic Diet/ or diet.mp. 
or Diet Surveys/ or Diet, Fat-Restricted/ or Diet, Carbohydrate-Restricted/ or Diet, Protein-
Restricted/ or Diet, Sodium-Restricted/ or Diet Therapy/ or Diet, Vegetarian/ or Diet, Mediterranean/ 
or Diet, Cariogenic/ or Diet Records/ or Diet Fads/ 
2. limit 1 to humans 
3. breast cancer.mp. or Breast Neoplasms/ 
4. limit 3 to humans 
5. 2 and 4 
2.7.2.2.7.  Medline  
 1. Diet, Reducing/ or Diet, Macrobiotic/ or Diet, Atherogenic/ or Diet/ or Diabetic Diet/ or diet.mp. or 
Diet Surveys/ or Diet, Fat-Restricted/ or Diet, Carbohydrate-Restricted/ or Diet, Protein-Restricted/ 
or Diet, Sodium-Restricted/ or Diet Therapy/ or Diet, Vegetarian/ or Diet, Mediterranean/ or Diet, 
Cariogenic/ or Diet Records/ or Diet Fads/ 
2. limit 1 to humans 
3. breast cancer.mp. or Breast Neoplasms/ 
4. limit 3 to humans 
5. 2 and 4 Chapter Two: Breast cancer  
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2.7.2.2.8.  PsycINFO 
 1. Diet, Reducing/ or Diet, Macrobiotic/ or Diet, Atherogenic/ or "Diet"/ or Diabetic Diet/ or diet.mp. 
or Diet Surveys/ or Diet, Fat-Restricted/ or Diet, Carbohydrate-Restricted/ or Diet, Protein-
Restricted/ or Diet, Sodium-Restricted/ or Diet Therapy/ or Diet, Vegetarian/ or Diet, Mediterranean/ 
or Diet, Cariogenic/ or Diet Records/ or Diet Fads/ 
2. limit 1 to humans 
3. breast cancer.mp. or Breast Neoplasms/ 
4. limit 3 to humans 
5. 2 and 4 
2.7.2.2.9.  Web of Science  
1. Diet, Reducing/ or Diet, Macrobiotic/ or Diet, Atherogenic/ or "Diet"/ or Diabetic Diet/ or diet.mp. 
or Diet Surveys/ or Diet, Fat-Restricted/ or Diet, Carbohydrate-Restricted/ or Diet, Protein-
Restricted/ or Diet, Sodium-Restricted/ or Diet Therapy/ or Diet, Vegetarian/ or Diet, Mediterranean/ 
or Diet, Cariogenic/ or Diet Records/ or Diet Fads/ 
2. limit 1 to humans 
3. breast cancer.mp. or Breast Neoplasms/ 
4. limit 3 to humans 
5. 2 and 4 
2.7.2.3.  Journal handsearching 
Journal of Nutrition and Dietetics 
2.7.2.4.  Conference proceedings 
American Association of Clinical Oncology; 2005; Atlanta 
American Association of Clinical Oncology; 2006; Washington 
2.7.2.5.  Efforts to identify unpublished studies 
National Research Register 
2.7.2.6.  Other sources 
Additional articles were located through searching references of key articles Chapter Two: Breast cancer  
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Study Design 
Experimental study  Observational study 
Randomised  
controlled trial 
Non-randomised 
controlled trial 
Analytical  Descriptive 
Cohort study 
Cross-sectional 
Case-control study 
Non-randomised 
No control 
 
2.8.  Nutrition in the secondary prevention of breast cancer 
The following section provides a review of the literature in this area and is organised according to study design (see figure 2.2).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-2 Study designs reviewed Chapter Two: Breast cancer  
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Study Design 
Experimental study  Observational study 
Randomised  
controlled trial 
Non-randomised 
controlled trial 
Analytical  Descriptive 
Cohort study 
Cross-sectional 
Case-control study 
Non-randomised 
No control 
  
2.8.1. Experimental studies 
2.8.1.1.  Randomised controlled trials 
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The following review is presented in accordance with the checklist from the CONSORT Statement 
for Parallel-Group Randomized Trials (2001).
23   Although many of the studies reviewed here were 
conducted before CONSORT, as it is now considered the “gold standard” for reporting RCT’s and 
therefore interpreting the quality of the studies, these guidelines formed the basis for the critical 
appraisal. 
 
This section begins with a summary of the publications reviewed and are listed by a trial code 
(which appear in table 2.6 in place of more lengthy trial descriptors).   Further trial details are 
provided in tables 9.1 and 9.2 which can be found in appendix 9.1. 
 
The review is then summarised in table 2.7 comparing each of the key elements outlined in the 
CONSORT statement (appendix 9.2) with the reviewed studies.  The main narrative follows on 
from the summary tables.Chapter Two: Breast cancer  
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Code  Trial/author  Author/s  Year  Title 
1a  Nutrition Adjuvant Study  Greenwald et al
24 
 
Chlebowski et al
25 
 
Chlebowski et al
26 
1987 
 
1987 
 
1990 
Feasibility studies of a low fat diet to prevent or retard breast 
cancer 
A breast cancer nutrition adjuvant study (NAS): protocol design 
and initial patient adherence 
Current status: Evaluation of dietary fat reduction as secondary 
breast cancer prevention 
1b  WINS Feasibility  Chlebowski et al
27  1993  Adherence to a dietary fat intake reduction program in 
postmenopausal women receiving therapy for early breast 
cancer 
1c  WINS Stage III RCT  Chlebowski et al
28  2007  Dietary fat reduction and breast cancer outcome: interim 
efficacy results from the Women’s Intervention Nutrition study 
2a  WHEL feasibility  Pierce et al
29  1997  Feasibility of a randomized trial of a high-vegetable diet to 
prevent breast cancer recurrence 
2b  WHEL RCT  Pierce et al
30  2007  Influence of a diet high in vegetables, fruit, and fiber and low in 
fat on prognosis following treatment for breast cancer 
 
Table 2-6 Trial codes and details Chapter Two: Breast cancer  
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Code  Trial/author  Author/s  Year  Title 
3  Djuric et al and Jen et al  Djuric et al
31 
 
Jen et al
32 
2002 
 
2004 
Combining weight-loss counselling with the weight watchers 
plan for obese breast cancer survivors 
Improvement of metabolism among obese breast cancer 
survivors in differing weight loss regimens 
4  Holm et al and Nordevang et al  Holm et al
33 
 
Nordevang et al
34 
 
Nordevang et al
35 
1990 
 
1990 
 
1992 
Dietary intervention as adjuvant therapy in breast cancer 
patients – a feasibility study 
Dietary intervention in breast cancer patients: effects on dietary 
habits and nutrient intake 
Dietary intervention in breast cancer patients: effects on food 
choice 
5  BRIDGES  Hebert et al
36  2001  Changes in women’s diet and body mass following intensive 
intervention for early-stage breast cancer 
6  De Waard et al  De Waard et al
37  1993  A feasibility study on weight reduction in obese 
postmenopausal breast cancer patients 
7  BCDIP  Kristal et al
38  1997  Feasibility of using volunteer research staff to deliver and 
evaluate a low-fat dietary intervention: The American cancer 
society breast cancer dietary intervention project 
 
Table 2.6 Trial codes and details (cont.) Chapter Two: Breast cancer  
 
  32 
   
 
Section and Topic 
 
 
Descriptor 
 
1a 
 
1b 
 
1c 
 
2a 
 
2b 
 
3 
 
4 
 
5 
 
6 
 
7 
Title and Abstract  How participants were randomly allocated to interventions 
  √  √  √  √  √  √  √  √  √  √ 
Introduction      
                     
Background  Scientific background and explanation of rationale 
  √  √  √  √  √  √  √  √  √  √ 
Methods 
 
                     
Participants 
 
Eligibility criteria for participants and the settings and 
locations where the data were collected  x  x  x  √  √  √  √  √  √  √ 
Interventions 
 
Precise details of the interventions intended for each 
group and how and when they were actually administered  √  x  √  x  √  √  √  √  x  √ 
Objectives 
 
Specific objectives and hypotheses  x  x  √  √  √  √  √  x  √  √ 
Outcomes 
 
Clearly defined primary and secondary outcome measures 
and, when applicable, any methods used to enhance the 
quality of measurements  
x  x  √  x  √  x  √  x  √  √ 
Sample Size 
 
How sample size was determined and where applicable, 
explanation of any interim analyses and stopping rules  x  x  √  x  √  x  x  x  x  x 
 
Table 2-7 Performance of reviewed studies compared to CONSORT checklist 
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Section and Topic 
 
 
Descriptor 
 
1a 
 
1b 
 
1c 
 
2a 
 
2b 
 
3 
 
4 
 
5 
 
6 
 
7 
Randomisation 
-  Sequence 
generation 
 
 
-  Allocation 
concealment 
 
-  Implementation 
 
Method used to generated the random allocation 
sequence, including details of any restriction 
 
Method used to implement the random allocation 
sequence 
 
Who generated the allocation sequence, who enrolled 
participants and who assigned participants to their groups 
 
x 
 
x 
 
 
 
x 
 
x 
 
x 
 
 
 
x 
 
√ 
 
X 
 
 
 
x 
 
x 
 
x 
 
 
 
x 
 
√ 
 
√ 
 
√ 
 
x 
 
 
 
x 
 
x 
 
x 
 
 
 
x 
 
x 
 
x 
 
 
 
x 
 
x 
 
x 
 
 
 
x 
 
x 
 
x 
 
 
 
x 
Blinding  Whether or not participants, those administering the 
interventions, and those assessing the outcomes were 
blinded to group assignment.  If done, how the success of 
blinding was evaluated 
 
x  x  √  x  √  x  x  x  x  x 
Statistical methods  Statistical methods used to compare groups for primary 
outcome(s); methods for additional analyses, such as 
subgroup analyses and adjusted analyses 
 
x  x  √  √  √  √  √  √  x  √ 
 
Table 2-7 Performance of reviewed studies compared to CONSORT checklist (cont.)Chapter Two: Breast cancer  
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Section and Topic 
 
Descriptor 
 
1a 
 
1b 
 
1c 
 
2a 
 
2b 
 
3 
 
4 
 
5 
 
6 
 
7 
Results 
 
                     
Participant flow  Flow of participants through each stage 
  √  √  √  √  √  √  √  √  √  √ 
Recruitment  Dates defining the periods of recruitment and follow-up 
  x  x  √  √  √  x  √  x  x  √ 
Baseline data  Baseline demographic and clinical characteristics of each 
group 
 
√  √  √  √  √  √  √  √  x  x 
Numbers analysed  Number of participants in each group included in each 
analysis and whether the analysis was by “intention-to-treat”.  
State the results in absolute numbers when feasible 
 
√  √  √  √  √  √  √  √  √  √ 
Outcomes and estimation  For each primary and secondary outcome, a summary of 
results for each group, and the estimated effect size and aits 
precision 
 
√  √  √  x  √  √  √  √  x  √ 
Ancillary analysis  Address multiplicity by reporting any other analyses 
performed, including subgroup analysis and adjusted 
analyses, indicating those prespecified and those 
exploratory 
 
n/a  n/a  √  n/a  √  n/a  n/a  n/a  n/a  n/a 
Adverse effects  All important adverse effects or side effects in each 
intervention  
group 
 
n/a  n/a  n/a  n/a  n/a  n/a  n/a  n/a  n/a  n/a 
 
Table 2-7 Performance of reviewed studies compared to CONSORT checklist (cont.)Chapter Two: Breast cancer  
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Section and Topic 
 
 
Descriptor 
 
1a 
 
1b 
 
1c 
 
2a 
 
2b 
 
3 
 
4 
 
5 
 
6 
 
7 
 
Comment 
 
                     
Interpretation  Interpretation of the results, taking into account study 
hypothesis, sources of potential bias or imprecision, and 
the dangers associated with multiplicity of analyses and 
outcomes 
 
x  x  √  √  √  √  √  √  x  √ 
Generalisability  Generalisability of the trial findings 
  x  x  ?  ?  √  x  x  x  x  x 
 
Table 2-7 Performance of reviewed studies compared to CONSORT checklist (cont.) Chapter Two: Breast cancer  
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2.8.1.2.  Methods 
2.8.1.2.1.     Participants 
Overall eligibility criteria were well documented however this was not the case for settings and 
locations, important considerations when assessing the relevance of the findings for the reader’s 
own setting.
39  
2.8.1.2.2.  Interventions 
Overall, precise details of the interventions were poorly documented.   For three of the trials 
reviewed, this information was not reported.
27 29 36  
 
For example trial 1b
27 reports “The dietary control group received minimal nutritional counselling”.   
 
Trial 3
29 provides the following description: Telephone counselling was provided across three 
phases of intensity and frequency of contact.  A brief high-frequency contact phase of the 
intervention was aimed to encourage women to quickly achieve the study goals, with the counsellor 
monitoring performance.  The second phase was less intense, and aimed to make changes so that 
the diet could be integrated into the women’s way of life as well as to train the women in self 
monitoring of their diets.  The third non-intensive phase was aimed at preventing relapse.  Cooking 
classes were offered monthly throughout the study.” 
 
Trial 5
37 states “A balanced diet of 1,500 kcal was prescribed and discussed”. 
2.8.1.2.3.  Objectives 
The majority of the publications reviewed (7/10) reported the objectives of the study. 
2.8.1.2.4.  Outcomes 
Despite good reporting of objectives, clearly defined primary and secondary outcomes were poorly 
described. 
 
The importance of clearly stating outcomes cannot be overstated.  Firstly a stated primary outcome 
is required to perform a power calculation and secondly without it the analysis cannot be 
considered transparent.  It provides an opportunity for investigators to cherry pick results to find 
significant findings.  Outcomes should be stated objectively.
40 
 
Of the papers reviewed only two publications objectively described their outcomes.  The WINS 
study
28 stated an expected difference in relapse free survival of 7.5% between groups and the 
WHEL study
30 estimated a 19% difference in breast cancer events between groups. Chapter Two: Breast cancer  
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2.8.1.2.5.  Sample size 
In order to estimate treatment effects a power calculation must be performed on the primary 
outcome.  This should always be done a priori and stated in the protocol.  The power calculation 
ensures that the study will have adequate power to detect the difference of interest in the two 
groups.
40 
 
Sample size calculations were only performed on two of the publications reviewed.
28 30 Most of the 
studies were feasibility studies and conducted many years ago which would explain the absence of 
such information.  This does however have major influences on how the findings of these studies 
should be viewed. 
2.8.1.2.6.  Randomisation  
 
Overall the randomisation process was poorly documented. Randomisation is the only way to 
ensure allocation to the comparison groups is unbiased and therefore the process should be 
reported clearly so that if the outcome differed between groups, the reader can be confident this 
difference occurred due to the treatment. 
 
  Random sequence generation 
 
Described in only two studies.
28 32 
 
  Allocation concealment 
 
Only one study
30 reviewed reported how allocation concealment was achieved thus creating 
uncertainty regarding how unbiased the process was. Schultz et al 
41 examined 250 randomised 
trials from 33 meta-analysis and found the treatment effect to be 30-41% higher in those trials 
without adequate allocation concealment. 
  Implementation 
Information on who generated the allocation sequence, who enrolled participants and who 
assigned participants to their groups was not reported in any of the studies reviewed. 
2.8.1.2.7.  Blinding 
Blinding can occur at three points in a study; patients, treatment team and treatment 
evaluator/assessor. In a dietary intervention study it would not be possible to blind either the patient 
or the intervention team however blinded outcome assessment should be employed to ensure the 
outcome assessment is not biased.  Outcome assessment blinding was reported in only two of the 
publications reviewed.
28 30 Chapter Two: Breast cancer  
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2.8.1.2.8.  Statistical methods 
In general, a priori statistical analyses were well reported.   
2.8.1.3.  Results 
2.8.1.3.1.  Participant flow 
Participant flow was poorly documented making it necessary to undertake a laborious task to 
determine numbers at each stage of the trial.   Only three of the publications reviewed provided a 
clear description of participant flow.
28 30 37 
2.8.1.3.2.  Recruitment 
Five publications reviewed reported dates defining the periods of recruitment.  The numbers of 
patients screened and invited is not always reported; an important consideration when assessing 
trials as the conversion rate from invitation to uptake indicates the interest in a dietary intervention.  
In the absence of this information, the length of time taken to recruit is the only proxy marker when 
considering this issue. 
2.8.1.3.3.  Baseline data 
A summary of baseline comparisons were reported in six instances.  Trial 7
38 provided baseline 
data but did do so separately for the control and interventions participants. 
2.8.1.3.4.  Numbers analysed 
Further as table 2-8 highlights, the majority of studies had small numbers of participants, a feature 
that undermines the quality and interpretability of the findings. 
 
Only two studies reviewed report an “intention to treat” (ITT) analysis.
28 30 The WINS Study
28 
reported analysing data on all 975 participants from the intervention group and 1462 from the 
control. However, there is no explanation offered as to how the missing dietary data, outlined in the 
paper is calculated.  Without this information it is difficult to assess whether the analysis is in fact 
ITT. 
 
The other study to report an ITT analysis (the WHEL study) despite losing numbers through 
withdrawals and loss to follow-up, included data from all 3088 original participants in the final 
analysis.  In the case of missing records, a conservative imputation model was utilised for follow-up 
data.Chapter Two: Breast cancer  
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1. WINS 
 
Nutrition Adjuvant study 
 
BL6 
 
3/127  
 
6/128 
 
12/129 
 
18/1210 
 
24/1211 
 
36/1212 
 
48/1213 
 
Control  19  14             
Intervention  30  18             
TOTAL  49  32  27  15         
 
WINS stage II 
 
 
BL 
 
3/12  
 
6/12 
 
12/12 
 
18/12 
 
24/12 
 
36/12 
 
48/12 
 
Control  147  111  100  72  55  36     
Intervention  143  108  96  83  55  35     
TOTAL  290  219  196  155  110  71     
 
Wins Stage III 
 
BL 
 
3/12  
 
6/12 
 
12/12 
 
18/12 
 
24/12 
 
36/12 
 
60/12 
 
Control  1461      1328      1077  648 
Intervention  975      840      654  380 
TOTAL  2436      2160      1731  1028 
 
Table 2-8 Numbers of participants with available data during each stage of study 
                                                    
6 Baseline 
7 Three months 
8 Six months 
9 Twelve months 
10 Eighteen months 
11 Two years 
12 Three years 
13 Four years Chapter Two: Breast cancer  
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2. WHEL  
 
WHEL Feasibility 
 
BL 
 
3/12  
 
6/12 
 
12/12 
 
18/12 
 
24/12 
 
36/12 
 
48/12 
 
Control  46    43  32         
Intervention  47    44  39         
TOTAL  93    87  71         
WHEL RCT  BL              72/12 
Control  1551              1488 
Intervention  1537              1465 
TOTAL  3088              2953 
3. Djuric et al and Jen et al 
   
BL 
 
3/12  
 
6/12 
 
12/12 
 
18/12 
 
24/12 
 
36/12 
 
48/12 
 
Control  13    13  12         
Weight Watchers  10    9  8         
Individualised  13    9  9         
Comprehensive  11    10  10         
TOTAL  47    41  39         
4.Holm et al and Nordevang  
   
BL 
 
3/12  
 
6/12 
 
12/12 
 
18/12 
 
24/12 
 
36/12 
 
48/12 
 
Control  119          106     
Intervention  121          63     
TOTAL  240          169     
 
Table 2-8 Numbers of participants with available data during each stage of study (cont.)Chapter Two: Breast cancer  
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5. BRIDGES 
   
BL 
 
3/12  
 
6/12 
 
12/12 
 
18/12 
 
24/12 
 
36/12 
 
48/12 
 
Control  56      49         
NEP  50      48         
SRC  51      46         
TOTAL  157      143         
6. De Waard 
   
BL 
 
3/12  
 
6/12 
 
12/12 
 
18/12 
 
24/12 
 
36/12 
 
48/12 
 
Control  43    39    24  21  17  15 
Intervention  59    55    27  25  23  18 
TOTAL  102    94    51  46  40  33 
   
BL 
 
3/12  
 
6/12 
 
12/12 
 
18/12 
 
24/12 
 
36/12 
 
48/12 
 
7. BCDIP 
   
BL 
 
3/12  
 
6/12 
 
12/12 
 
18/12 
 
24/12 
 
36/12 
 
48/12 
 
Control  71  59  53  53         
Intervention  73  63  62  57         
TOTAL  144  122  115  110         
 
Table 2-8 Numbers of participants with available data during each stage of study (cont.)Chapter Two: Breast cancer  
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2.8.1.4.  Outcomes and estimation 
Overall, summaries of outcome measures were reported.   
2.8.1.4.1.  Ancillary analysis 
In the majority of cases, due to the relatively small numbers of participants involved there were no 
subgroup analyses conducted.   
 
The WINS Stage III
28 study did however conduct several sub group analyses (not pre specified in 
the protocol) and several interim analyses were conducted.  In these instances the Haybitle-Peto 
approach to α-spending was documented. 
 
Similarly, the WHEL study also addressed issues of multiplicity in their design paper.
30 
2.8.1.4.2.  Adverse effects 
There are no known adverse effects in following both a low-fat or high fruit and vegetable, low fat 
diet. 
2.8.1.5.  Comment 
2.8.1.5.1.  Interpretation 
Given the methodological issues presented in this discussion, the interpretation of the findings by 
the authors for all the studies reviewed was more positive that the results would indicate (table 2.9).   
 
For example, it is the opinion of this reviewer that given the largely negative scores for the conduct 
of study 1b using CONSORT it is not appropriate for the authors to conclude “Substantial and 
sustained dietary fat reduction with associated weight change can be achieved at relatively low 
cost within the context of conventional multimodality clinical management of postmenopausal 
women with localised breast cancer.  Thus full-scale study of the potential influence of dietary fat 
intake reduction of breast cancer patient relapse and survival can now be considered”. Chapter Two: Breast cancer  
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Trial  Conclusions 
1a  Results suggest that a somewhat larger population of potential study participants will be 
required to successfully meet targeted accrual goals for studies involving alteration of 
dietary fat intake in the adjuvant cancer setting 
1b  Substantial and sustained dietary fat reduction with associated weight change can be 
achieved at relatively low cost within the context of conventional multimodality clinical 
management of postmenopausal women with localised breast cancer.  Thus full-scale 
study of the potential influence of dietary fat intake reduction of breast cancer patient 
relapse and survival can now be considered 
1c  A way of life intervention reducing dietary fat intake, with modest influence on body weight, 
may improve relapse-free survival of breast cancer patients receiving conventional cancer 
management 
2a  Results from the present study support the feasibility of conducting a large clinical trial to 
investigate the effect of this diet intervention on recurrence of breast cancer 
2b  Among survivors of early stage breast cancer, adoption of a diet that was very high in 
vegetables, fruit, and fiber and low in fat did not reduce additional breast cancer events or 
mortality during a 7.3 year follow-up period 
3  Despite the small size of the study, the differences in weight loss observed between 
intervention arms were large, with the combination of individualised counselling and the 
commercial weight watchers program proving to be more effective.  This approach should 
be applicable to larger studies that test whether weight loss in breast cancer survivors can 
reduce their risk of disease recurrence 
4  Dietary counselling resulted in a significant difference in intakes of dietary fat and 
carbohydrate between the intervention group and the control group after a two year period 
5  Not clearly stated 
6  With proper advice and guidance it is possible to achieve a weight reduction of 6kg or 
more in 50% of obese postmenopausal breast cancer patients 
7  It is feasible to develop research protocols that include complex dietary interventions 
delivered by volunteer research staff 
 
Table 2-9 Publication conclusions 
 
The only study which provided an accurate interpretation giving due consideration to both strengths 
and limitations was the WHEL study.
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2.8.1.5.2.  Generalisability 
A number of issues bring the generalisability of these studies under question. 
 
Firstly, it is unclear as to whether trial participants represented breast cancer patients in the wider 
context.    Stringent specific inclusion and exclusion criteria were set out for the studies reviewed 
thus impacting of the external validity of the results. 
 
Secondly, it is difficult to assess the proportion of women who were invited to enter the trial 
agreeing to participate, further limiting the strength of determining the generalisability of the 
findings.  In those instances where conversion rates from screening to participation are reported, 
they highlight a relatively poor uptake. 
 
Thirdly losses in the treatment arm are consistently higher than in the comparison group 
suggesting an inability to comply with the dietary intervention for many of the participants.  
Surprisingly this issue is not discussed in any of the reviewed publications. 
 
Further, the sample sizes in the studies with the exception of trial WINS Stage III
28 and  
WHEL
30 were small making extrapolation to a larger population cautionary.   
 
Lastly, the settings and locations were also poorly documented which could influence the 
generalisability of the findings. 
 
Overall, these data cannot be assessed as generalisable.  This is of some concern given that many 
of these trials were feasibility studies from which larger studies were based. 
 
2.8.1.5.3.  Summary of studies 
With eight of the ten publications reviewed which can only be described as having plausible bias 
that seriously weakens confidence in the results, the quality of this body of work can only be 
summarised as poor.  That said, a further discussion on the two large randomised controlled trials, 
the WINS
28 study and the WHEL
30 study is warranted. 
 
The first to publish the results of their work was the Women’s Intervention Nutrition Study (WINS).   
The study, a large randomised controlled trial investigated the effect of a low-fat diet on relapse 
free survival in postmenopausal women with breast cancer.   
 
The study recruited 2437 postmenopausal women with breast cancer over the period of seven 
years, from February 1994 to January 2001.  Women were assigned to either a low-fat diet (15% of Chapter Two: Breast cancer  
 
  45 
energy from fat) or an attention control group who received written information on general dietary 
guidelines.  
  
The end points for the study were relapse events including local, regional and distal recurrences; 
ipsilateral recurrence following lumpectomy; and contralateral recurrence.  Overall survival defined 
as death from any cause was a secondary endpoint. 
 
The results showed that women in the intervention arm of the study had a 24% lower risk of 
relapse compared to the control group (HR = 0.76; 95% CI = 0.60 – 0.98).  Further, the greatest 
effect, although not statistically significant, was observed in the oestrogen receptor negative group, 
a group for whom adjuvant treatment is limited. 
 
The authors conclude that this interim efficacy analysis suggests a low fat diet may improve 
relapse free survival in postmenopausal women with breast cancer. 
 
In contrast, the Women’s Healthy Eating and Living Study (WHEL), another large, randomised 
controlled trial found no relationship between a diet, high in vegetables and fruit and fibre and low 
in fat and subsequent survival from breast cancer. 
 
The WHEL study recruited 3088 women, both premenopausal and postmenopausal, from 1995 – 
2000, a similar time period as in WINS.  Women were assigned to the intervention (high vegetable 
– 5 serves and fruit – 3 serves and fibre – 30g, low fat – 15-20% of total energy intake) or the 
attention control group who received written materials on a healthy diet including five or more 
serves of vegetables and fruit, more than 20g of fibre and less than 30% total energy from fat.  
 
Study endpoints were 1/ recurrence, which included local/regional or distal metastasis or new 
primary breast cancer and 2/ death from any cause. 
 
Results showed that risk of recurrence or death was similar for both the intervention and control 
arm of the study. Therefore no survival benefit from consuming a diet high in vegetable, fruit and 
fibre, and low in fat was observed. 
 
The discrepancy in the results of both of these studies is disappointing as it was hoped that these 
studies would provide strong evidence for the role of diet in the secondary prevention of cancer. 
 
It is important to note at this stage the differences between the studies.  Firstly, whilst both studies 
recruited large numbers of women, the WINS study was limited to postmenopausal women.  Both 
dietary interventions prescribed low fat diets however levels in the WINS study were significantly 
lower with a target of 15% compared to 30% in WHEL.  In addition the WHEL study targeted other 
dietary components, including vegetables, fruit and fibre.   Chapter Two: Breast cancer  
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Despite these differences in study design, a comparison between the WINS and the WHEL study 
results on the effect of dietary fat reduction on breast cancer outcomes is warranted and has been 
the subject of several publications since the original articles appeared in the scientific literature.
42 43 
44 45 
 
The following explanations have been put forward which may help understand these differences. In 
total, four potential reasons have been identified; differences in baseline characteristics, differences 
in fat reduction, differences in weight loss and differences in time since diagnosis.  
 
Firstly, both studies despite randomisation resulted in potentially important baseline differences 
between the intervention and control group.  Specifically for WINS, there were higher numbers of 
women who had mastectomies (reported to have better outcomes than lumpectomy) in the 
intervention group and this in itself may have confounded the findings.  The authors state that 
statistical adjustment was made and therefore any advantage in this group should have been 
eliminated.   
 
The WHEL study too observed differences in baseline characteristics, again in treatment variables. 
The percentage of women in the intervention group who received adjuvant anti-oestrogen therapy 
and bilateral oophorectomy was slightly higher.  Again the authors dealt with these differences 
through statistical analyses.  The results yielded similar results for both adjusted and unadjusted 
models.   
 
In both scenarios the baseline differences favoured the intervention group. In the case of the 
WHEL study, this suggests the null effect of the dietary intervention was even greater than 
reported.  In the case of WINS, given a statistically significant finding was found, it may be possible 
that the observed difference was due to baseline differences favouring the intervention group.  
Thiebaut et al 
44 state that post hoc covariate adjustment is not as inferentially as strong as 
analyses conducted on groups whose baseline characteristics are well matched and  conclude by 
stating a degree of uncertainty must be taken into consideration when interpreting the overall 
findings of the WINS. 
 
Secondly, change in fat intake after the intervention differed slightly between the two studies.  The 
mean % fat intake at baseline for women in the intervention groups was 29.6% in the WINS study 
and 28.5% in WHEL and in the control groups 29.6% and 28.7% respectively.  At one year fat 
intake had fallen to 20.3% in the WINS study compared to 22.7% in WHEL. Therefore at one year 
the reduction in fat in the WINS study was 2.4% greater compared to that achieved by participants 
in WHEL. 
 
Whilst both studies followed participants for similar periods, five years in WINS and six in WHEL, 
no raw data was presented at the last follow up for the WINS study.  Only mean % difference in fat Chapter Two: Breast cancer  
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intake from baseline between the intervention and control groups was reported.  Over the five 
years the mean % difference was -8.9 at one year, -9.0 at three years and -8.0 at five years.  For 
the similar time intervals in WHEL (1,2 and 6 years), mean % difference in fat intake between 
groups was -5.7, -5.2 and -3.5 respectively.  The mean % difference in fat intake does however 
expose an interesting point.  Mean % fat intake for women in the intervention arm of the WHEL had 
not only returned to that levels observed at baseline but had slightly surpassed them (28.9%).  The 
reason a 3.5% mean difference was observed was due to an even greater increase in % fat intake 
in the control group.  Without the raw data from the WINS, it is difficult to assess if low intakes of fat 
were maintained as stated by the authors or whether the control group has increased their fat 
intake over the period thus artificially providing evidence for maintenance.  This is further 
compounded by the degree of missing data in the WINS study which was approximately 30% at 
year three and 60% at year five. 
 
This is an important observation as the latest endocrine therapy recommended for newly 
diagnosed breast cancer patients is aromatase inhibitors which essentially reduce up to 99% of 
oestrogen activity within the body.
15  If indeed the proposed mechanism by which a low fat diet 
works is by reducing circulating oestrogens, if this dietary pattern cannot be maintained after 
cessation of endocrine therapy (usually five years), any benefit from dietary modification is negated 
as women are protected via this medication. 
 
Thirdly, weight loss observed in both studies differed. The mean weight at baseline for women in 
the intervention groups was 72.7 kg in the WINS study and 73.5 kg in WHEL and in the control 
groups 72.6 kg and 73.3 kg respectively.  At one year weight had fallen to 70.6 kg in the WINS 
study compared to 73.0 kg in WHEL. Therefore at one year the reduction in weight in the WINS 
study was 1.6 kg greater compared to that achieved by participants in WHEL.  
 
As seen in % fat intake no raw data was presented at the last follow up for the WINS study with 
results presented as mean difference in weight from baseline between the intervention and control 
groups.  Over the five years the mean difference in weight was -2.3 kgs at one year, -1.8 at three 
years and -2.7 at five years.   
 
For similar time intervals in WHEL (one, two and six years), mean difference in weight between 
groups was + 0.2 kgs, - 1.0 and + 0.4 respectively.   
 
This observed difference in weight loss between the two studies may explain the findings of the 
WINS study and it has been suggested that weight loss and not a diet low in fat may be 
responsible for the survival benefit found by the WINS study group.
44 
 
Lastly WINS recruited women within one year of their breast cancer diagnosis whereas the 
average time since diagnosis in WHEL was four years.  This may have resulted in an under Chapter Two: Breast cancer  
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sampling of women most likely to experience a recurrence and therefore explained the findings that 
the WHEL eating pattern did not improve breast cancer outcomes. 
 
Further, an unplanned sub group analysis in the WINS data found that women with oestrogen 
receptor negative tumours were conferred a greater survival benefit when compared to those with 
oestrogen receptor positive tumours.  Whilst this finding is welcomed as currently this group has 
fewer adjuvant treatment options, it must be viewed cautiously.  The finding may have occurred by 
chance or have arisen through confounding.  Thiebaut et al
44 raise the possibility that the 
differences in mastectomy rates may have been more evident in the ER-ve group. 
 
The WINS study has yet to report its final results.  Once published, the findings may lay to rest 
many of the issues raised.  
 
Taken in totality, despite two large, randomised controlled trials the question regarding the role of 
diet in the secondary prevention of cancer remains unclear. 
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Study Design 
Experimental study  Observational study 
Randomised  
controlled trial 
Non-randomised 
controlled trial 
Analytical  Descriptive 
Cohort study 
Cross-sectional 
Case-control study 
Non-randomised 
No control 
2.8.1.6.  Non-randomised non controlled trials 
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  Year  Author  Title 
1  1998  Goodwin et al
46  Multidisciplinary weight management in locoregional breast 
cancer: results of a phase II study 
2  1998  McTiernan et al
47  Anthropometric and hormone effects of an eight-week 
exercise-diet intervention in breast cancer patients: results 
of a pilot study 
3  1988  Boyar et al
48  Response to a diet low in total fat in women with 
postmenopausal breast cancer: A pilot study 
 
Table 2-10 Publication details 
 
 Chapter Two: Breast cancer  
 
  51 
  Aim  Invited  Started  Finished  Intervention details  Conclusions 
1  To prevent weight gain and in 
those who were overweight to 
promote weight loss 
  61  39  Group (6-10) sessions 
90 minute sessions weekly for ten weeks 
then monthly for ten months 
Education covered information on breast 
cancer and its treatment, nutrition, physical 
activity and psychological adaptation to 
breast cancer 
The multidisciplinary team successfully 
prevented weight gain in women with newly 
diagnosed locoregional breast cancer and 
helped overweight women lose weight 
2  To test the feasibility of recruiting, 
screening, enrolling and 
maintaining breast cancer patients 
in an intensive 8-week exercise 
and low-fat diet program 
99    9  Dietary program consisted of a low fat 
diet(20% of total calories).  After an initial 
visit where patients learned skills to change 
eating behaviours to adopt the dietary 
program and were provided with written 
information, they were contacted every 3 
weeks by a nutritionist to assess adherence 
and provide further counselling.  Participants 
were able to contact the nutritionist outside 
these arrangements 
These pilot data indicate that breast cancer 
patients are highly motivated to join and 
adhere to an intense exercise-diet 
intervention and can experience significant 
measurable changes in anthropometric and 
fat mass measures 
3  To determine whether 
postmenopausal breast cancer 
patients would adhere to a low fat 
diet 
  27  20  An individual initial consultation one month 
after baseline was provided to introduce the 
low fat eating plan after which group 
sessions (max 20) were held monthly for four 
months 
Self selected patients can adhere to a low-
fat diet 
 
Table 2-11 Study details Chapter Two: Breast cancer  
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The three studies reviewed here represent early works that were by and large feasibility studies 
focused on two of the prominent theories for the potential role of nutrition in the secondary 
prevention of cancer at the time; low-fat diets and weight reduction diets.   
 
The studies do not provide solid evidence, due largely to the methodological weaknesses 
associated with non randomised, non controlled trials that either low fat diet or weight reduction diet 
interventions are either taken up and/or tolerated by breast cancer patients as suggested by some 
of the authors.   
 
In contrast, participant flow would suggest the opposite with only half the original cohort left at the 
end of study one, only one-tenth of those invited agreeing to participate in study two, and only 
three- quarters of what was a small group to start with completing study three. Chapter Two: Breast cancer  
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Study Design 
Experimental study  Observational study 
Randomised  
controlled trial 
Non-randomised 
controlled trial 
Analytical  Descriptive 
Cohort study 
Cross-sectional 
Case-control study 
Non-randomised 
No control 
 
2.8.1.7.  Observational studies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Chapter Two: Breast cancer  
 
  54 
 
  Year  Author  Title 
1  1999  Saxe et al
49  Diet and risk for breast cancer recurrence and survival 
2  2003  Goodwin et al
46  Diet and breast cancer; evidence that extremes in diet are 
associated with poor survival 
3  2005  Kroenke et al
50 51  Dietary patterns and survival after breast cancer diagnosis 
4  2006  Fink et al
52  Fruits, vegetables, and micronutrient intake in relation 
5  2006  McEligot et al
53  Dietary fat, fiber, vegetable, and micronutrients are 
associated with overall survival in postmenopausal women 
diagnosed with breast cancer 
 
Table 2-12 Publication details 
 
In all, five studies were identified for review.  Although all studies investigated the association 
between diet and breast cancer outcomes, the varying methodologies make it difficult to draw 
conclusions regarding this relationship.  
 
Various dietary measures were used to assess the relationship.  These included nutrient (1, 4, 
and 5) and micronutritient (3) analysis, dietary pattern analysis (2) and food group analysis (3, 5). 
 
Various endpoints were investigated including recurrence (1), death from breast cancer (2), 
deaths from all causes excluding breast cancer (2, 5) and all cause mortality (1, 2, 3, 4). 
 
Diet histories were taken at different points after a breast cancer diagnosis, from at the time of 
diagnosis (1, 3 and 5) and from 3 months after diagnosis (4) to a minimum of two years after 
diagnosis (2). 
 
The menopausal status of participants varied between, with three of the studies (1, 3 and 4) 
including both pre and postmenopausal women for which the prognosis if significantly different, the 
fourth was limited to postmenopausal women only (5) and the last with premenopausal women (2). 
 
Four of the studies used multivariate analyses to assess the relationship between dietary variables 
and breast cancer outcomes, adjusting for important known prognostic factors (1, 2, 4 and 5) whilst 
one did not (4). 
 
Numbers of participants varied considerably between studies with the lowest at 149 (1) up to 
2619 (2). 
 
In addition to the methodological issues outlined above, the ability of Food Frequency 
Questionnaires (FFQ’s) (which were used to measure diet in all of the studies reviewed) to 
accurately measure dietary nutrients is a source of great debate
54-57.  Whilst they may be useful in Chapter Two: Breast cancer  
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determining an overall dietary pattern, it is doubtful whether they are useful/accurate at a nutrient 
level. 
 
In addition, a further source of error exists in the dietary assessment as participants in all studies 
were asked to recall their usual diet in the twelve months before they received their breast cancer 
diagnosis; in effect introducing recall bias. 
 
Reported results found a significant positive association between energy and recurrence (1), 
energy and all cause mortality using a linear model (1) and all cause mortality using a quadratic 
model (4), a western diet and mortality excluding breast cancer (2) and BMI adjusted for arm 
muscle circumference and all cause mortality (1).  No other significant results were reported. 
 
Overall, given the methodological issues outlined and the non divergence of reported results, no 
valid conclusions can be drawn from this body of literature on the relationship between diet and 
breast cancer outcomes. 
2.8.2. Summary of secondary prevention studies  
Several studies, including both experimental and observational studies investigating the role for 
diet in the secondary prevention of breast cancer over the last two decades were reviewed.  The 
majority of the studies were feasibility studies investigating whether women could follow either a 
low fat or healthy diet, the results of which would inform future large scale randomised controlled 
trials.   
 
To date, two large randomised controlled trials have been conducted investigating the role of diet in 
the secondary prevention of breast cancer. 
28 30  The results of these two trials were published 
recently with the WINS study suggesting a lifestyle intervention aimed at reducing dietary fat intake 
may improve the relapse free survival of postmenopausal breast cancer patients in contrast to the 
WHEL study which found no such association.  Several reasons have been identified to explain the 
conflicting findings including differences in study population; baseline characteristics; time since 
diagnosis and weight changes.  The future publication of the final results from the WINS study may 
resolve some of these issues.   
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2.8.3. Tertiary prevention
14  
There is a paucity of evidence concerning the late effects of cancer treatments that could 
potentially be addressed by tertiary prevention activities.  The evidence is largely derived from the 
paediatric literature therefore caution must be exercised when extrapolating long term health 
effects of cancer treatments to adult cancer survivors.   
 
Breast cancer treatments do have associated complications however these are usually well 
tolerated with serious events confined in most instances to rare cases.  Further, over the last five 
years there has been significant progress in treatments for breast cancer resulting in more 
effective, targeted and safe therapies.  
 
At present it is not possible to reliably link specific treatment regimens to late or long term health 
effects and therefore no evidence exists for the role of dietary interventions in tertiary prevention 
activities. 
2.9.  Chapter summary 
Breast cancer is the most common cancer in the UK accounting for 30% of all female cancers.  
Breast cancer will affect one in eight women in the UK over the course of a lifetime.  The incidence 
of breast cancer has been rising steadily over recent years and this trend is expected to continue in 
the future.  In contrast, survival rates from breast cancer have been steadily improving largely due 
to earlier detection and better treatments.  The net result is an increasing number of women 
surviving a breast cancer diagnosis. 
 
The hormone oestrogen plays a central role in the development of breast cancer and the risk 
associated with the disease are largely related to a women’s lifetime exposure to oestrogen.  Two 
predominant models for the role of oestrogen in both the initiation and progression of breast cancer 
have been proposed. 
 
Known causes of breast cancer include, demographic, environmental, medication, and lifestyle 
factors along with reproductive and menstrual history.  Whilst many risk factors are not amenable 
to change, especially in later life many are.  The latest reports suggest that around 42% of all 
breast cancers could be prevented through appropriate food, nutrition, physical activity and body 
fatness.
22  
 
 
                                                    
14 Tertiary prevention is defined at preventing late or long term effects of cancer treatment. 
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Despite almost twenty years of research into the role of nutrition in the secondary prevention of 
breast cancer, to date no evidence base guidelines exist specifically for this group other than to 
follow the recommendations for the primary prevention of breast cancer.   
 
Further, there is a paucity of evidence on the late or long term effects of cancer treatment thus 
leaving a large evidence gap in the role for nutrition in tertiary prevention strategies.  
 
At present we have limited knowledge regarding the health status of breast cancer survivors both 
at the time of diagnosis and beyond.  The literature suggests that cancer survivors experience 
poorer health outcomes when compared to age matched individuals in the general population.  
Therefore, identifying appropriate interventions to improve health outcomes for this group is 
paramount.    
  58 
Chapter Three 
Breast cancer services in the NHS 
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3.0  Breast cancer services in the NHS 
3.1.  Chapter Introduction 
With cancer classed as a chronic disease, the adoption and maintenance of healthy behaviours 
has become of paramount importance.
58 Cancer survivors face a diverse range of physical and 
emotional sequelae
59 and therefore health promotion could potentially play an integral role in the 
length and quality of survival.
60 61 Demark-Wahnefried et al
62 stated that data clearly indicates 
cancer survivors are at greater risk for developing secondary cancers and other non-cancer 
diseases brought on by one or a combination of factors including treatment effects, genetic 
predisposition and common way of life factors providing us with a unique opportunity for health 
promotion. 
 
The following chapter is presented under two main headings; the first outlines what services are 
currently provided by the NHS to women diagnosed with breast cancer and the second focuses on 
the types of services, based on the views of women which might better meet their needs and 
expectations.  It should be noted that currently, on a National level, the views of breast cancer 
patients are not routinely assessed.  In the absence of this information, the views of this patient 
group have been elicited from the scientific literature.   
3.2.  Current NHS services offered to breast cancer patients 
3.2.1. Background 
 
Current NHS breast cancer services have developed over the last 14 years as a result of several 
Department of Health initiatives beginning with the publication of the Calman Hine report.
63  The 
report was commissioned in response to the rising number of cancer diagnoses, variation in cancer 
outcomes and the resultant economic cost to the community.  The work was undertaken by an 
expert advisory group on cancer whose task was to consider the direction in which cancer services 
should be developed.   
 
The report was key is establishing a direction for cancer reform and its recommendations formed 
the basis of the 2000 NHS Cancer Plan 
64, a document outlining a comprehensive strategy to 
tackle cancer.   
 
Today, the types of services offered to breast care patients remained relatively unchanged.  The 
extensive period of reform which has taken place over recent times has understandably focused on 
broader issues, such as reducing waiting times and providing high standard and quality care.  Chapter Three: Breast cancer services in the NHS 
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Substantial improvements have been made in this area with services now provided by specialist 
cancer units/centres under a local multidisciplinary team.  However, the broader needs of cancer 
patients remain unmet.  Without question further scope for developing services that better meet the 
needs and expectations of cancer patients still exist. 
3.2.2. Short term care
15 
The current guidelines for the treatment of early breast cancer are as follows:
65   
 
Stages of treatment from the time of diagnosis until the end of curative therapies 
Referral, diagnosis and preoperative treatment 
Providing information and psychological support 
Surgery 
Postoperative assessment 
Endocrine therapy 
Chemotherapy 
Radiotherapy 
Primary systemic therapy 
Complications of local treatment and menopausal symptoms 
Table 3-1 Current guidelines for the treatment of breast cancer 
 
Almost all patients will have first line surgery following a breast cancer diagnosis.  This may 
sometimes be preceded with neoadjuvant chemotherapy to reduce the size of the tumour prior to 
surgery.  Surgery is then followed with or without adjuvant treatments which may include 
chemotherapy, radiotherapy and endocrine therapy.   The treatment regime is determined on an 
individual basis depending on the factors such as tumour size, grade and type, lymph node 
involvement and evidence of metastatic disease.
15 
3.2.3. Long term care
16 
The long term recommended follow-up for breast cancer patients are categorised as follow-up 
imaging and clinical follow up.
65 Clinical follow-up usually last for five years however there is a push 
for this to be reduced for three.  Typically, follow up would occur on an annual basis or earlier if 
requested by the patient. 
 
 
                                                    
15 Short term care is defined as care offered from the time of diagnosis to the end of primary surgery +/- chemotherapy, 
radiotherapy and the commencement of endocrine therapy 
16 Long term care is defined as care offered after the initial treatment for breast cancer and generally occurs at around one 
year post diagnosis if all primary treatments are involved. Chapter Three: Breast cancer services in the NHS 
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3.3.  Summary of NHS breast cancer services 
 
By and large, services provided by the specialist multidisciplinary teams include, surgery, 
radiotherapy, chemotherapy and endocrine therapy. In the treatment pathway set out by NICE, it is 
clear that only one ancillary service i.e. the provision of psychological support is recommended in 
the short term treatment of breast cancer.  There are no recommendations for ancillary services in 
the long term follow-up of breast cancer patients.   
 
The multidisciplinary team responsible for service provision provides a variety of services which 
according to the Manual for cancer services
66 can include both core and ancillary services such as 
Dietetic representation, however in practice this does not occur.  Historically, dietitians provide 
oncology services for patients who require enteral feeding due to compromised digestive systems, 
for example, head and neck cancer patients will often require nasogastric feeding due to surgery 
which renders the patient unable to feed under normal conditions.  As a practising oncology 
Dietitian for many years, the only patients referred were those that required 
supplemental/alternative feeding.   
 
As most breast cancer patients present as over nourished with more than half either overweight or 
obese, these patients are not referred to dietetic services.  It has only been in recent years, that the 
evidence relating to overweight and obesity for this patient group and potentially negative 
outcomes have come to light.  In an audit of all local hospitals (seven in total), none provided 
dietetic input to the MDT.  Having locumed as an Oncology Dietitian in several UK hospitals, this 
situation was mirrored suggesting dietietic services do not contribute to either the short term or long 
terms care of breast cancer patients. 
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3.4.  Developing breast cancer services: The NHS perspective 
 
Public and patient involvement (PPI) has been a characteristic of the health service dating back to 
1974 when Community Health Councils were established.  Since that time, the structures have 
remained relatively unchanged until 2000 with the publication of the NHS Plan.  These changes 
occurred largely as a result of the Kennedy Report 
67 published after the Bristol Royal Infirmary 
Inquiry which investigated serious failures in the management of the care of children at Bristol 
Royal Infirmary who received complex heart surgery.    
 
In making its recommendations the Kennedy report highlighted the need for great emphasis on the 
role of patient and public involvement in the health service.  The report went on to recommend 
patients and the public should be entitled to participate in every aspect of healthcare. 
 
As a direct consequence to this report, giving patients greater choice and greater say became a 
key area of reform for the new NHS.  Today patient and public involvement are supported by both 
policy 
68; there are currently three key policy areas for patient and public involvement; policies that 
promote patient and carer participation in personal health care decisions, policies that promote 
better information and advice for patients and carers and lastly the focus of this chapter, policies 
that promote patient and public involvement in NHS planning, delivery and standard setting, and 
legislation through the “Health and Social Care Act 2001” and guidance 
69.  
 
Whilst acknowledging a constitutional duty to involve patients and the public in healthcare there are 
other potential benefits for PPI.  Patient and public involvement in healthcare is described by the 
Government as key to the modernisation of the NHS being central to improving patients’ 
experiences of health services. 
 
The perceived benefits of patient and public involvement in healthcare include better health 
outcomes, better service delivery and planning, and greater patient experience with the health 
service. 
3.4.1. Evidence of PPI in cancer services 
 
As part of the “Health in Partnership” research programme,  a study entitled “Developing and 
evaluating best practice for user involvement
17 in cancer services” was undertaken collaboratively 
with University of Warwick, University of West England, Macmillan Cancerlink, Bristol Cancer Help 
Centre and the Avon, Somerset and Wiltshire Cancer Services (ASWCS). 
                                                    
17 User involvement is defined as activities involving users to evaluate and develop cancer services.  It is noted by the 
authors that this definition excludes many activities regarded as involvement that related to opportunities for users to 
engage in decision making about their own care. Chapter Three: Breast cancer services in the NHS 
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The project was set up to explore current mechanisms for user involvement, to establish if these 
mechanisms were effective and finally to develop a consensus statement on the suitable scope 
and role of users involvement in the assessment and development of cancer services. 
 
The project was conducted in three stages.  The first stage was a mapping exercise to document 
current ways in which users within ASWCS were involved in cancer services.  The second stage 
was a consensus development exercise.  Interviews were conducted with 37 users of cancer 
services and elicited views on their understanding, experience and satisfaction with user 
involvement.  The final stage of the project was a questionnaire on users’ attitudes toward user 
involvement.  The questionnaire was developed from results from stage two.  The overall outcome 
of the project was the development of a practical guide to help providers develop user involvement 
systems in cancer services.  The twelve key findings from the study were as follows; 
 
 Key findings 
 
1  There is general agreement on the importance of user involvement across the diverse 
professionals that provide and manage services for people with cancer 
 
2  There is general consensus among stakeholders that users should be involved in decisions about 
their care and that the purpose of user involvement should be to improve cancer services 
 
3  There is little agreement among stakeholders about other key issues, including the definition of 
users and the scope of user involvement.  There is a need therefore to develop consensus around 
these areas 
 
4  There is limited evidence of formal user involvement policies in cancer services within NHS 
organisations and there is little designated funding to promote such activities at all levels 
 
5  There is evidence that user involvement is often elided or integrated with complaints procedures 
and/or clinical governance strategies.  When this occurs it increases distrust and resistance among 
staff to undertaking user involvement activities 
Table 3-2 Key findingsChapter Three: Breast cancer services in the NHS 
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6  There is evidence that user involvement often takes the form of ‘one off’ activities.  There is a need 
to develop systematic approaches that integrate a cycle of user involvement into basic service 
practice 
 
7  The most effective forms of user involvement seem to be based on collaboration with the voluntary 
sector.  There is evidence that resources currently provided do not meet the full costs of such 
participation 
 
8  Professional responses are key to the success of user involvement and can also serve as a barrier 
to its development.  There is evidence that categories of professionals perceive and approach user 
involvement in different ways.  Policy and practice needs to be based on a recognition of 
professional experiences and standpoints 
 
9  Professional education and support for user involvement in cancer services is an important 
prerequisite for the development of user involvement.  Where professionals participate in user 
involvement activities, either voluntarily or because they are required to, there is often a 
demonstrable change in their orientation towards users.  Professional education and support can 
also make a difference to the user experience, enhancing general satisfaction with care and with 
information and communication between professionals and users 
 
10  Some users may not want to be involved in the development of cancer services, although 
this may be influenced by the fact that the vast majority do not perceive themselves as 
being asked to be involved.  A third of users surveyed who said that they would like to be 
involved also stated that they did not know how to get involved and were not given 
information about user involvement 
 
11  Less than a quarter of users surveyed had actually experienced involvement: this 
experience primarily related to participation in drug trials, fundraising and questionnaires.  
There was limited evidence of ‘direct’ (i.e. decision making) as opposed to ‘indirect’ (i.e. 
providing information) involvement 
 
12  Among users with a positive orientation to involvement, a variety of methods were preferred 
including giving informal feedback to staff, participating in research and serving as a representative 
on a local NHS committee.  Multiple methods are therefore needed to respond to the different aims 
of user involvement and respond to the preferences of users for getting involved 
 
Table 3.5   Key findings cont 
 
What is striking about these results is that there is little evidence that user involvement in cancer 
service development is taking place.  Users are unsure of how to get involved.  Further, in what 
little involvement there is, it is largely related to participating in cancer research projects, an activity 
that is unlikely to influence service planning or delivery. Chapter Three: Breast cancer services in the NHS 
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3.5.  Breast cancer services: the patients perspective 
Despite little or no voice into the development of breast cancer services in the NHS, the views on 
the types of services breast cancer patients are interested in are widely reported in the scientific 
literature.  The following section reviews the relevant literature from both observational and 
experimental studies. 
3.5.1. Observational studies 
Several observational studies have been conducted exclusively with breast cancer patients or as a 
subgroup within a larger study of cancer patients.  Outcomes reported include the proportion of 
cancer patients reporting dietary change, the nature of these changes and lastly the reasons for 
these reported dietary changes.   The details of these studies are summarised as follows: Chapter Three: Breast cancer services in the NHS 
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Author 
 
Cancer site 
 
Eligible 
 
Agreed 
 
Recruited 
 
Analysed 
 
Outcome measure 
 
Results 
Maunsell et al
70  Breast 
 
282   
 
  250  1.  Describe the nature and frequency of dietary change in 
the year after breast cancer diagnosis 
 
 
2.  Identify characteristics of women more likely to initiate 
such change 
 
3.  Determine whether initiating such change is 
associated with psychological distress, an important 
component of quality of life 
- 41% reported making dietary   
changes 
- Reduction in Meat intake was 
most common dietary change 
 
More likely to be younger 
 
 
Higher initial psychological 
distress associated with initiation 
of dietary change 
Maskarinec et al
71  All  2452  439  143  143 
 
 
 
 
69 
 
 
69 
1.  Describe how cancer patients made long-term dietary 
changes after diagnosis 
 
 
 
2.  Compare commonly adopted nutritional strategies to 
the scientific evidence 
 
3.  Explore the rationale on which the decisions for 
dietary change were based 
- 48% reported making dietary 
changes 
- Increase in vegetable was most 
common dietary change 
 
Not reported in results 
 
 
1.  Increase well-being 
2.  Maintain health 
3.  Prevent recurrence 
4.  Avoid causes of 
cancer 
5.  Eat cancer-preventive 
foods 
6.  Take control 
7.  Follow advice 
Salminen et al
72 73 
 
Breast 
prostate 
    303   
 
Assess patient beliefs among Finnish women suffering from 
breast cancer or rheumatoid arthritis and to clarify the 
sources of information and dietary changes made by the 
patients during treatment and follow-up 
- 30 % of breast cancer patients 
had changed their diet since 
diagnosis 
- reduction in animal fat and red 
meat most commonly change 
reported 
- reasons for dietary change 
were  
1. desire for cure  
2. alleviate symptoms of nausea  
3. follow doctor’s instruction 
Table 3-3 Studies reporting proportions/reasons for dietary changes after a breast cancer diagnosis Chapter Three: Breast cancer services in the NHS 
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Author 
 
 
Cancer 
site 
 
Eligible 
 
Agreed 
 
Recruited 
 
Analysed 
 
Outcome measure 
 
Results 
 
McBride et al
74 
Demark-Wahnefried
10 
 
 
Breast 
Prostate 
 
1667 
 
988 
 
920 
 
920 
 
To explore the relationship between psychological impact of 
cancer diagnosis and motivation for behaviour change 
 
- 47% of breast patients reported 
consuming > 5 serves of fruit and 
vegetables 
- 73% of breast patients 
reportedt fat intake <30% 
- 79% of overall patients were 
interested in health promotion 
programs 
-80% expressed a desire for 
intervention at within first 6 
months after the cancer 
diagnosis 
 
 
Tangney et al
75 
 
 
Breast 
 
212 
 
 
 
118 
 
118 
 
1.  To describe dietary intake and overall diet quality 
2.  To describe symptomatology using Survey of feelings 
and attitudes 
3.  Describe potential interrelationships between dietary 
intake estimates and healthy eating index with 
symptom scores 
4.  Describe DEI, dietary estimates and symptomatoligies 
according to breast cancer stage, receptor status, or 
node status 
 
 
-Mean energy intake 1230 
-50% carbohydrate 
-18% protein 
-32% fat 
-67.2% “needs improvement 
category of healthy eating index 
 
Patterson et al
76 
 
 
Breast 
Prostate 
Colorectal 
 
 
509 
 
504 
 
356 
 
356 
 
1.  Self reported changes in diet, physical activity, and 
dietary supplement use among cancer patients 
diagnosed up to 24 months in the past 
2.  Did patients feel any changes made improved their 
health and well-being 
 
 
-40.4% respondents made 
dietary changes 
-Most common change an 
increase in fruit and vegetables 
-90% of respondents report the 
change improved their health 
and well-being 
 
Table 3-3 cont. Studies reporting proportions/nature/reasons for dietary changes after a breast cancer diagnosis Chapter Three: Breast cancer services in the NHS 
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Author 
 
Cancer site 
 
Eligible 
 
Agreed 
 
Recruited 
 
Analysed 
 
Outcome measure 
 
Results 
 
Blanchard et al
9 
 
 
Breast 
Prostate 
Colorectal 
Non-
Hodgkins 
Lung 
 
572 
   
352 
 
352 
 
1.  To examine whether or not adult cancer survivors 
changed their way of life behaviours since their cancer 
diagnosis 
2.  To examine whether or not a physician 
recommendation had a significant influence on adult 
cancer survivors changing their way of life behaviours 
3.  To conduct exploratory analyses examining the 
potential influence of various demographic variables 
on the way of life behaviour changes in adult cancer 
survivors 
 
 
50.5% reduced fat intake 
43.5% increased fibre 
42.9% reduced red meat 
 
Caan et al (LACE study
77) 
 
   
5656 
 
2614 
 
2321 
   
To examine modifiable way of life predictors of recurrence, 
survival and quality of life 
 
 
Mean energy 1393kcal 
47.9% carbohydrate 
16.8% protein 
34.7% fat 
Fruit 1.95 serves 
Vegetables 2.2 serves 
 
 
Thomson et al
78 
 
 
Breast 
 
7572 
screened 
   
3109 
 
3084 
 
To describe self reported dietary intake patterns before and 
after a breast cancer diagnosis 
 
 
Self reported 
Decrease in red meat (61%) 
Increase in vegetables (60%) 
Increase in fruit (58%) 
Actual changes 
Fruit 2.3 serves for non-changers 
for changers 
Vegetables 2.8 for non-changers 
 3.0 for changers 
Total energy 
- non changers 1727 kcal 
- changers 1721 kcal 
% fat 
- non-changers 29.5% 
- changers 28.5% 
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Author 
 
n = 
 
Age 
 
Cancer 
site 
 
Method of Ax 
           
 
Maunsell et al
70 
 
250 
 
All ages 
 
Breast 
 
Interview 
           
 
Maskarinec et al
71 
 
91 
   
Breast 
 
Interview 
           
 
Salminen et al
72 73 79 
 
303 
   
Breast 
Prostate 
 
Self-admin  
questionnaire 
           
 
McBride et al
74 
Demark-Wahnefried
10 
 
 
978 
 
28-91 
 
Breast 
Prostate 
 
Mailed 
Questionnaire 
           
 
Tangney et al
75 
 
 
117 
   
Breast 
 
Self-
administered 
FFQ 
           
 
Patterson et al
76 
 
356 
 
20-79 
 
Breast 
Prostate 
Colorectal 
 
Telephone 
interview 
           
 
Blanchard et al
9 
 
 
352 
 
No range 
given 
 
All sites 
 
Self 
administered 
questionnaire 
           
 
Caan et al
77 
 
2048 
 
 
18-79 
 
 
Breast 
 
 
Self-
administered 
FFQ 
           
 
Thomson et al
78 
 
3084 
 
18-70 
 
Breast 
 
Telephone 
dietary recalls  
           
                     
                     
                           
                                                                                                          -1                   Diagnosis               1                        2                       3                        4                       5                      >5 
 
Figure 3-1 Studies reporting proportions/nature/reasons for dietary changes after a cancer diagnosis  Years since diagnosis 
   
 
   
 
 
Range not reported  ? 
   
   
 
  
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These studies indicate that the proportion of women making changes to their diets after a breast 
cancer diagnosis range from 30-60%.  These figures compare favourably with those found in the 
general cancer literature suggesting that significant numbers of cancer patients, irrespective of the 
cancer type, make changes to their diets after their diagnosis.  Of interest is that the adoption of 
healthy eating behaviours occurs irrespective of the patient’s belief in the diet-disease relationship.  
For example in a cross-sectional study of 378 breast cancer survivors only 15.5% of respondents 
believed diet was in some way responsible for their disease; however when asked about current 
health behaviours 94.6% reported consuming a healthy diet.
80  These results have been found 
elsewhere in the literature.
81 
 
The most common dietary changes reported were reduction in meat/animal fat and an increase in 
fruit and vegetable consumption which relate well to current nutritional guidelines.  However there 
are reports of negative eating behaviours such as restrictive dieting practices with some women 
eliminating entire food groups.
82  Further dietary modifications are largely found in association with 
the widespread use of supplements which may or may not be of benefit.
83    
 
Overall these studies show that when put into the context of national nutritional recommendations 
for a healthy diet, changes are relatively small and therefore likely to be of little benefit and in some 
cases bear no resemblance to national guidelines. Whilst these results suggest that the majority of 
breast cancer patients are opportunistically making changes to their diets, caution is warranted as it 
could be argued that those patients who adopt healthier way of life behaviours are more likely to 
participate in such studies.   
 
In the studies where the conversion rate from those approached to those who participate in the 
study is calculated, the response rates are of interest.  These ranged from as low as 18% to as 
high as 100%.
9 10 70 71 73-76 78  In general however most of the studies had response rates of around 
50%.  In essence, this could potentially mean that with around half of those surveyed agreeing to 
participate in the study and of those around half report making dietary changes, the actual numbers 
of breast cancer patients making dietary changes in the general population could be as low as 
25%.   
 
Despite this cautionary note, the literature does suggest that dietary changes are both practiced 
and of interest to breast cancer patients.  Further many of these studies
10 74 84 85 report that patients 
believe their health care teams should provide this information.   Chapter Three: Breast cancer services in the NHS 
  71 
3.5.2. Experimental studies 
Several experimental studies have been conducted with breast cancer patients whereby patients 
were invited to participate in dietary intervention studies.  Whilst the purpose of these studies was 
not to assess interest in participating in a nutrition education programme, recruitment rates for 
these studies contribute to the overall understanding in this area. 
 
Table 4.2 charts the conversation rates from invitation to participation in all randomised controlled 
trials conducted with breast cancer patients   
 
The majority of reports did not document the number invited on the trial.  As a proxy marker the 
time taken to recruit participants suggests that it took many years to recruit relatively few patients, 
indicating the uptake for these studies was poor.    
 
For the one study that documented these figures
38 the conversion rate from eligibility to 
randomisation showed that 56% or around half of those invited agreed to participate, supporting 
the evidence found in observational studies. Chapter Three: Breast cancer services in the NHS 
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  Trial  Active 
recruitment 
Time since Dx  Screened  1
st Eligibility  Invited  2
nd 
Eligibility 
Randomised  Completed 
trial 
Completed 
follow-up 
 
1 
 
WINS Stage One -Nutrition Adjuvant 
Study
25 
 
 
 
 
<60days since 
surgery 
 
Not reported 
 
59 
 
59 
 
 
 
 
   
 
2  WINS Stage Two -  feasibility
27 
 
   
<190 days from 
surgery 
 
 
Not reported 
 
Not reported 
 
Not reported 
   
290 
 
155 
 
108 
 
3  WINS Stage Three – RCT
28 
   
<190 days from 
surgery 
 
Not available 
 
Not available 
 
Not available 
   
2437 
 
Not 
available 
 
Not 
available 
 
 
4 
 
WHEL Feasibility
29 
 
 
May 93 
Oct 94 
 
 
<12 months to >55 
months 
 
Not reported 
 
Not reported 
 
Not reported 
   
93 
 
83 
 
83 
 
5  WHEL RCT
30 
 
1995 
2000 
 
Within 4 years of 
Tx 
 
7572 
 
4708 
 
4708 
   
3088 
 
3023 
 
3023 
 
6 
 
Djuric et al (2002)
31 Jen et al (2004)
32 
 
   
Within 4 years of 
Dx 
 
Not reported 
 
Not reported 
 
Not reported 
   
48 
 
37 
 
37 
 
7 
 
Holm (1990) and Nordevang et al 
(1990 and 1992)
33-35 
 
 
1983 
1986 
 
Between 
4-6 months 
 
Not reported 
 
Not reported 
 
Not reported 
   
240 
 
187 
 
169 
 
8 
 
BRIDGES trial
36 
 
   
Not reported 
 
Not reported 
 
Not reported 
 
Not reported 
   
157 
 
146 
 
143 
 
9  de Waard et al (1993)
37 
 
1987 - ? 
 
Not reported 
 
Not reported 
 
107 
 
Not reported 
   
102 
 
94 
  
Not 
reported 
 
10 
 
BCDIP
86 87 
 
 
June 93 
Mar 95 
 
<6 months to >18 
months 
 
Not reported 
 
521 
 
521 
 
 
293 
 
144 
 
110 
 
110 
 
Table 3-4 Randomised controlled trials 
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Author 
 
 
Screened 
 
Eligible 
 
Invited 
 
Agreed to participate 
 
Commenced trial 
 
Completed trial 
 
1. 
 
Goodwin et al
46 88 
 
 
Not reported 
 
Not reported 
 
Not reported 
 
61 
 
61 
 
39 
 
2. 
 
McTiernan et al
47 
 
 
Not reported 
 
 
99 
   
40 
 
 
11 
 
9 
 
3. 
 
Boyar et al
48 
 
 
Not reported 
 
Not reported 
 
Not reported 
 
27 
 
27 
 
18 
 
Table 3-5 Non-randomised trials 
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3.6.  Opportunities for the development of health promotion 
activities in breast cancer services 
Survival rates have improved for most cancers in both men and women in recent years and it is 
expected that they will continue to rise for most cancers in the future.  With this upward trend in 
cancer survival set to continue the long term health issues facing cancer patients has fast emerged 
as a public health concern.
62 At present around one third of cancer patients survive their diagnosis 
and are considered completely cured.  By 2010 this figure could rise to 50% and by 2020 80% of 
people diagnosed with cancer could expect to live a normal lifespan.
89   
  
Despite the recognition that future services need to be developed to meet the needs and 
expectations of the growing number of cancer survivors
59 very little is known about the long term 
issues that this group face.  As such, understanding “Cancer survivorship” was labelled a national 
priority by the National Cancer Research Institute who in 1996 set up the Office of Cancer 
Survivorship (OCS) in the United States.   
 
In order to address “cancer survivorship”, information regarding the issues facing this group was 
required.  Unfortunately these data did not exist.  At the time there were four main sources of 
information on cancer survival.
90  These are described as 
 
1.  The first, the Surveillance, Epidemiology and End Results (SEER) registries provided 
demographic information on cancer survival but no information on health status was 
collected.   
2.  A second source of information came from the National Health Interview Survey which 
provided national data on the health of the US non-institutionalised civilian population.   
3.  The third source was the Childhood Cancer Survivorship study a collaborative, multi-
institutional study of the long term health patients who survived five or more years after 
cancer treatment during childhood or adolescence. 
4.  In addition to these were descriptive reports from survivor cohorts from specific regional 
treatment centres or results from experimental studies. 
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By and large these sources did not provide adequate information in order to commence developing 
a clear strategy for tackling cancer survivorship.  As a result the OCS set about to identify the 
poorly understood needs of cancer survivors and outlined six areas for research development (see 
table 5-1). 
 
Number  Area 
 
1 
 
Descriptive, epidemiologic data on outcomes for cancer survivors who are more 
than one year post diagnosis 
 
 
2 
 
 
Intervention studies that develop and test strategies to prevent or diminish 
adverse outcomes or promote optimal health practices in survivors 
 
 
3 
 
Elucidation of the patterns of care recommended for and received by cancer 
survivors who are post treatment 
 
 
4 
 
Information on the experiences of survivors previously underrepresented in the 
literature 
 
 
5 
 
Instruments that accurately reflect the outcomes for and experiences of survivors 
across the post treatment trajectory 
 
 
6 
 
Research on the impact of cancer on the family 
 
 
Table 3-6 Areas identified for research development 
 
In addition to the work undertaken by the OCS a number of national reports on cancer survivorship 
have been developed through collaborative work with cancer survivors, health care providers, 
researchers and organisations that promote, plan and deliver programmes and services which aim 
to improve the lives of cancer survivors.  The overall message from these reports highlights the 
need for a coordinated public health approach in addressing the needs of cancer survivors.
91 92   
 
In response to this call several initiatives have commenced aimed at addressing these gaps in 
evidence.  The American Cancer Society’s Behavioural Research Center has set up a series of 
three studies collectively know as the “Studies of Cancer Survivors” (SCS).
93  
 
The first study is a national prospective longitudinal study in both men and women which has 
enrolled over 6,000 cancer patients.  The cohort will be followed for up to ten years and health data 
will be collected at one, two, five and ten years after diagnosis.   Chapter Three: Breast cancer services in the NHS 
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The second study is a national cross-sectional study of approximately 10,000 cancer patients in 
three cohorts of two, five and ten year survival categories.  This study will provide data on short, 
medium and long term cancer survivors.   
 
The third study involving over 16,000 cancer survivors and caregivers is comparing the quality of 
life and functioning of cancer survivors to their primary caregiver in the hope of gaining a deeper 
understanding of the issues faced by cancer caregivers.   
 
To date, enrolment of all three studies is complete and it is hoped that the results of these studies 
will help to identify the physical, emotional and social issues faced by long term cancer survivors 
and their families. 
 
Whilst the UK has been slower to engage with this new paradigm for cancer care
18, the 
Government has begun to address these issues and in 2004 the “Supportive and Palliative Care 
Guidelines” 
94 were published detailing ways of improving cancer services in the UK.  The guidance 
defines service models and details recommendations that ensure cancer patients, their families 
and carers receive support and care aimed at helping them cope with cancer and its treatment at 
all stages.  One of the key recommendations of this guidance states that “Commissioners and 
providers working through Cancer Networks should institute mechanisms to ensure that patients’ 
needs for rehabilitation are recognised and that comprehensive rehabilitation services ….are 
available to patients…..”.
94 
 
3.7.  Rationale for study 
 
Despite government policy, procedures and legislation, clearly, patient involvement in the 
development of either general or specialist NHS services such as cancer services are, at present, 
alarmingly underperforming.   
 
There is no question that cancer services have seen dramatic improvements since the publication 
of the NHS Cancer Plan in 2000.  For example, cancer mortality rates are down, we have seen 
improved access and choice to cancer services; better screening and detection for cancer are in 
place, however, the vision of a patient-led NHS is far from a reality. 
 
In acknowledging the expressed needs of breast cancer patients for health promotion activities, 
currently not offered within the NHS, the purpose of the present study was to assess interest in a 
                                                    
18 In the period between submitting the thesis for examination and addressing reviewer’s comments, the UK has launched 
the National Survivorship Initiative, a joint partnership between the Department of Health and Macmillan Cancer Support.  
The purpose of this joint venture is” to consider a range of approaches to survivorship care and how these can be best 
tailored to meet individual patients’ needs”. Chapter Three: Breast cancer services in the NHS 
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group health eating programme in an attempt to provide evidence for health care providers which 
may lead to the expansion of services to include nutrition advice.   
 
3.8.  Chapter Summary 
In summary, we have experienced a major shift in the focus of care for cancer patients from one in 
which interest has turned from acute care to managing long term health. We are now in a position 
where health care providers accept that we need to develop services that address the expressed 
long term health of cancer patients; currently these types of services are not generally part of the 
cancer trajectory.
95   
 
The challenge for the health service is to identify the types of services to develop and to 
understand the best ways in which to deliver these services that overcome barriers such as time, 
resources and expertise
96 that are faced in the NHS. 
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4.0  Methods 
4.1.  Chapter Introduction 
The following chapter describes the methods used to investigate the uptake and response to 
dietary intervention in postmenopausal women newly diagnosed with breast cancer.  The methods 
were developed with representatives from patient, clinical and academic backgrounds. The specific 
roles they played are described in detail where appropriate throughout this chapter. 
 
The chapter begins with an overview of the entire project which consisted of two studies, study one 
used focus groups to ascertain the views of patients in the development of study two (3 phases) 
which offered newly diagnosed postmenopausal women with breast cancer, a series of group 
healthy eating classes. 
 
Both studies are presented separately and within each study the following subsections have been 
utilised; pre study planning followed by study protocol. Chapter Four: Methods 
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4.2.  Project overview 
 
Overall Aims 
 
1. To develop a group healthy eating programme for 
postmenopausal women newly diagnosed with breast cancer in 
partnership with breast cancer patients 
 
2. To understand the factors that influenced enrolment and 
subsequent participation in a “healthy eating” program for 
newly diagnosed postmenopausal women with breast cancer. 
 
3. To assess if a group “healthy eating” program improved the 
diets of newly diagnosed postmenopausal women with breast 
cancer 
 
 
Purpose 
 
 
 
To inform cancer service development initiatives 
 
Study design 
 
Mixed methods – embedded experimental model 
 
Study One: Focus Groups (QUAL) 
 
Study Two:  
 
1. Cross-sectional study (Qual + Quan) 
2. RCT (QUAN) 
3. Cross-sectional study (Qual + Quan) 
 
 
 
Table 4-1 Project summary Chapter Four: Methods 
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Stage One          AIMS 
Focus group     
 
QUAL  
 
   
1.  To develop a group healthy eating programme for postmenopausal 
women newly diagnosed with breast cancer in partnership with 
breast cancer patients 
           
           
Stage Two           AIMS 
1. X-sectional 
 
         
       
Qual 
baseline 
1.  To understand the factors 
that influenced enrolment in 
a group healthy eating 
programme 
    Quan 
baseline 
1.  To estimate the proportion of newly 
diagnosed postmenopausal women with 
breast cancer who enrolled on a group 
healthy eating programme 
 
           
2. RCT           
 
 
 
QUAN 
Premeasure 
       
 
 
QUAN 
Postmeasure 
1.  To assess if a group healthy eating 
programme improved the diets of newly 
diagnosed postmenopausal women with 
breast cancer compared to usual care 
2.  To determine the impact of participating in a 
group healthy eating programme of self 
reported quality of life scores compared to 
usual care 
           
3. X-sectional           
           
 
Qual  
end of study 
1.  To understand the factors 
that influenced participation 
in a group healthy eating 
programme 
     
Quan  
end of study 
2.  To estimate the proportion of newly diagnosed 
postmenopausal women with breast cancer who 
completed a group healthy eating programme 
 
Figure 4-1 Project summary 
  Interpretation based on QUAN(qual) results 
Intervention 
T
I
M
E
 Chapter Four: Methods 
 
  82 
4.3.  Study One – Focus Groups 
4.4.  Pre study planning 
4.4.1. Stakeholder involvement 
4.4.1.1.  NCRN consumer research panel 
As a key component of good clinical practice, the views of patients in the development of the study 
were sought.  A one hour presentation and subsequent discussion session was delivered by the 
Chief Investigator to the group. The presentation gave an overview of the proposed study to gauge 
interest in the project from a cancer patient’s perspective. 
4.4.2. Study approvals
19 
4.4.2.1.  Ethical approval 
Ethical approval was applied for as per standard National Ethics Approval procedures and policies.   
4.4.2.2.  R&D approval 
Research and Development (R&D) approvals were applied for separately for each of the three 
participating NHS trusts, Basingstoke and North Hampshire NHS trust, Portsmouth NHS trust and 
Winchester and Eastleigh Healthcare trust as per standard trust procedures and policies. 
4.4.2.3.  NCRN adoption 
An application was made to the National Cancer Research Network for adoption into the Networks 
Clinical Trials Portfolio as per standard procedures and policies. 
4.4.2.4.  Macmillan Cancer Centre  
Portsmouth Hospitals Macmillan Cancer Centre was approached for approval to conduct the focus 
group at the centre. 
                                                    
19 Dates for applications and approvals appear in the results Chapter Four: Methods 
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4.5.  Study protocol 
4.5.1. Aims 
To engage cancer patients in the development of a group healthy eating programme for newly 
diagnosed postmenopausal women with breast cancer. 
4.5.2. Objectives 
To determine participants’ consensus on the practical elements of the healthy eating programme to 
be offered to postmenopausal women newly diagnosed with breast cancer in study two. 
Specifically, to elicit views regarding the timing, number, duration, location and size of classes, in 
addition to preferred class topics and methods for class delivery.  
4.5.3. Study design 
Qualitative Study Design using Focus Groups.  Focus Groups have been shown to be a useful 
research tool for the purpose of developing new programmes.  They are unique in that they allow 
for group interaction whereby group members influence each other by responding to ideas and 
comments in the discussion.  This results in a greater insight into the topic of interest.
97  
4.5.4. Study participants 
4.5.4.1.  Sampling frame 
Postmenopausal women previously diagnosed with breast cancer at three local NHS trusts, 
Southampton Universities NHS hospitals trust, Portsmouth Hospitals NHS trust and Basingstoke 
and North Hampshire NHS trust. 
4.5.4.2.  Inclusion/exclusion criteria 
Subjects for the focus groups were selected using purposeful sampling so that a diverse group of 
breast cancer patients were involved to ensure a broad range of views/experiences were captured. 
 
Factors deemed important in describing the sampling matrix were as follows: 
  Length of time since diagnosis 
  Age  
  Household size * 
  Employment status * 
* relevant when designing nutrition programmes  
(see Appendix 9-3 for Sampling Matrix) Chapter Four: Methods 
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4.5.5. Screening 
4.5.5.1.  Basingstoke and North Hampshire NHS trust 
Screening was conducted by both the chief investigator and the NCRN research nurse assigned to 
the study.  Patients were randomly selected from a list of previously diagnosed breast cancer 
patients provided by the Breast Unit Data coordinator. Individual medical records were searched by 
hand until a woman representing each of the predetermined criteria in the sampling matrix was 
found. 
4.5.5.2.  Winchester and Eastleigh Healthcare trust 
As above however screening was conducted solely by the chief investigator at this site.  
4.5.5.3.  Portsmouth NHS trust 
As above however screening was conducted solely by the NCRN research nurse at this site.  
4.5.6. Recruitment 
Once potential participants were identified, these patients were contacted by letter asking them if 
they would like to take part in the focus group.  The letter was signed by their Consultant.  
Correspondence (see appendices 9-4, 9-5) included: 
  Covering letter from consultant 
  Patient Information Sheet 
  Consent form (consent obtained on the day of the focus group) 
  GP letter 
4.5.7. Study outcomes 
The focus group was conducted in a non-threatening environment, off hospital premises.   
Expected group size was between 6-12 patients and the session was scheduled to run for 
approximately 1.5 hours.  Light refreshments and travelling expenses were available.    
 
The session was conducted by the chief investigator with the assistance of an oncology nurse 
practitioner and a representative from the National Cancer Research Network’s consumer research 
panel, herself a breast cancer survivor.  The session was conducted with a pre written topic guide 
(see table 4-2). 
 
The information participants gave was anonymous and was used to develop the nutrition 
programme implemented in Study Two.  Focus group participants were offered a copy of the 
results if they wished.  Participation was voluntary and if patients could not come to the group, or 
decided not to attend, they were assured that their future care would not be affected in any way. Chapter Four: Methods 
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Type of 
Question 
 
 
Question 
 
Opening  
 
 
1.  After your diagnosis, did you make any changes to your diet? 
 
 
Introductory 
 
 
2.  If so, did you seek dietary advice to help you make these changes? 
 
 
Transition 
 
3. What other sources did you use to find nutrition information? For 
example,   a health professional, the internet, family/friends. 
 
4. How helpful/unhelpful was the information you found? 
 
 
Key Questions 
 
 
Thinking about your past experiences, if you had the chance to help design 
a nutrition education program for breast cancer patients….. 
 
5. What type of setting would you like to be offered these sessions? 
 
6. Thinking about your cancer journey, when do you think the best time 
would be to schedule the sessions to fit in with your treatment and lifestyle?  
 
7. What size group would be feel most comfortable in? 
 
8. How much time would you be willing to give up to attend these sessions? 
 
9. What are the key nutrition topics you would like to see covered?  
 
10. How would you like the information to be delivered?  For example, 
lecture, group discussion, guest speakers. 
 
 
Ending  
 
11. Suppose you had one minute to talk to the Minister for Health on the 
topic of dietary advice for breast cancer patients, what would you say? 
 
(after a short oral summary by the facilitator) 
 
12. Is this an adequate summary? 
 
(after a short overview of the purpose of the study) 
 
13. Have we missed anything? 
 
 
Table 4-2 Topic guide for focus groups Chapter Four: Methods 
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4.5.8. Adverse Reactions and Their Management 
Although there were no anticipated adverse reactions associated with taking part in focus groups, 
each patient’s Clinical Nurse Specialist was advised of participation and was available to discuss 
any issues with the patients if they so chose. 
4.5.9. Statistical analysis 
Data were analysed manually using quantitative analyses.  
4.5.10.  Data Collection 
Sessions were tape recorded as well as handwritten notes taken and transcribed at a later date. Chapter Four: Methods 
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4.6.  Study Two – Stages one, two and three 
4.7.  Pre study planning 
4.7.1. Stakeholder involvement 
4.7.1.1.  Steering Group  
Prior to the writing of the following research protocol for Study Two, a steering group was set up.  
In total, sixteen senior clinical and academic staff was invited to attend the meeting where the 
background to the proposed study was presented by the chief investigator.  At the end of the 
presentation, one hour was scheduled for discussion. 
 
The purpose of creating a steering group was threefold.  Firstly, it provided an opportunity for the 
chief investigator to gauge interest and receive feedback in the proposed study and secondly, it 
was hoped that by engaging senior clinical and academic staff in the design of study two, it would 
result in a research protocol that had been vigorously scrutinised by peers, thus potentially 
improving the likelihood of success of the study.  Lastly, for more personal reasons, it was a 
networking exercise which could potentially benefit the chief investigator in future research 
projects.  
4.7.1.2.  Local stakeholder involvement 
In order to gain local clinical support for the study, a request was made to present at the breast 
cancer multidisciplinary team meeting.  By engaging breast unit staff early, it was anticipated that 
any issues/concerns regarding the study could be raised and dealt with prior to study 
commencement. 
4.7.1.3.  NCRN consumer research panel 
As a key component of good clinical practice, the views of patients in the development of the study 
were sought.  A one hour presentation and subsequent discussion session was delivered by the CI 
to the group. The presentation gave an overview of stage two of the study.  Specifically, patients’ 
views were elicited on both the appropriateness and perceived burden of the questionnaires 
proposed for use with the study. Chapter Four: Methods 
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4.7.2. Study approvals 
4.7.2.1.  Ethical approval 
Ethical approval was applied for as per standard National Ethics Approval procedures and policies.   
4.7.2.2.  R&D approval 
Research and Development (R&D) approvals were applied for separately for each of the two 
participating NHS trusts, Portsmouth NHS trust and Southampton Universities NHS Hospitals trust 
as per standard trust procedures and policies. 
4.7.2.3.  NCRN adoption 
An application was made to the National Cancer Research Network for adoption into the Networks 
Clinical Trials Portfolio as per standard procedures and policies. 
4.7.2.4.  Randomisation service 
An application was made to the Birmingham Clinical trials unit to conduct telephone randomisation 
for the randomised controlled trial.  
4.7.2.5.  Macmillan Cancer Centre  
Two Macmillan Cancer Centres were approached, Portsmouth NHS trust and Southampton 
Universities Hospitals NHS trust for approval to conduct the group healthy eating classes at the 
respective centres. 
4.8.  Study protocol 
4.8.1. Aims, Objectives and Hypotheses 
Refer table 4-3 
4.8.2. Study design 
A mixed methods study design was employed (embedded experimental model).  In total, the study 
was conducted in three phases, phase one at baseline and phases two and three at follow-up (see 
figure 4-1) 
 
Study Two:  
 
Stage 1. Cross-sectional study (Qual + Quan) 
Stage 2. RCT (QUAN) 
Stage 3. Cross-sectional study (Qual + Quan) Chapter Four: Methods 
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Stage  Aims  Objectives  Hypothesis 
2.1  1.  To estimate the proportion of newly diagnosed 
postmenopausal women with breast cancer who 
enrolled on a group “healthy eating” programme 
2.  To understand the factors that influenced 
enrolment in a “healthy eating” programme 
 
1.  To invite 400 newly diagnosed postmenopausal women 
with breast cancer to a group “healthy eating” 
programme during the recruitment period of six months 
2.  To describe the factors that determined whether or not 
newly diagnosed postmenopausal women with breast 
cancer enrolled on a “healthy eating” programme 
 
1.  50% of newly diagnosed 
postmenopausal women with 
breast cancer will enrol in a 
“healthy eating” programme 
 
2.2  1.  To assess if a group “healthy eating” programme 
improved the diets of newly diagnosed 
postmenopausal women with breast cancer 
compared with usual care 
2.  To determine the impact of participating in a 
“healthy eating” programme on self reported 
quality of life scores compared with usual care  
1.  To compare change in overall diet quality scores in the 
“healthy eating” group with usual care 
2.  To compare difference in weight change in the “healthy 
eating” group with usual care 
3.  To compare self reported quality of life scores in the 
“healthy eating” group with usual care 
1.  Difference in change of overall diet 
quality scores would be 10 points 
higher for women in the “healthy 
eating” group compared to women 
in usual care. 
2.  Difference in weight change over the 
course of the intervention would be 
3 kgs less in women enrolled in the 
“healthy eating” group compared to 
women in usual care. 
2.3  1.  To understand the factors that influenced 
participation in a “healthy eating” programme 
 
1.  To describe the factors that determined whether or not 
newly diagnosed postmenopausal women with breast 
cancer completed a  “healthy eating” programme 
 
 
 
Table 4-3 Summary of aims, objectives and hypotheses Chapter Four: Methods 
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Figure 4-2 Participant flow 
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4.8.3. Study participants 
4.8.3.1.  Sampling frame 
All postmenopausal women newly diagnosed with breast cancer at two local NHS trusts, 
Southampton Universities NHS hospitals trust and Portsmouth Hospitals NHS trust. 
4.8.3.2.  Inclusion/exclusion criteria 
All post-menopausal women newly diagnosed with breast cancer were eligible to enter the trial.  
There were no exclusion criteria as this trial is a pragmatic trial intended to mimic a real life 
programme which could be feasibly implemented into the National Health Service. 
 
As an inclusive trial, it was possible that a small number of women newly diagnosed with breast 
cancer would have metastatic disease.  If this group of women wished to participate in the “healthy 
eating” programme, they were allowed to enrol as there are no contraindications to following a 
healthy diet.  However, if the Dietitian delivering the “healthy eating” programme assessed the 
patient as at nutritional risk, they were immediately referred for individual dietary counselling by the 
Dietetic Department at the respective NHS trust.   
4.8.4. Screening  
Several methods for identifying patients at the time of a breast cancer diagnosis were employed, 
including review of the breast unit’s cancer register, attending the breast teams’ multidisciplinary 
meetings and liaising with the breast unit coordinator.  As a member of the wider breast unit team, 
the precise method employed by the NCRN research nurse was left to their discretion. 
4.8.5. Recruitment 
Patients were sent a covering letter (appendix 9-13) signed by the lead Consultant surgeon at the 
participating NHS trust along with the patient information sheet (appendix 9-14) approximately one 
week after discharge from their primary surgery.   
 
One week after receiving the letter a specialist research nurse from the Breast Unit telephoned the 
patient to see if they were considering entering the trial.  If at that time patients expressed an 
interest in participating in either the “healthy eating” programme (study two phase two or the 
enrolment study (study two phase one), the nurse made arrangements to meet the patient during 
their next outpatient appointment where they were formally consented (appendix 9-15) to the trial.  
Once consented, patients GP’s were notified of their involvement in writing (appendix 9-16). 
 
Recruitment figures were scheduled to be emailed on a proforma document (provided by the CI) at 
the end of each month to the chief investigator over the course of the six-month intervention.  The 
purpose of the monthly recruitment notifications was to monitor recruitment to the nutrition 
programme.   Chapter Four: Methods 
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4.8.6. Outcomes Measures 
4.8.6.1.  Stage 1 - Cross-sectional study - Baseline 
4.8.6.1.1.  Primary outcome – Enrolment  
The primary outcome measure was to estimate the proportion newly diagnosed postmenopausal 
women who enrolled on the group healthy eating programme.   
4.8.6.1.2.  Secondary outcome – Health determinants 
The secondary outcome measure was to understand the factors that influenced enrolment in the 
group healthy eating programme.   
 
Health determinants were assessed using the following questionnaires.  All questionnaires are 
validated and are widely used to assess health related behaviours. 
  Rosenberg’s self esteem scale
98 (appendix 9-8) 
  A ten item Likert scale with answers to each item scored on a four point scale – 
from strongly agree to strongly disagree.  Scores are summed for each item.  The 
higher the score, the higher the self esteem 
 
  Multidimensional health locus of control (MHLC)
99 (appendix 9-9) 
  The MHLC is a self administered questionnaire that takes about five minutes to 
complete. The questionnaire has a total of 18 items, and used a six point likert 
scale for responses.  The 18 items are categorised into the three separate 
subscales, and provides a measure of three dimensions of health locus of control, 
internality, chance and powerful others.  Separate scores for each subscale are 
derived by summing the scores on the six items in each subscale.  The score on 
each item ranges from 1 = strongly agree to 6 = strongly disagree resulting in a 
scoring range for each subscale of 6-36. 
 
  Self rated overall health (appendix 9-10) 
  A self rated 5 point likert scale – from poor to excellent 
 
  Food frequency questionnaire (FFQ)
100 (appendix 9-11) 
  The Health Education Authority Health and Way of life Survey (HEA3), a validated 
42 item FFQ which asks participants to describe their eating habits over the 
previous seven days will be used to collect dietary information.  It is a simple self 
administered dietary assessment tool based on portion size and food frequency 
which takes about ten minutes to complete.   
  Socio-demographic variables 
  Age Chapter Four: Methods 
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  Education 
  Occupation 
  Income 
  Postcode 
  Anthropometric measures 
  Height 
  Weight 
4.8.6.2.  Stage 2 – Randomised Controlled Trial  
4.8.6.2.1.  Primary outcome 
Diet quality scores, weight and quality of life scores were measured at baseline and at six months.   
4.8.6.2.2.  Diet quality score 
Diet quality was assessed based on the Diet Quality Index-Revised (DQI-R).
101 The DQI-R was 
chosen for its simplicity and ease of administration.  The primary aim of this study was to 
understand factors that influenced enrolment on a “healthy eating” programme and therefore 
patient burden was a major consideration in selecting a dietary assessment tool.  The DQI-R 
provided an estimate of diet quality relative to national dietary recommendations and is validated 
and used widely to measure eating patterns.   Differences over time in scores derived from the 
DQI-R should reflect overall relative improvements in eating patterns.  The index comprised ten 
components with scores derived from how closely the estimated intake met the target intake as 
indicated by prevailing dietary recommendations.  Each of the ten components contributed a 
maximum of ten points to the overall DQI-R score with overall scores ranging between 0-100. 
 
For the purposes of this study, a limited number of modifications to the original index were made.  
Six of the original categories were retained* (see table 4-4) to make five categories in the modified 
DQI-R (fruit and vegetables which are separate categories in the original index have been 
combined).  Four new categories were assigned which reflect UK national dietary guidelines as 
outlined in the “Balance of Good Health” which formed the basis of the “healthy eating” programme. 
 
 Chapter Four: Methods 
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  Dietary Component   Scoring 
Criteria 
Score 
 
1 
 
Total fat < 30% energy intake 
 
< 30% 
30 - < 40 
>40 
10 
5 
0 
 
2 
 
Saturated fat < 10% % energy intake 
 
< 10% 
10 - < 13 
> 13 
10 
5 
0 
 
3 
 
5 servings of fruit and Vegetable per day
+ 
> 100% 
50 – 99 
<50 
10 
5 
0 
 
4 
 
5 servings of breads, cereals and potatoes 
 
> 100% 
50 – 99 
<50 
10 
5 
0 
 
5 
 
3 serves of meat, fish or alternatives 
 
> 100% 
50 – 99 
<50 
10 
5 
0 
 
6 
 
3 serves of dairy  
 
> 100% 
50 – 99 
<50 
10 
5 
0 
 
7 
 
Alcohol consumption < 3 units per day 
 
<3 
3 
>3 
10 
5 
0 
 
8 
 
Sodium <2500mg per day 
 
< 2500 mg 
2501 – 3000 
>3000 
10 
5 
0 
 
9 
 
Dietary diversity score 
> 6 
> 3 - <6 
<3 
10  
5 
0 
 
10 
 
Dietary moderation score 
> 7 
> 4 - <7 
<4 
10 
5 
0 
  Total Score     
100 
 
Table 4-4 Modified Diet Quality Index Score 
 
The outcome measure for diet quality was the differences in change of diet quality scores.   Chapter Four: Methods 
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4.8.6.2.3.  Secondary Outcomes 
4.8.6.2.4.  Weight  
Body weight was measured to the nearest 0.1kgs.  The outcome measure for weight was the 
differences in change of weight. 
4.8.6.2.5.  Quality of life  
The FACT-ES 
102 (appendix 9-12) is a validated questionnaire designed to measure quality of life of 
women with breast cancer who are being treated with endocrine therapies.  The FACT-ES 
measures five aspects of quality of life, physical, social/family emotional and additional concerns 
specific to breast cancer.  Quality of life was measured at baseline and six months. 
 
4.8.6.3.  Stage 3 - Cross-sectional study – Follow up 
4.8.6.3.1.  Primary outcome – Health determinants  
The primary outcome measure was to estimate the proportion of newly diagnosed postmenopausal 
women with breast cancer who completed a group healthy eating programme. 
4.8.6.3.2.  Secondary outcome – Health determinants 
The secondary outcome measure was to understand the factors that influenced participation in a 
group healthy eating programme.   
 
Health determinants were assessed using the following questionnaires.  All questionnaires are 
validated and are widely used to assess health related behaviours. 
  Rosenberg’s self esteem scale
98 (appendix 9-8) 
  A ten item Likert scale with answers to each item scored on a four point scale – 
from strongly agree to strongly disagree.  Scores are summed for each item.  The 
higher the score, the higher the self esteem 
 
  Self rated overall health (appendix 9-10) 
  A self rated 5 point likert scale – from poor to excellent 
 
  Food frequency questionnaire (FFQ)
100 (appendix 9-11) 
  The Health Education Authority Health and Way of life Survey (HEA3), a validated 
42 item FFQ which asks participants to describe their eating habits over the 
previous seven days will be used to collect dietary information.  It is a simple self 
administered dietary assessment tool based on portion size and food frequency 
which takes about ten minutes to complete.   
  Socio-demographic variables Chapter Four: Methods 
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  Age 
  Education 
  Occupation 
  Income 
  Postcode 
  Anthropometric measures 
  Height 
  Weight 
4.8.7. Sample size 
4.8.7.1.  Stage 1 – Cross sectional Study 
4.8.7.1.1.  Primary Outcome 
4.8.7.1.2.  Enrolment  
With 400 participants and a proportion of women agreeing to enrol of 50%, the true proportion 
agreeing to enrol can be estimated within a width of +/- 5%, with 95% confidence 
4.8.7.2.   Stage 2 – Randomised Controlled Trial 
4.8.7.2.1.  Primary Outcome 
4.8.7.2.2.  Difference in diet quality scores 
With a predicted enrolment rate of 50% and allowing for a 20% loss to follow-up, 160 women (80 
per group) would remain at the end of the six month follow-up period.  With 160 women the study 
would have more than 90% power to detect a mean difference of change in dietary scores of 10 
points or more.  A two sided 5% level of significance and standard deviation of 12kg was 
assumed
103).  A difference of 10 points in diet quality scores was considered clinically significant. 
4.8.7.2.3.  Secondary Outcome 
4.8.7.2.4.  Differences in weight change 
Chlebowski et al (1993) reported a mean weight difference at six months of 3.26 + 5.5 (mean and 
SD) between two groups of postmenopausal breast cancer patients enrolled in a dietary 
intervention study.  With 160 women (80 per group) the study would have 80% power to detect a 
mean difference in change of weight of 3kg or more.  A two-sided 1% level of significance and 
standard deviation of 5.5kg was assumed.   A difference of 3 kgs was considered clinically 
significant. Chapter Four: Methods 
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4.8.7.3.  Stage 3 – Cross-sectional study – Follow up 
No sample size calculations were conducted for stage three. 
4.8.8. Randomisation 
Telephone randomisation was utilised in this trial.  The Birmingham Clinical Trials unit provided the 
randomisation service.  All baseline data was collected before group allocation occurred. 
4.8.9. Blinding 
As usual care for this group of patients is no routine dietetic contact; it was not possible to blind 
participants to their group allocation.   
4.8.10.  Data collection 
All data was to be collected in person by the NCRN research nurse. This procedure was 
highlighted both verbally (at the training session) and in writing (within the training manual). 
4.8.11.  Intervention schedule 
The intervention schedule was developed through focus group work with breast cancer patients 
conducted in study one. 
 
Patients consenting to participate in the group “healthy eating” programme were required to attend 
4 x 2 hour sessions.  After the first class patients could choose when to attend the remaining three 
classes which did not have to be attended in order.  This allowed some degree of flexibility for 
patients.  Patients were asked to complete all four classes within six months of commencing the 
“healthy eating” programme.    
 
With approximately 200 new diagnoses expected in each of the two proposed trusts over the 
course of the six month recruitment period and assuming a 50% enrolment rate, it was anticipated 
that numbers in the “healthy eating” classes would average around eight.  Classes were held in the 
training rooms of the Macmillan Centres at each of the proposed sites. 
 
The classes were delivered by the Chief Investigator, a State Registered Dietitian, registered with 
the Health Professionals Council.  Classes were based on the “Balance of Good Health”.  The 
“Balance of Good Health” was produced by the Food Standards Agency, and is based on the 
Government’s guidelines for a healthy diet.
104  The guide is comprised of five food groups and its 
key message is that both balance and variety are important for health. The aim of the programme 
was on improving general health and well-being of participants.  In addition, nutrition during 
treatment and alternative diets and supplements were covered. Chapter Four: Methods 
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Lesson  Topics Covered  Learning Outcomes 
1  Introduction 
Nutrition during cancer treatments 
Alternative diets/supplements 
Participants will be able to 
-Understand common nutrition problems that occur 
during cancer treatments 
-Understand how to optimise nutrition during cancer 
treatments 
-Make informed choices about complementary 
and/or alternative therapies 
2  The balance of good health
104  Participants will be able to 
-Understand the ‘balance of good health’ 
-Identify the five food groups 
-Be familiar with and recall nutrients provided by the 
five good groups and their roles in the body 
-Calculate recommended portion sizes 
-Count portions 
-Be familiar with and recall safe levels of alcohol 
consumption 
3  Cutting down on sugar, salt and fat 
Understanding food labels 
Eating out 
Participants will be able to 
-Understand how to reduce salt, sugar and fats in 
the diet 
-Demonstrate the ability to read and understand 
food labels 
-Describe how to choose healthy options when 
eating out 
4  Menu planning workshop  Participants will be able to 
-Plan a balanced weekly menu 
 
Table 4-5 Details of nutrition education classes 
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4.8.12.  Quality control measures 
4.8.12.1.  Screening and recruitment 
Screening and recruitment was conducted by a specialist National Cancer Research Network 
Clinical Trials Nurse.   
 
To provide a further level of quality control measures, a training session conducted by the chief 
investigator supported by a written training manual was undertaken with the relevant research staff.  
At this session, all aspects of the trials procedures were discussed in detail with the staff involved.  
At that point an opportunity to raise any issues/concerns that required clarification was presented.   
4.8.12.2.  Data 
4.8.12.2.1.  Diet quality  
Each participant was to be given both verbal and written instructions on how to complete the food 
record by the NCRN research nurse consenting the patient to the trial at baseline and at six months 
follow-up.  The questionnaires were to be checked for accuracy and completeness at that time.   
4.8.12.2.2.  Weight  
Weights were measured on calibrated scales by a trained nurse.   
4.8.12.2.3.  Quality of Life 
Each participant was to be given both verbal and written instructions on how to complete the 
FACT-ES by the NCRN research nurse consenting the patients to the trial at baseline and six 
months.  The questionnaires were to be checked for accuracy and completeness at that time.   
 
All data was to be collected in person by the NCRN research nurse. This procedure was 
highlighted both verbally (at the training session) and in writing (within the training manual).  
Further all data was set up to be electronically scanned independently by the School of Medicine’s 
IT department who at study closure would provide a results spreadsheet. 
4.8.12.2.4.  Healthy eating classes 
Lesson plans which clearly outlined the content and timing of how the class will be conducted were 
prepared prior to the commencement of the programme.  This ensured uniformity in the delivery of 
the “healthy eating” programme throughout the intervention period.   Chapter Four: Methods 
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4.8.13.  Study period 
Task  Date 
Recruitment commenced  1 April 2007 
Recruitment closed  30 September 2007 
1
st group commenced intervention  1 May 2007 
Last group commenced intervention  1 October 2007 
Last follow-up  31 March 2008 
TOTAL TRIAL PERIOD  April 2007 – March 2008  
 
Table 4-6 Trial dates 
4.8.14.  Data collection 
  Stage 1 
 
Stage 2 
Baseline 
 
Stage 2 
6 months 
Rosenberg’s self esteem scale
98  √    √ 
MHLC
99  √    x 
Self rated overall health  √    √ 
Food frequency record  √    √ 
Socio-demographic data  √    x 
Height (m)  √    x 
Weight (kg)  √    √ 
Fact-ES  x  √  √ 
 
Table 4-7 Data collection points 
4.8.15.  Data analysis 
All data forms were to be delivered in a sealed envelope to the School of Medicine’s IT department 
for electronic scanning.  Once data collection was completed, a final results spreadsheet was to be 
given to the CI for analysis by the principal investigator.   
4.8.15.1.  Stage 1– Cross sectional study 
4.8.15.1.1.  Enrolment  
The proportion of women who agreed to enrol on the “healthy eating” programme was reported 
with a 95% confidence interval. 
4.8.15.1.2.  Health behaviour determinants Chapter Four: Methods 
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Logistic regression was used to predict whether or not women chose to enrol in the “healthy eating” 
programme using questionnaire data and diet quality scores. 
4.8.15.2.   Stage 2 – Randomised controlled trial 
4.8.15.2.1.  Diet quality, weight and quality of life 
Intention to treat (ITT) analysis was performed on the primary outcome on all subjects who were 
randomised. Per protocol analysis was also performed on the primary outcome. The primary 
outcome was the change in dietary score (at 6 months after enrolment compared to baseline). The 
outcomes of the two groups (usual care and “healthy eating” programme) were evaluated using 
ANCOVA (analysis of covariance), reporting the difference in scores with 95% confidence interval.  
 
The secondary outcome of change in weight was also analysed using ANCOVA, but used a 
significance level of 1%. The change in quality of life scores was explored using ANCOVA.  
 
All outcome variables were checked for the assumption of normality.  If the assumption was not 
met, data transformations or equivalent non-parametric tests were conducted.  SPSS for Windows 
(SPSS Inc., Chicago) and STATA for Windows (StataCorp) were the statistical packages of choice. 
The study was reported in accordance with the CONSORT (Consolidated Standards of Reporting 
Trials) statement and ICH Guidelines for Good clinical Practice. 
4.8.15.3.  Stage 3 – Cross sectional study 
4.8.15.3.1.  Health behaviour determinants 
Logistic regression was used to predict whether or not a) women completed the “healthy eating” 
programme and b) whether women improved their diets using questionnaire data and diet quality 
scores.  An exploratory logistic regression analysis was performed to assess whether the number 
of classes attended was a factor in women’s ability to complete and/or improve their diets. 
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5.0  Results 
5.1.  Chapter introduction 
The following chapter presents the findings of this study.  Each study is presented separately.  
Study one – Focus Groups is presented first followed by study two.   As study two failed to achieve 
its aims and objectives, and therefore produced limited outcome data only stage one (uptake) 
results are presented in this chapter.  Results from stages two and three can be found in appendix 
9-18 for information purposes only.   
5.2.  Study One – Focus groups 
5.3.  Pre study planning 
5.3.1. Stakeholder involvement 
5.3.1.1.  NCRN consumer research panel 
A meeting was held with the local NCRN user group prior to commencement of the PhD in the pre 
funding planning stage.  From there, panel members nominated themselves for further 
involvement.  Three members provided expertise resulting in fine tuning of both the Patient 
Information Sheet (PIS) and the focus group question template.   
5.3.2. Study approvals 
5.3.2.1.  Ethics 
Stage of application  Date 
Prepared  September 05 - November 05. 
Submitted  The ethics application was lodged on 21 October, 2005 
Reviewed  18 November, 2005 
Provisional approval granted  2 December, 2005 
Final approval granted  A favourable ethical opinion on 27 December, 2005 by the 
Southampton & South West Hampshire Research Ethics 
Committee B (REC Reference Number – 06/Q1704/144). 
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5.3.2.2.  R&D  
Stage of application  Date 
Prepared  September 05 – November 05 
Submitted  23 November, 2005 
Approval granted 
NHHT 
WEHT 
Portsmouth 
 
13 February 2006 
Not granted 
6 January 2006 
 
5.3.2.3.  NCRN adoption 
Stage of application  Date 
Prepared  September 2005 
Submitted  October 2005 
Outcome  Rejected.  Advised to resubmit project as two separate 
applications for each study. 
Study One submitted  9 December 2005 
Approval granted  April 2006 
5.3.2.4.  Macmillan Cancer Centre 
Stage of application  Date 
Prepared  September 2005 
Approval granted  October 2005 
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5.4.  Study protocol 
5.4.1. Aims and objectives 
The aims and objectives of the focus group were met. The results are presented in 5.4.6. 
5.4.2. Study design 
As the focus groups aims and objectives were met, the study design was appropriate for the 
research questions. 
5.4.3. Study participants 
5.4.3.1.  Sampling frame 
The proposed sampling from three local NHS trusts was not achieved. The results are presented in 
table 5-1. 
5.4.3.2.  Inclusion/exclusion criteria 
Due to a poor response from the initial mail out and subsequent changes to focus group 
participants, the proposed sampling matrix developed to ensure inclusion of diverse group of breast 
cancer patients was not achieved. 
5.4.4. Screening 
Despite recruitment problems, the initial screening procedures were conducted as planned.  
Participants were selected and subsequently invited to attend one of the three proposed focus 
groups, in accordance with the sampling matrix.  In two sites however, two categories from the 
sampling matrix were not met as no patients could be identified as meeting the criteria.  This 
resulted in sixteen rather than eighteen invitations being sent out for those two sites (see table 5-1).  
5.4.5. Recruitment 
Three NHS trust sites agreed to conduct one focus group respectively as per the sampling matrix.  
Reponses to invitations were as follows: 
  Agreed  Declined  No Reply  Total invites 
Trust One  4  2  10  *16 
Trust Two  1  5  12  18 
Trust Three  3  5  8  *16 
TOTAL  8  12  30  50 
 
Table 5-1 Response to focus group invitations 
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As a result of the poor response rate from initial mailing (refer table 5-1) the desired sampling 
frame was not achieved. Consequently an alternative recruitment approach was employed.  At the 
recommendation of the breast care nurses, presentations were made to two of the three trusts’ 
breast cancer support groups.  For those women who were interested in taking part in the focus 
groups, contact details of the chief investigator were provided.  This recruitment strategy resulted in 
the running of one focus group on May 23, 2006.   
 
Of the seven women participating in the focus group, all but one were post menopausal (85.7%), 
three women received surgery alone (42.8%), two women had both surgery and radiotherapy 
(28.6%) and the remaining two had surgery alone (28.6%). Just over half of the women (57.1%) 
lived alone (Table 5-2).  
 
  Diagnosis 
date 
Treatment Received  Employed  Post 
Menopausal 
Living 
alone 
    Surgery  Surgery + 
Radiotherapy 
Surgery + 
Chemotherapy + 
Radiotherapy 
     
1  Oct 05      √  √  √  √ 
2  May 01    √    √  √  √ 
3  Sept 01  √      √  √  √ 
4  Mar 05  √      √  √  x 
5  Jan 05    √    √  √  √ 
6  May 01      √  √  x  Data not 
provided 
7  Jun 02      √  x  √  √ 
  TOTALS  2/7  2/7  3/7  6/7  6/7  5/6 
 
Table 5-2 Participant characteristics Chapter Five: Results 
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5.4.6. Study outcomes  
As stated in the protocol, unlike many focus groups where the aim is to explore patients’ feelings 
and thoughts, the purpose of the focus groups in this study was a more qualitative exercise held to 
elicit patients’ preferences on the practical aspects of the nutrition education classes.  In total, six 
aspects of the nutrition education programme were discussed.  Patients were offered a choice of 
several options in each aspect, with the view that where a clear majority was evident, these 
choices would be incorporated into the design of the “healthy eating” programme. The results were 
as follows: 
5.4.6.1.  Introductory questions 
5.4.6.1.1.  Question one 
Of the seven women attending the focus group, four women reported changing their diet at the time 
of diagnosis. The remaining three reported changing their diet approximately six months after 
diagnosis. 
5.4.6.1.2.  Question two  
All seven women sought nutrition advice to help them make changes to their diet.   
5.4.6.1.3.  Question three 
When asked where they went for this information a variety of sources were reported. 
 
Source  Count  Rating 
    Very 
unhelpful 
Unhelpful  Neither 
helpful or 
unhelpful 
Helpful  Very 
helpful 
Books  6    1      5 
Bristol Cancer Clinic  2          2 
Internet  2          2 
Newspapers/magazines  7          7 
Lecture  2        1  1 
Macmillan Centre  7          7 
Hospital leaflets  1      1     
Other cancer patients  7          7 
Breast Care Nurse  2    1  1     
 
Table 5-3 Sources of nutrition information 
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The most common sources of nutrition information for participants was the Macmillan Centre (n=7), 
newspapers and magazines (n=7), and other cancer patients (n=7).  Interestingly, information was 
only sought from one health care professional (Breast Care Nurse) and the information was found 
to be unhelpful or neither helpful nor unhelpful. 
5.4.6.2.  Key questions 
5.4.6.2.1.  Question four 
Participants were asked where they thought the classes should be held.  They were given a choice 
between running the classes on hospital premises or, alternatively, classes could be held externally 
(such as a local library facility). 
 
All participants agreed that attending the classes on hospital premises would be preferable. The 
venue should be chosen with the following factors in mind: 
  Comfortable room 
  Not in a clinical area 
  Comfortable chairs 
  Positive attitude of staff working in the area chosen 
  Room should contain resources for cancer patients 
  Tea/coffee making facilities should be available 
5.4.6.2.2.  Question five 
Participants were asked by whom and when it would be best to approach patients to enrol on the 
study.  All participants agreed that they would prefer to be approached by the breast care nurse on 
the ward whilst they were in hospital for their surgery. 
5.4.6.2.3.  Question six 
The majority felt the best time to commence the classes would be no sooner than four to six weeks 
after their breast cancer diagnosis. This often corresponded to the time after surgery and before 
further treatment such as chemotherapy or radiotherapy. 
5.4.6.2.4.  Question seven 
Participants were asked their preference regarding optimal class size.  The group felt that a 
minimum of six and a maximum of ten would be ideal. 
5.4.6.2.5.  Question eight 
Participants were initially asked to estimate the length of time, in their opinion it would take to teach 
a “healthy eating” programme.  Opinion was divided with estimates ranging from one hour (n=1), 
three hours (n=1), 4-5 hours (n=4) and ten hours (n=1).   
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Participants were then asked over how many sessions the programme should be run.  Again, 
opinion was divided with preferences of two sessions (n=1), four sessions (n=3) and six sessions 
(n=3) cited. 
 
After being advised that the total time allocated to deliver the programme would be eight hours20, 
they were then asked to decide between four x 2 hour sessions or eight x 1 hour sessions.  All 
agreed that four x 2 hour sessions would be preferable, with around half dedicated to education 
and the latter half for discussion and questions. 
5.4.6.2.6.  Question nine 
Participants were asked what key nutrition topics would they like covered in the classes in the 
context of a “healthy eating” programme.  A range of topics were suggested and included; 
  Vegetarianism 
  Dairy free diets 
  Alcohol 
  Osteoporosis 
  Smoking 
  5-a-day 
  Organic 
  Water – bottled or tap 
  Fibre 
  Food additives 
  Food supplements 
 
                                                    
20 Based on healthy eating programme in WINS UK Chapter Five: Results 
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From this list, participants were then asked to individually prioritise no more than five areas and 
record their preferences on paper. Lists ranged from three to six suggestions. 
 
Topic  Count  Percentage of 
participants 
choosing topic  
Alternative diets (dairy free, vegetarianism)  7/7  100 
Food supplements  5/7  71.4 
Nutrition during treatment  4/7  57.1 
Organic foods  3/7  42.9 
Ideal body weight  3/7  42.9 
Osteoporosis  2/7  28.6 
Alcohol  2/7  28.6 
Food additives  1/7  14.3 
Water (bottled or tap)  1/7  14.3 
 
Table 5-4 Number of times topics cited by individual participants  
 
All participants (100%) cited interest in alternative diets, closely followed by food supplements 
(71.4%) , cited by five of the seven women, nutrition during treatment, cited four times (57.1%), 
ideal body weight, cited three times (57.2%), osteoporosis, cited twice (28.6%), alcohol, cited twice 
(28.6%), food additives, once (14.3%) and lastly water, once (14.3%) see table 5-4. 
5.4.6.2.7.  Question ten 
Participants were asked to suggest different ways in which the class convenor could deliver the 
information.  The following methods were suggested; 
  Presentation 
  Question/discussion time 
  Videos 
  Practical sessions such as taste testing healthy foods Chapter Five: Results 
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5.4.7. Summary of focus group outcomes 
In light of the discussions outlined, the design of the “healthy eating” programme incorporated the 
following practical components which were elicited from breast cancer patients taking part in the 
focus group. 
 
Topic  Result 
Timing of classes  To commence after surgery and before any 
further treatment begins 
Number of classes  4 
Duration of classes  2 hours 
Location for classes  Macmillan Centres 
Class size  6-12 
Class topics  Healthy eating 
Alternative diets and supplements 
Class delivery  Talks and practical sessions 
 
Table 5-5 Focus group results summary 
 
5.4.8. Adverse reactions and their management 
No adverse reactions were observed. 
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5.5.  Study Two  
5.6.  Pre study planning 
5.6.1. Steering group 
 
The steering group was set up with representatives from a wide range of backgrounds (see 
member list in appendix 9-17).  The steering group were supportive of the project and through their 
involvement the research questions, hypotheses and methods were finalised and the project 
protocol was drawn up.  
 
It was agreed at the time of this meeting, that further meetings would not take place; however 
individual member from the group agreed to be contacted if required.  A data monitoring committee 
was discussed but unanimously rejected.  The reason recorded from the minutes of the meeting 
stated that as there was no harm in the proposed intervention, no monitoring committee was 
required. 
5.6.2. NCRN consumer research panel 
Three members of the consumer research panel provided feedback on the patient information 
sheet (PIS).  Comments were considered and where appropriate were incorporated into the final 
PIS. 
5.6.3. Study approvals 
5.6.3.1.  Ethics 
Stage of application  Date 
Booked  9 August 2006 
Submitted  24 August 2006 
Reviewed  15 September 2006 
Outcome  Rejected 28 September 2006 
2
nd submission prepared  September 2006 
Booked  16 October 2006 
Reviewed  29 November 2006 
Outcome  A favourable ethical opinion on 27 December 2006 by the 
Southampton & South West Hampshire Research Ethics 
Committee B (REC Reference Number – 06/Q1704/144). 
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5.6.3.2.  R&D  
Stage of application  Date 
Prepared  November – December 2006 
Submitted 
SUHT 
Portsmouth 
 
14 December 2006 
3 January 2007 
Approval granted 
SUHT 
Portsmouth 
 
19 March 2007 
Unable to obtain exact date
21 
 
5.6.3.3.  NCRN adoption 
Stage of application  Date 
Prepared  July 2006 
Submitted  July 2006 
Approval granted  2 February 2007 
 
5.6.3.4.  Macmillan Cancer Centre 
Stage of application  Date 
Application made to use premises 
for group healthy eating classes 
21 September 2006 
Approval granted 
Portsmouth 
SUHT 
 
September 2006 
11 April, 2007 
 
                                                    
21 All trial documents were archived at the University of Southampton when I left the UK.  Whilst I am able to reconstruct 
most of the dates I required through email and electronic documents, I was unable to locate an exact date for R&D approval 
at Portsmouth.  Chapter Five: Results 
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5.7.  Enrolment and participation 
5.7.1. Study period 
During the period between April 2007 and September 2007, ninety seven newly diagnosed 
postmenopausal women with breast cancer were screened for eligibility at Southampton 
Universities NHS Hospital Trust.  Figure 5-1 provides a diagram outlining participant flow.Chapter Five: Results 
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Screened for eligibility 
(n = 97) 
Ineligible (n = 35) 
Premenopausal (n = 25) 
Male (n = 1) 
Non invasive cancer (n = 1) 
Recurrent disease (n = 6) 
Reason not recorded (n = 2) 
Initial screening eligible (n = 62) 
Declined (n = 31) 
Not interested in healthy eating (n = 6) 
Travel (n = 5) 
Poor health (n = 3) 
Reason not recorded (n = 1) 
Been through too much (n = 1) 
Too anxious (n = 6) 
Went private (n = 1) 
Class time unsuitable (n = 1) 
Not interested at this time (n = 3) 
Not interested in research (n = 1) 
Following strict diet (n = 1) 
Reported being too old (n = 1) 
Unable to contact (n = 1) 
Stage One (n = 10) 
Not interested in healthy eating (n = 2) 
Travel (n = 2) 
Poor health (n = 1) 
Class time unsuitable (n = 4) 
Not interested at this time (n = 1) 
Stage Two 
(n = 11)  Other (n = 6) 
Staff unavailable for follow-up (n = 4) 
Staff declared patient unsuitable (n = 1) 
Unable to contact (n = 1) 
 
Intervention (n = 5)  Control (n = 6) 
Second screening eligible (n = 58) 
 
Recurrent disease (n = 2) 
Unable to contact (n = 1) 
Reason not stated (n = 1) 
 
6/12 Follow up (n = 5)  6/12 Follow up (n = 5) 
 
 
 
 
 
 
 
 
 
 
Figure 5-1 Participant flow Chapter Five: Results 
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5.7.2. Study Two - Stage One – Enrolment 
5.7.2.1.  Baseline characteristics 
Baseline characteristics of those women who agreed to participate and those women who 
declined were comparable (see table 5-6). The mean age of women who agreed was 66.6 + 
7.3 compared to slightly older group, 71.0 + 9.8 who declined and in both groups 
approximately 75% of women were retired. 
 
 
Characteristics 
 
Agreed enrolment 
 
 
Declined enrolment 
   
Yes 
 
n = 11 
 
% 
 
No 
 
n = 41 
 
% 
 
Age 
 
66.6 + 7.3 
   
71.0 + 9.8 
 
 
Employment status 
  Full time 
  Part time 
  Unemployed 
  Self employed 
  Other  (retired) 
  Status not recorded 
 
 
2 
1 
0 
0 
8 
0 
 
 
18.2 
9.1 
0 
0 
72.7 
0 
 
 
4 
0 
0 
0 
31 
6 
 
 
9.8 
0 
0 
0 
75.6 
14.6 
Figures reported as means and standard deviation 
 
Table 5-6 Baseline characteristics of women invited to attend group healthy eating classes 
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Percentage uptake in healthy eating programme
21%
79%
Yes No
5.7.2.2.  Enrolment 
During the recruitment period of six months (April 2007 – September 2007), 97 women newly 
diagnosed with breast cancer were identified by the research nurse of whom, 52 were 
subsequently invited to participate in the group health eating classes.  In total eleven women 
(21%) enrolled on the healthy eating programme (see figure 5-2).  
 
 
 
Response 
 
Number 
 
Percentage 
Yes  11  21% 
No  41  79% 
Total Invited  52  100% 
 
Table 5-7 Enrolment rates in healthy eating programme 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-2 Percentage uptake in healthy eating programme 
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A wide range of reasons were cited for non-participation (see table 5-8).  The most common 
reason given was not interested in health eating, which accounted for 19.5% or one-fifth of 
refusals.  This was closely followed by travel (17.1%), too anxious (14.6%), class times 
unsuitable (12.2%), poor health (9.8%) and not interested at this time (9.8%). 
 
 
Reason 
 
n = 41 
Not interested in healthy eating  8 
Travel   7 
Too anxious   6 
Class time unsuitable   5 
Poor health   4 
Not interested at this time   4 
Reason not recorded  1 
Been through too much   1 
Went private   1 
Not interested in research   1 
Following strict diet   1 
Reported being too old   1 
Unable to contact   1 
 
Total 
 
41 
 
Table 5-8 Reasons for non-enrolment Chapter Five: Results 
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5.7.2.3.  Health Behaviour Determinants 
Of the 41 women who declined participation, ten women agreed to complete baseline data in 
order to test whether health behaviour determinants predicted enrolment. 
 
Binary logistic regression was used to analyse what effect the predictor variables had on 
whether or not women chose to enrol on the healthy eating programme22.  As expected due to 
lack of power, no statistically significant differences were found between any predictor 
variables and whether or not women choose to enrol on the health eating programme.  
Summary statistics are presented in table 5-9. 
 
That said a discussion of each of the four predictor variables (for which data was available) in 
terms of clinical significance follows. 
 
Predictor  Agreed (n=11)  Declined (n=10) 
Body mass index  31.3 + 6.0  31.3 + 8.6 
Self rated diet  2.25 + 0.5  2.57 + 0.8 
Self Esteem  24.3 + 4.4  22.14 + 4.8 
Internal health locus of control  24.4 + 4.6  23.9 + 4.9 
CHLC  16.1 + 4.8  18.7 + 2.6 
Personal health locus of control  16.6 + 5.2  18.4 + 3.9 
 
Table 5-9 Summary data for health determinants 
 
                                                    
22 Diet quality could not be assessed due to missing/incomplete data sets Chapter Five: Results 
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5.7.2.3.1.  Body mass index 
Body mass index was highly comparable between groups, with a mean score 31.3 in both 
those women who declined and those who agreed participation.  Of all the women, only three 
who had data (15.8%) were considered normal weight with the remaining women (84.2%) 
categorised as overweight (42.1%), obese (31.6%) or morbidly obese (10.5%).  These figures 
compare favourably to other estimates of obesity in women diagnosed with breast cancer.
105 
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Declined healthy eating programme  Accepted healthy eating programme 
Study number  Score  Study number  Score 
205  22.3  201  25.3 
208  27.8  204  22.9 
212  31.8  210  24.3 
231  Data missing  213  28.2 
233  Data missing  217  40.6 
238  49.5  221  28.9 
240  27.0  223  36.0 
241  27.4  228  36.2 
253  26.8  230  34.2 
257  37.4  235  29.8 
    245  37.8 
Mean and SD  31.3 + 8.6  Mean and SD  31.3 + 6.0 
Median23  27.6    29.8 
 
Note: Women with normal BMI scores appear in bold   
 
Table 5-10 Body mass index scores 
 
                                                    
23 Median scores are reported as a reference alternative summary statistic only.  Results where appropriate are 
discussed as means and standard deviations.  Chapter Five: Results 
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5.7.2.3.2.  Self rated diet 
 
Study participants were asked to respond to the question “to what extent do you agree or 
disagree that you have a healthy diet overall?” using a five-point likert scale.  Results were 
similar with the most common response in both groups agreeing with the statement. 
 
Declined healthy eating programme  Accepted healthy eating programme 
Study number  Score  Study number  Score 
205  3  201  2 
208  2  204  2 
212  Data missing  210  Data missing 
231  4  213  2 
233  Data missing  217  3 
238  2  221  2 
240  Data missing  223  2 
241  2  228  2 
253  3  230  Data missing 
257  2  235  3 
    245  Data missing 
 
Table 5-11 Self rated diet scores 
 
Frequencies were as follows: 
 
Score  Response  Declined  Accepted 
1  Strongly agree  0  0 
2  Agree  4  6 
3  Neither agree or disagree  2  2 
4  Disagree  1  0 
5  Strongly disagree  0  0 
  Mode  Agree  Agree 
 
Table 5-12 Self rated diet response frequenciesChapter Five: Results 
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5.7.2.3.3.  Self esteem 
 
The results indicate that those women who enrolled on the programme had slightly higher self 
esteem with scores of 24.33 + 4.6 compared to those women who declined participation 
scoring 22.14 + 4.8.  
 
As stated by the scales developers, there are no discrete cut-off points to define high or low 
self esteem. Of all the studies reviewed in chapter seven, only one utilised this scale; however 
the authors did not report observed scores.
36 
 
Declined healthy eating programme  Accepted healthy eating programme 
Study number  Score  Study number  Score 
205  30  201  30 
208  23  204  21 
212  Data missing   210  Data missing  
231  20  213  28 
233  Data missing   217  28 
238  15  221  19 
240  Data missing   223  21 
241  26  228  23 
253  21  230  29 
257  20  235  20 
    245  Data missing  
Mean and SD  22.14 + 4.8  Mean and SD  24.33 + 4.6 
Median  21    23 
 
Table 5-13 Self esteem scores (highest possible score = 30) 
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5.7.2.3.4.  Locus of control 
Small differences in scores were observed between groups.  Those women who enrolled on 
the programme had slightly higher internal locus of control scores 24.4 + 4.6 compared to 
those who declined enrolment 23.9 + 4.9.  This observation is supported in the literature 
where it has been reported that individuals with a high internal locus of control are more likely 
to engage in healthy behaviours.
107   
 
Again, very little comparison data could be found in the scientific literature.  None of the 
studies reviewed in chapter seven utilised the MHLC. One diet intervention study where 
participants in a Polyp prevention trial completed the MHLC reported the following.  In the 
intervention group, IHLC was 27.8 + 4.9, CHLC 16.2 + 6.1 and PHLC 22.5 + 6.3.  In the 
control group scores were IHLC 26.2 + 5.2, CHLC 19.1 + 5.7 and PHLC 24.5 + 6.2.  These 
scores vary from those observed in the current study.   
 
When compared to healthy adult reference data provided by the authors of the scale, again 
the scores vary considerably.  In healthy adults, IHLC was 25.55, CHLC 16.21 and 19.16.
99 
 
Dimension  Declined  Accepted 
Internal health locus of control (IHLC)  23.9 + 4.9  24.4 + 4.6 
Chance health locus of control (CHLC)  18.7 + 2.6  16.1 + 4.8 
Powerful others locus of control (PHLC)  18.4 + 3.9  16.6 + 5.2 
 
Table 5-14 Summary data for multidimensional health locus of control scales 
 
Individual scores are described in table 5-15.Chapter Five: Results 
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Declined healthy eating programme 
 
Accepted healthy eating programme 
  Internal 
IHLC 
Chance 
CHLC 
Powerful 
Others 
PHLC 
  Internal 
IHLC 
Chance 
CHLC 
Powerful 
others 
PHLC 
Study 
number 
      Study 
number 
     
205  18  20  21  201  26  25  18 
208  28  21  20  204  24  14  11 
231  23  16  16  210  26  17  17 
233  Missing 
data 
Missing 
data 
Missing 
data 
213  29  15  9 
238  28  20  19  217  16  15  24 
240  Missing 
data 
Missing 
data 
Missing 
data 
221  21  23  16 
241  29  20  12  223  29  12  17 
253  17  14  17  228  29  13  24 
257  24  20  24  230  20  11  13 
        235  Missing 
data 
Missing 
data 
Missing 
data 
        245  Missing 
data 
Missing 
data 
Missing 
data 
 
Mean and 
SD 
 
23.9 + 
4.9 
 
18.7 + 
2.6 
 
18.4 + 3.9 
 
Mean and 
SD 
 
24.4 + 4.6 
 
16.11 + 
4.8 
 
16.6 + 5.2 
Median  23  20  19    26  15  17 
 
 
Table 5-15 Multidimensional health locus of control data Chapter Five: Results 
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5.8.  Chapter summary 
 
Fifty-two postmenopausal women newly diagnosed with breast cancer were invited to attend a group 
healthy eating programme.  Of those 11 (21%) agreed to participate.  Reasons for declining 
participation varied, with “not interested in healthy eating” cited in approximately one-fifth of cases. 
At the end of the six month follow up, one woman from the usual care group withdrew from the study.  
No reason was provided. 
 
The findings suggest that offering a group healthy eating programme for newly diagnosed 
postmenopausal women with breast cancer would not be feasible as the likely uptake would not justify 
such a service.   
 
However the influence of inadequate screening resulting in low numbers of women invited to 
participate in the group healthy eating programme and further the degree of missing data for those 
women who did enrol must not be ignored when interpreting these data.  These issues are explored in 
detail in the following chapter.  Chapter Six: Discussion 
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6.0  Chapter introduction 
In 2007, the World Cancer Research Fund (WCRF) published the most comprehensive scientific report 
on “Food, Nutrition, Physical Activity and Cancer”, recommending all newly diagnosed cancer patients 
should receive nutritional advice.
19  Currently in the NHS, routine nutrition advice is not offered to 
cancer patients. 
 
A relatively large body of qualitative evidence exists supporting the introduction of health promotion 
activities for newly diagnosed cancer patients.
9 19 70 71 73-76 78 79 94  However, to date, no data exists for 
policy makers to determine what the likely interest in these types of activities would be; an important 
consideration when planning and developing new services.  Interest in such programmes could be 
extrapolated by reviewing enrolment data from the vast literature base of dietary intervention studies; 
however uptake in these interventions are generally poorly reported and very few have been 
conducted with breast cancer patients. 
 
This project was set up to investigate uptake and response to dietary intervention in women newly 
diagnosed with breast cancer, in order to assist future cancer service development.  Funding was 
provided by the Department of Health through their Research Capacity Development Award scheme.  
The project began recruitment in April 2007, concluding six months later in September 2007.   
 
As the study did not achieve its goals and objectives, the following discussion does not focus on a 
review of the study as would normally occur.  Instead the review is reflective of my experience of the 
study process, identifying where mistakes were made and suggesting ways in which to avoid such 
problems in future research programmes.  The purpose of this reflective process was to demonstrate 
that the overall goal of both the Doctoral programme and the funding stream, that is the development 
of advanced research skills, has been achieved. 
 
In view of the above, the discussion is set out in accordance with the health promotion planning and 
evaluation cycle described by Nutbeam (2006)
108 (see figure 6-1) which provides a structured 
framework with which to evaluate health promotion activities.   
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Figure 6-1 Health promotion planning and evaluation cycle 
 
During the lifespan of the project, four levels of evaluation are proposed; formative, process, impact 
and outcome (the outer circle) (see figure 6.1).     
 
The four types of assessment; formative, process and impact and outcome are discussed in their own 
right, with each section categorised further into subheadings describing 1) the purpose of the 
evaluation,  2) assessment of the current project,  and 3) summary and 4) lessons learned. 
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6.1.  Formative evaluation 
6.1.1. Purpose of formative evaluation 
Formative evaluation enables the development of an intervention that utilises the most relevant 
methods and materials, potentially resulting in an effective programme.  It should be conducted in 
consultation with stakeholders and/or members of the target population.
108 
 
Several strategies were employed during the planning stage of this project and are discussed below.  
These included; 
1.  Focus groups with patients 
2.  Adoption of study into the local NCRN research portfolio 
3.  Macmillan Cancer Centre 
4.  Steering group 
5.  Involvement of independent and external Clinical Trials Unit for peer review and randomisation 
6.  Stakeholder engagement 
6.1.2. Assessment  
6.1.2.1.  Focus groups 
Whilst some of the parameters in which the intervention was to operate were predetermined (group 
education, during working hours, Dietetic led), in order to make the intervention feasible within the NHS 
setting, the views of cancer patients were sought when designing the practical components of the 
intervention.  These included; number of sessions, length of sessions, preferred topics, location of 
sessions and lastly preferred size of group for sessions. 
6.1.2.2.  National Cancer Research Network  
Both study one (focus groups) and study two (main study) projects were put forward and were 
successfully accepted to the local NCRN networks research portfolio.   The benefits of being part of the 
NCRN research portfolio include training opportunities and assistance with conducting the research 
through network research nurses. Specifically the NCRN research nurses were tasked with carrying 
out the screening and recruiting for the focus groups and the screening, recruiting, and data collection 
for the intervention study.   
 
In addition, the local NCRN network established a Consumer Research Panel which was set up to 
provide researchers with access to representatives from the target group i.e. cancer patients, in order 
to obtain feedback on all elements of proposed studies.  Prior to applying for funding, the idea for the 
project was presented to this group. The feedback given after the presentation was very positive with a Chapter Six: Discussion 
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number of members indicating their willingness to continue involvement in the project.  This offer was 
accepted and at a later stage two members of the group were enlisted to review all patient 
documentation and a third member became part of the research team working on a paid basis to assist 
with the focus group work.  In addition, this member went on to sit on the steering group. 
 
Whilst ultimately, NCRN adoption was granted, it was not without its problems.  After initially applying 
for NCRN adoption for the entire project, the application was declined.  It was recommended that a 
separate application be made for each stage of the project.  Despite, timely adoption for the focus 
group, approval for stage two was extremely drawn out.  In total, submission to approval took seven 
months.  This occurred as a result of the suspension of the application process for NCRN adoption 
which took place during the course of this study as a review of the procedure for adoption into the 
NCRN portfolio took place. 
6.1.2.3.  Macmillan Cancer Centre 
As with other approval processes outlined previously, gaining permission to use the Macmillan 
premises at SUHT presented planning challenges.  Despite making initial enquires as early as 
September 2006, approval was gained seven months later on 11 April, 2007. As with the NCRN, the 
Macmillan centre at SUHT was reviewing their guidelines for approving the use of Macmillan premises 
for research purposes. 
 
After attempting to secure a slot at the board’s meeting for several months (Macmillan postponed the 
meeting on three separate occasions), a meeting was finally held which resulted in approval to use the 
premises for the purposes of conducting the healthy eating classes. 
 
Interestingly no such review was taking place at the Macmillan centre located at Portsmouth NHS trust, 
thus showing once again, a lack of consistency across organisations in policies and procedures. 
 
Finally, both centres gave approval for their premises to be utilised for the group healthy eating 
programme. 
6.1.2.4.  Steering Group 
Whilst the steering group was a success in terms of engaging with senior clinical and academic 
members and subsequent revisions to the protocol based on feedback, the steering group was not 
used to its full advantage.  The terms of reference should have been more formalised with future 
meetings scheduled to assess the progress of the study.  If such provisions had been in place, earlier 
remedial action could have been taken which may have improved the study outcomes. 
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6.1.2.5.  Independent Peer review 
The protocol was independently peer reviewed by the Birmingham Clinical Trials Unit.  The summary 
review stated “the proposal is well-written and thought out (they have discussed the project with a 
variety of leading experts within the field), and asks an interesting question (with an easy to implement 
intervention) in an important disease area” (see appendix 9-18).   
6.1.2.6.  Stakeholder involvement (the local healthcare team) 
When developing this project, the importance of local clinician support had been completely 
underestimated.   
 
In order to gain hospital approval to conduct the study, a letter of approval was required from a lead 
clinician.  At both sites, this approval letter was sought and gained from the respective lead surgeons.  
Despite similar approaches to obtaining this letter, the outcomes were quite different with one site 
eventually been withdrawn from the study.    
 
In order to introduce the study to the clinical teams, a request to present at the multidisciplinary team 
meetings was made.  At one of the two sites (the site which was withdrawn) no suitable date to present 
the study could be arranged.  As a result, the principal investigator liaised only with the chief surgeon 
who went on to authorise the study at this site.  The principal investigator had been involved with this 
clinician on an earlier, unrelated project and had therefore previously established a good rapport. 
 
Further, from the principal investigators view, it was considered a benign intervention in terms that 
adopting a healthy diet is unlikely to cause any harm in this patient group.  In the rare event where 
adopting a healthy diet was contraindicated for a particular participant, procedures were in place to 
identify and refer immediately to the dietetic department for nutrition support. 
 
For both of these reasons, the principal investigator did not envisage any problems by not consulting 
with the wider clinical team.  What became apparent at a later date however was that the dynamics of 
the clinical team differs from hospital to hospital and at this particular site it was suggested that it would 
have been more appropriate to discuss the study with clinical members within the different specialities; 
surgeons, oncologists, nursing and radiography.   
 
Subsequently, a meeting was held where the principal investigator presented the study to a group of 
approximately twenty people including, oncologists, nursing staff and radiologists.  In the opinion of the 
principal investigator, the meeting was quite hostile with comments suggesting the lead surgeon could 
not authorise a study independently.  In the end however the group agreed to support the study.  
Again, only in the opinion of the principal investigator, this was due to the fact that recruitment rates at Chapter Six: Discussion 
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each trust within a cancer research network are recorded and published as part of assessing networks 
against NCRN performance measures.  With the high levels of predicted accrual numbers (this point 
was made during the meeting), this study had appeal on that basis only.  
 
The study opened for recruitment on the proposed start date, however within one week of opening 
further problems were experienced.  A senior nursing member of the team who was not present at the 
meeting did not support the study. Two main reasons were cited; firstly this member felt it inappropriate 
to invite women to eat healthily at the time of diagnosis and secondly, this person was uncomfortable 
with the fact that the research nurse who had been identified to screen and recruit for the study was 
male.  
 
Attempts were made to reconcile the differences but in the end the decision was to withdraw the study 
from the site. The decision made was based on two grounds.  Firstly, the original sample size of 400 
was set based on the point estimate being within 5% either side of the true population value.  For 
example if the point estimate was found to be 50%, then the true value or number of postmenopausal 
women newly diagnosed with breast cancer in the wider breast cancer population likely to enrol on a 
group healthy eating programme would be between 45% and 55%.  By extending this range from + 5% 
to + 7.5% the target was recalculated given a revised sample size of 129 which was deemed 
achievable with only one remaining site taking part.  Secondly, the time required to pursue a resolution 
was assessed as endangering the timely completion in the allocated three years for the Doctoral 
programme.   
 
At the second site, no problems were encountered despite the same process being followed.  Once 
again a request was made to present at the multidisciplinary team meeting and once again, this 
request could not be fulfilled.  Subsequently, approval was gained from the lead surgeon after a 
presentation to his surgical team and only after experiencing the problems described above did the 
principal investigator arrange a meeting with the wider clinical team who raised no concerns and gave 
full support to the study. 
 
The experience in gaining local support at these two sites provides a clear example of how local 
politics can undermine research studies from getting off the ground. 
 
In addressing reviewers’ comments in this revised thesis an important publication was identified. 
Following a consultation period, in March 2007 new mandatory measures, the “Cancer Research 
Network Measures”
109 were issued as part of the Manual for Cancer Services.  Specifically, whilst 
acknowledging the National Cancer Research Network Co-ordinating Centre’s procedures for cancer 
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for Cancer Research Networks.  Of note, measure 1C-152 states “The NSSG and the Clinical Lead of 
the Research Network should agree remedial actions for improving recruitment into approved trials and 
other well designed studies, with each of its MDT’s following its meeting to discuss the MDT’s 
recruitment”.  Compliance to this measure will be assessed through demonstrated remedial actions 
agreed by the NSSG Chair and the Research Clinical Lead.
109 
 
Further, measure 2 states that “the MDT must provide a written response annually to the NSSG’s 
approved list of trials and other well designed studies which fulfils the following: for each clinical trial 
and other well designed study the MDT should agree to enter patients or state the reasons why it will 
not be able to; and the remedial action arising from the MDT’s recruitment results, agree with the 
NSSG.  Compliance with this measure will be assessed by demonstration of an appropriate written 
response to the aforementioned”. 
 
Interestingly, had these measures been in place at the time this study was underway, a more formal 
and hence satisfactory explanation may have been forthcoming as to why Portsmouth were unable to 
follow the approved protocol. 
 
Secondly, the issue of unsatisfactory screening procedures by the NCRN research nurses could have 
been raised in an appropriate setting which may have lead to remedial action which could have 
potentially improved screening numbers. 
6.1.3. Summary 
Several strategies were employed during the planning stages of this project from as early as prior to 
the funding application, up to and including the design of the intervention.  These strategies elicited the 
views from a wide range of stakeholders which included patient representatives, hospital 
representatives, a funding body representative, academic representatives, and charity representatives.  
In all these consultations, support for the project was high resulting in a project with clear research 
aims and objectives, hypotheses and outcomes.   
 
 
Overall, the formative stage of the project was thorough; however two unforeseen problem areas were 
identified; lack of local support and the use of inaccurate screening methods, which ultimately 
undermined the success of the project. 
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6.1.4. Lessons learned 
Neglecting to ensure adequate local support proved costly with one of the two sites not taking part in 
the study.  Both the procedures for gaining hospital approval to conduct research and selection of 
NCRN adopted studies at individual NHS sites should be reviewed.   
 
If, as in this example, the chief surgeon was deemed suitable to be the sole authorising person on the 
application by the hospital R&D department, how was it that other members of the clinical team were 
able to challenge the approval leading to the withdrawal of the site? 
 
Further, the procedure used for selecting studies should be transparent.  In the case of the site that 
was withdrawn, as stated previously, it is the opinion of the principal investigator that the main reason 
the current study was supported at the time of the meeting was for reasons of recruitment numbers 
and had very little (if anything) to do with the study itself.   
 
With large numbers of protocols being received at each hospital site, if studies are chosen based on 
individual preferences, this system is undoubtedly unfair and requires immediate review. Indeed by its 
own admission in the 2004 review of the NCRN, local studies are not well supported and overall have 
contributed only a small proportion of total accrual into the NCRN research portfolio
110. 
 
6.2.  Process evaluation 
6.2.1. Purpose of process evaluation 
Process evaluation assesses how the intervention was implemented and was carried out during the 
delivery of the intervention.  It concerns itself with the following questions; 
1.  Did the focus groups reach their target group? 
2.  Did the intervention reach its target group? 
3.  Was the intervention delivered as intended? 
4.  Were stakeholders/partners engaged in the process? 
 
If done correctly, process evaluation will identify how a successful programme was conducted and 
conversely if the programme was unsuccessful, it will identify reasons for failure, so modifications can 
be made to improve the likelihood of future success 
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6.2.2. Assessment 
6.2.2.1.  Focus groups target group 
As stated in the study protocol, three focus groups were planned at three different NHS trust sites.  
However; no focus groups were conducted as planned.  As the results indicated, interest shown in 
attending the focus groups when recruited as per protocol was limited.  Overall, with 50 invitations 
sent, a positive response was received on only eight occasions.   
 
It was recommended by members of the health care teams that potential participants might be 
recruited from the support groups which are established at each hospital site.  Subsequently, the three 
relevant support groups were approached, of whom two expressed an interest in the project.  
Presentations were made to both groups and from one of these presentations sufficient women were 
recruited to hold one focus group. 
6.2.2.2.  Intervention target group 
Over the six month recruitment period, the NCRN research nurse assigned to run the trial identified 97 
women to be assessed for eligibility (including women with recurrent disease who were ineligible).   
 
In contrast, figures provided by the Breast Unit Coordinator24 stated that over the same period 146 new 
cases (not including recurrences) were registered.  Using an estimate of ~20% cases occurring in 
premenopausal women, this left 118 women eligible women who should have been invited on the 
programme against the actual number of 58 (50%). 
 
Based on these figures, clearly the study did not reach its target group which were all newly diagnosed 
postmenopausal women with breast cancer. To date, no reason for this disparity has been identified.   
 
Further, a small number of women were excluded for reasons not specified by the protocol reducing 
the numbers of eligible women invited to participate in the programme. 
6.2.2.3.  Intervention delivery 
6.2.2.3.1.  Baseline data collection 
As part of the remit of the NCRN research nurse, all baseline data were to be collected at the time of 
consent.  What occurred, however, was that a number of data collection forms were posted to 
participants in direct violation of the specified protocol.  When questioned, the research nurse stated 
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that this transgression would be acceptable and was common practice in other clinical studies.  The 
result of this error was twofold; firstly, a number of data collection forms were not returned and 
secondly the data on some of the returned forms were either missing or incomplete as these were not 
subsequently checked by the research nurse and followed up for data inaccuracies.   
6.2.2.3.2.  Resources 
Allocated resources including, venue, electronic equipment, patient information resources, dietetic time 
were adequate to conduct the study as planned.  No unforeseen expenditure occurred during the 
course of the programme. 
6.2.2.3.3.  Repeatability 
All programme materials were pre-selected and the presentation pre-written to ensure the classes 
could be repeated.   
6.2.2.3.4.  Programme variability 
Unfortunately as the programme did not run in two sites as originally planned and the programme 
leader delivered all the classes, there was no opportunity to assess variability between sites or 
between programme leaders. 
6.2.2.3.5.  Programme attendance 
With so few participants an assessment of programme attendance would be inappropriate. 
6.2.2.4.  Stakeholder engagement 
No measures were used to assess stakeholder engagement.    With the problems experienced in the 
screening and recruitment processes, data regarding the strengths and weaknesses of the partnership 
would have been extremely useful. 
6.2.3. Summary 
Implementation problems were identified in both phases of the project.  
 
In study one, the focus group work was not supported as planned.  The predicted numbers were based 
on the qualitative literature that suggested half of all newly diagnosed breast cancer patients were 
interested in health promotion programmes specifically dietary services.  From these data, numbers 
invited were twice those needed to successfully run a focus group.  In retrospect, this may have been 
the first indication that in reality the interest in such a programme differed substantially from what the 
literature suggested.  
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In study two, several problems were experienced.  Firstly, the screening process failed to identify all 
eligible patients and therefore reach its target group.  This in turn resulted in fewer women being 
invited to participate in the programme and subsequently the observed recruitment rates could not be 
generalised beyond the cohort participating in the study.  No provision was made a priori to deal with 
screening procedure failures.  NCRN research staff are highly experienced in all aspects of trial 
management and therefore no concerns regarding the ability to accurately record each new breast 
cancer diagnosis could have been anticipated.  This information is routinely collected by the Breast 
Unit as part of the minimum data sets required nationally by the Department of Health and should 
therefore have been freely accessible to the NCRN research nurse.  For this reason, no piloting of the 
screening process was undertaken.   
 
Secondly, the data collection procedures were not followed which led to missing and incomplete data. 
When coupled to substantially lower screening/recruitment rates than predicted, the study outcomes 
were severely compromised. 
 
Lastly, on a positive note, the planning and development of all class materials prior to the start of the 
programme was well conceived and should ensure repeatability. 
 
 
 
Overall the implementation phase of the project was poorly conducted. 
 
6.2.4. Lessons learned 
Whilst numbers recruited to the focus groups fell well short of those predicted, with only qualitative data 
available on the likely interest in health promotion activities, the best estimate was made with the 
available evidence.  If similar studies were to be conducted in the future, alternative methods for 
estimating recruitment rates should be considered.   
 
In phase two of the project, two potential measures could have been employed to improve the 
implementation stage of this project. 
 
Firstly, had the procedure for screening been pre-tested/piloted these errors would be been highlighted 
and the procedure subsequently modified, in turn eliminating the problems that arose. 
 
In the absence of the piloting phase, the problem could have been ameliorated had appropriate action 
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early in the six month recruitment period outlining concerns regarding poor screening/recruitment 
statistics.  At that point the research nurse provided assurance that all potential patients were currently 
being screened and identified.  This response was not checked with the breast unit data manager by 
the principal investigator.  Had this occurred, the discrepancy would have been highlighted earlier and 
potentially may have been resolved.   
 
Secondly and most importantly, the main problem was the lack of partnership between the principal 
investigator and the NCRN research nurse.  The principal investigator wrongly used an autocratic 
approach to conduct the study.   
 
In part, this was premeditated as it was felt at the time that in order to be scientifically credible, given 
the outcome was to assess the level of interest in a healthy eating programme in a “real life” situation, 
a conscious decision was made to distance the principal investigator from the practical aspects of the 
study so that no influence could be exerted on the uptake rate though coercion on either the research 
nurse or patients.   
 
To this end, although not mandatory by the NCRN, a procedures manual (see appendix 9-19) was 
provided to the NCRN research nurse with a detailed description of all aspects involving screening and 
recruiting patients.  It was assumed that if any problems arose they would be dealt with appropriately 
or alternatively the principal investigator would be contacted for guidance. 
 
Further, having NCRN support was seen as an advantage as the staff would have already established 
a working relationship with their colleagues and this would potentially translate into a smoother working 
environment rather than if outside academic researchers came into a team with no prior working 
relationships.  Whilst acknowledging these positive aspects of NCRN involvement, the process 
evaluation has highlighted some negative aspects of this arrangement.   
 
Two potential areas for improvement have been highlighted.  Firstly, a detailed agreement with regards 
to specific tasks between the two parties would have been advantageous, similar to the model clinical 
trial agreement (mCTA) published in 2003 and revised in 2006
111 for pharmaceutical research.  The 
mCTA was the result of a joint Government and Industry initiative which reported on the performance 
of commercially sponsored clinical trials in the NHS.  The report identified a number of problems in 
common with those experienced in the current study.  These included poor recruitment and data 
quality.
112 
 
To date, there is no mandate to include Clinical Trials Agreements for non-pharmaceutical research 
however, in the NCRN 2004 review
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that the focus of performance to date as been largely on accrual rates to clinical trials.  With those 
targets met and exceeded, the performance measures for future reviews needs to be expanded and 
crucially include measures of quality.
110 Whilst the UKCRN have extended their performance measures 
in 2007 the initial focus will concentrate on three key criteria; “balance of portfolio, accrual of study 
participants to pre-defined targets and speed of conduct to pre-defined timelines”. (personal 
communication, Morgan, C, UKCRN 9/07/08). To date, no performance measures for data quality have 
been established and therefore this area remains unaccountable. 
 
At present a working group (currently in the early stages) has been formed to develop national 
competencies for research nurses.  At the time of writing this revised thesis, draft competencies have 
been published and are currently open for consultation by invitation. 
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6.3.  Outcome evaluation 
6.3.1. Purpose of outcome evaluation 
The purpose of outcome evaluation is to assess the extent of how the programme achieved its aims 
and objectives.  It is often categorised into two separate measures, impact assessment, which focuses 
on short term/intermediate goals and outcome assessment focused on the long term outcomes of the 
study. 
 
The structure for the following outcome evaluation is best described pictorially and is depicted below in 
figure 6-2. Chapter Six: Discussion 
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Phase One 
Focus Groups 
Phase Two 
Stage One  
Cross sectional study 
Stage Two  
Intervention 
Impact assessment 
1.  uptake assessment  
2.  ability to characterise women agreed 
to participate 
 
Impact Assessment 
1.  change in diet quality 
2.  ability to characterise women who 
adhered to intervention 
3.  improvement in overall health and 
wellbeing 
 
 
Outcome Assessment 
1.  Did the study provide quality data for 
future cancer service development 
initiatives?  
Impact assessment 
1.  were the practical elements of the programme 
elicited during the focus groups? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-2 Summary of impact and outcome assessment Chapter Six: Discussion 
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6.3.2. Impact assessment 
6.3.2.1.  Assessment - Study One  
The goals and objectives for the focus groups were met.  Specifically, the practical aspects of the study 
as proposed by the focus group participants were incorporated into the study intervention. 
6.3.3. Summary 
Despite not achieving the number of focus groups planned, the one which was conducted elicited the 
information needed to develop the programme which was to be tested in phase two. 
 
Overall, phase one achieved its desired impact 
 
6.3.4. Lessons learned 
In future, when planning focus groups, alternative methods of recruiting patients would be investigated.  
6.3.4.1.  Study Two – Stage One 
6.3.4.1.1.  Uptake 
Today, more and more people are surviving their cancer diagnosis, leading to a growing need for 
health providers to offer services that better meet the long term health needs of this group.   
 
Over the last two to three decades, several research groups have become focussed on providing 
evidence that demonstrates health benefits ranging from enhanced quality of life through to improved 
relapse free and overall survival when adopting healthy lifestyle behaviours after a cancer diagnosis.  
As a clinical dietetic practitioner, it was apparent that if such evidence once established were to be 
translated into practice, such programmes would have to been acceptable to the women for whom they 
were intended.  As such, a gap was identified in the literature leading to the present study, the first to 
assess uptake in a group healthy eating programme for newly diagnosed postmenopausal women with 
breast cancer. 
 
Over a period of six months, 58 newly diagnosed postmenopausal women with breast cancer were 
invited to enrol in a group health eating programme.  Of those invited, eleven (21%) agreed to 
participate.  With feasibility established at 50%, the results indicate that interest in such a programme 
fell well short of the benchmark set, suggesting that such a programme would not be a feasible 
addition to services currently offered by NHS dietetic departments.  
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As a stand alone study, where the outcome of interest was to measure participation rates in a health 
promotion activity whereby all patients were eligible to enrol, direct comparisons to other data cannot 
be made.  Data however does exist from other dietary intervention studies with select subsets of this 
patient group and these are presented below. 
 
Of the studies reviewed in chapter two, only two, the Womens Healthy Eating and Living Study 
(WHEL) and the Womens Intervention Nutrition Study (WINS), both conducted in the US reported 
uptake data.   
 
In the WHEL study, of the 4708 eligible patients identified, 1601 (34%) did not participate in the study 
with 1284 (27%) declining to participate, 315 (7%) failing to complete the run-in period, and 2 (0.04%) 
refusing randomisation after completing the run-in period.  The remainder, 3107 (66%) went on to be 
randomised.  Recruitment for this study took five and a half years. 
 
For the WINS study, the following participation rates were found.  Of the 5466 eligible, 2537 (45%), 
went on to be randomised, leaving 55% of all eligible women declining participation.  The recruitment 
period for this study took seven years. 
 
In unpublished data from the Womens Intervention and Nutrition Study (UK), of the 1528 women 
invited to take part, 301 (19.7%) consented to the study with the remainder (80.3%) declining 
participation. 
 
In the studies presented above, participation rates ranged from 19% in this study to 64% in the WHEL 
study.   Two possible explanations are suggested to explain such disparities.  Firstly, the WHEL study 
with the highest recruitment rate of 64% did not require participants to attend dietary counselling 
sessions as these were conducted over the telephone.  This suggests that participant burden may 
significantly impact on uptake in dietary interventions for this group.  
 
Secondly, women enrolling in the WINS and WHEL studies were aware that both studies were 
investigating the role of diet in improving survival from breast cancer.  Such knowledge may have been 
a powerful motivator for enrolment.  In both the WINS UK and this study, participants had no such 
incentive, with the WINS UK investigating the feasibility of adopting a low fat diet, and the present 
study assessing interest in a health eating programme. 
 
The preceding discussion highlights the problems faced by the health service providers in developing 
future services.  Not only is there a paucity of evidence as to the likely interest in health promotion 
activities, existing evidence varied markedly, largely due to differences in the type of dietary Chapter Six: Discussion 
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intervention, low fat (WINS US and WINS UK) and healthy eating (WHEL and this study), mode of 
intervention, telephone counselling (WHEL), and group sessions (WINS US, WINS UK and this study), 
and length of intervention, (months to years).   
 
6.3.4.1.2.  Characteristics that predict uptake 
Although statistical tests were applied to the data showing no differences between women who agreed 
to participate and those who refused in predicted health behaviour determinants, due to insufficient 
sets of data, conclusions cannot be reliably drawn.   
6.3.4.2.  Summary  
Clearly, the impact of stage one on the overall project was undermined by poor accrual.  Only since 
closing the study have the challenges of trial recruitment come to light.   What is now apparent is that 
failing to meet recruitment targets is a widespread problem in clinical research and for that reason 
recruitment rates have been extensively researched. 
 
Two main areas have been addressed.  Firstly, the reporting of recruitment rates have been 
investigated as this has important implications for researchers when predicting both target numbers 
and time taken to meet recruitment targets. 
 
Gross
113 et al conducted a systematic review of 172 randomised controlled clinical trials published in 
1996-2000 and found only 52% of studies reported the numbers of patients who were screened for 
eligibility, of which less than half went on to report numbers meeting eligibility requirements.  The 
authors concluded that random and incomplete reporting of the recruitment process was common. 
 
Whilst acknowledging the guidelines for reporting clinical trials have been greatly improved, largely due 
to the publication of the CONSORT guidelines, the reporting of recruitment data remains a problem.   
 
Of the data that does exist, recent commercial clinical trial data report <30% of UK based trials reach 
their recruitment targets.
112  For non industry sponsored trials
114 the picture is similar with 45% 
reaching their recruitment targets and one-fifth recruiting less that 25% or their recruitment target. 
 
Secondly, the reasons for non-participation have been investigated so that barriers to recruitment can 
be identified and subsequently addressed, potentially resulting in greater recruitment rates. 
 
Whilst the reasons for non-participation are wide ranging, three key areas have been identified to 
explain poor recruitment; clinician characteristics, patient characteristic and protocol eligibility. Chapter Six: Discussion 
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On the clinician side, several reasons have been cited and include; lack of interest in research, time 
demands, availability of suitable study, resource constraints and ethical considerations. Patient factors 
including age, ethnicity, gender and socio-economic status have been identified as potential reasons 
for non participation.  Practical issues such as time demands and transport for extra visits can be 
barriers to participation.  In addition, patients often report poor understanding and/or hold negative 
views of the clinical trial process which in turn leaves them reluctant to participate. Lastly, in many 
cases study protocols exclude large numbers of patients in order to maintain internal reliability.
113 115-123   
 
Together, these published data suggest that currently recruitment to clinical trials is generally poor.   
Further there is no clear evidence outlining successful strategies to improve clinical trial participation 
rates.
124  
 
With an ever growing push, due to both the high profile research agenda as outlined in “Best Health for 
Best Research” and a greater understanding of the causes of disease, new opportunities for research 
into prevention, cures and palliation exist.  In our “evidence based” health culture, this means an ever 
increasing number of clinical trials are being established and the impact therefore of poor recruitment 
cannot be underestimated.  In the commercial sector alone, there has been a 20% growth in the 
number of clinical drug trials between the years 2000-2005. 
 
In future, sites that have a reputation as “good recruiters” may be targeted by commercial research 
organisations as the ability to conduct a study within proposed timeframes is paramount to cost 
effective practice.  If future trials are focused in such “research hubs”, an inequitable system will occur 
whereby patients who are not seen at these sites will not have access to new and promising 
treatments.  Secondly, with more trials opening, it will create competition to enrol patients on studies 
within these “research hubs” potentially compromising individual trial recruitment targets. 
 
Clearly this is situation that should be avoided and highlights barriers to recruitment as an important 
area for future research.  The research agenda may benefit by expanding its scope to include 
investigations on the effect of specific interventions and disease type on recruitment rates.  
 
 
Overall, the impact of phase two, stage one was poor.   Chapter Six: Discussion 
 
  146 
6.3.5. Lessons learnt 
In retrospect, given the complexities of trial recruitment, the research question “what is the likely 
interest in a group healthy eating programme” could not reliably be gained through a clinical trial and in 
effect, the outcomes were unachievable even before implementing the programme. 
6.3.6. Study Two - Stage Two  
6.3.6.1.  Change in diet quality 
Unable to assess due to numbers and quality of data. 
6.3.6.2.  Characteristics that predicted adherence to the programme 
Unable to assess due to numbers and quality of data. 
6.3.6.3.  Improvement in overall health and well-being 
Unable to assess due to numbers and quality of data. 
6.3.6.4.  Summary 
Significant numbers of missing and incomplete data were found (see tables 10-1and 10-2).  In total of 
the 105 sets of data that should have been completed, 23 (22%) was missing and all 17 (100%) food 
frequency questionnaires were unable to be analysed due to incomplete data. 
 
Data form  Incomplete  Missing 
Food frequency questionnaire  17/21  4/21 
Multidimensional health locus of control  1/21  4/21 
Self rated diet  0/21  6/21 
Body mass index  0/21  2/21 
Self esteem  0/21  5/21 
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Table 6-1 Summary of incomplete/missing data at baseline 
 
Data form  Incomplete  Missing 
Food frequency questionnaire  8/10  2/10 
Body mass index  0/10  3/10 
Self esteem  0/10  2/10 
 
Table 6-2 Summary of incomplete/missing data at six-month follow-up 
 
Despite both verbal and written instructions on the procedures for collecting data, clearly, serious 
problems with data collection was evident.  As the data was not handed over to the CI until recruitment 
for the study had closed, these problems were not identified until it was too late.  As per the study 
protocol, all data forms were to be scanned independently and therefore no provision was made for 
early collection of forms.  In hindsight, a random sample of the data forms should have been collected 
for quality assurance purposes.  Had this occurred, the issue of poor data would have been identified 
at an earlier date and could have been rectified. 
 
A search of the scientific literature revealed little evidence for the scope and nature of poor data quality 
and therefore the extent to which it affects the overall integrity of research is difficult to assess.  
 
In 2004 Wood et al
125 reviewed all published randomised trials over a six month period in 2001 from 
four high impact journals to examine how missing outcome data was both reported and examined.   In 
total 71 trials were analysed, of which 89% reported missing outcome data and of these only 40% 
reported reasons for the missing data.  20% reported more than one-fifth of the outcome data missing.  
In concluding, the authors state missing outcome data is common in randomised controlled trials and 
often these missing data are inadequately dealt with in the statistical analysis. 
 
Both the local research ethics committee and NHS trust R&D department were contacted requesting 
information on recruitment rates and prevalence of missing or incomplete data in locally conducted 
trials.  On both counts no information was forthcoming. 
 
The impact of the study could not be assessed as the problems which occurred during implementation 
compromised the ability of the study to achieve its goals and objectives 
6.3.7. Lessons learned 
The success of any health promotion programme is inextricably linked to how well the implementation 
phase has been executed.  The belief that careful planning would ensure successful implementation Chapter Six: Discussion 
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was ill-founded.  Clearly, equal importance must be placed on ensuring the protocol is carried out as 
planned. Ultimately, failure to do this led to the failure of the study to meet its goals and objectives. In 
future, an impact assessment will be designed a priori and form part of any further research proposals.    
6.3.8. Outcome assessment 
The purpose of outcome evaluation is to demonstrate that the intervention was effective, affordable 
and well implemented.  If these elements can be demonstrated, the intervention can lead to 
programme replication studies thus resulting in large scale evidence based health promotion activities.  
Clearly, the current study did not provide this evidence. 
6.3.9. Assessment 
Outcomes were not achieved 
6.3.10.  Lessons learnt 
Poor implementation led to the failure of this study emphasising the importance of ensuring adequate 
quality control measures during the implementation phase are in place prior to commencement.  This 
in turn will improve the likelihood that outcomes are achieved. Chapter Six: Discussion 
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6.4.  Evaluation summary 
The following table sets out lessons learned whilst conducting this study which will be carried through 
when planning future research. 
 
Type of evaluation  Lesson 
Formative evaluation  Ensure good local support for the study 
Ensure good understanding of procedures for adopting 
studies in local research portfolios  
 
Process evaluation  Test methods prior to implementation 
Ensure clear job roles and responsibilities are set up and 
agreed if outsourcing work 
 
Outcome evaluation  Ensure implementation phase is well executed 
Ensure adequate quality assurance methods are in place for 
data collection 
 
 
Table 6-3 Summary of lessons learnt 
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6.5.  Chapter summary 
The results of this study suggest that in this cohort of postmenopausal women newly diagnosed with 
breast cancer, interest in attending a group healthy eating was limited.  However, given the lack of 
statistical power due to inadequate screening procedures identifying and subsequently inviting women 
to participate, the observed recruitment rates cannot be generalised to all postmenopausal women 
newly diagnosed with breast cancer.   
 
Further, for those women who participated in the programme, the effects of the programme were 
undeterminable due to poor data quality.  
 
Not only should the results of this study be interpreted with caution for the reasons aforementioned, but 
in addition, it is plausible that the results of this study reflect interest in clinical trial participation as 
opposed to interest in a group healthy eating programme as highlighted by the scientific literature on 
the challenges in clinical trial recruitment.  
 
Overall the failure of the study in meeting its aims and objectives can be attributed to the lack of 
women invited to attend the group health eating programme.  This came about largely due to the 
withdrawal of one site from the study and inadequate screening procedures at the remaining NHS 
trust.  Both these problems could have potentially been avoided had appropriate procedures been in 
place to identify and deal with non compliance to the study’s protocol.  Failure to ensure such 
safeguards were in place prior to implementation was due to inexperience on the part of the chief 
investigator who in assessing the risk benefit ratio of intervening in the working environment of the 
NCRN staff and policies, and in the interest of future collaborations, chose the path of least resistance.  
This proved to be a costly judgement. 
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7.0  Conclusions 
In undertaking the current study, it was clear that conducting clinical research in the NHS, particularly 
as a sole local investigator posed many challenges.  During the course of this Doctoral programme, 
research culture in the UK has gone through many changes.  For example ethical and NHS trust 
approval has been streamlined with a central application replacing the two application process which 
was in practice during this study.  Had such measures been in place, study approvals would have been 
much timelier, potentially allowing more time (several months) to appropriately assess and rectify non 
compliance to the study protocol.  One potential outcome may have been to restart recruitment once it 
was known that not all women were being identified and subsequently being invited to attend the group 
healthy eating programme. 
 
Secondly, in very recent times there has been a move to ensure transparency and accountability for all 
research staff including employees of the National Cancer Research Network with the publication of 
the Cancer Research Network Measures (as part of the Manual for Cancer Services) and the proposed 
Model Clinical Trials Agreements being extended to include non-commercial research.  Further, plans 
are underway to ensure appropriate training and certification of research nurses.  In totality, these 
measures will ensure improvements in the conduct and therefore the outcomes of clinical research in 
the UK, a key goal if the UK is remain a competitive environment for multi-national research 
programmes. 
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7.1.  Direction of future research 
Given the study was unable to estimate what level of interest newly diagnosed women with breast 
cancer have in a group healthy eating programme, and whether attending such a programme led to 
improvements in overall health and well-being, should this study be undertaken again?   
 
To answer this question, the assumptions that underpinned this trial must be revisited.  At the time of 
conceiving this project, several key drivers were identified including; Current services failing to meet 
the long term health needs of this patient group, patient interest and improving patient health 
outcomes.   
7.1.1. Current NHS services 
Since this project started there has been no change in health service provision for breast cancer 
patients.  Health service policy continues to highlight the need for expansion and diversification of 
cancer services and the issue remains high on the NHS agenda.
126 127   
 
Further, with the 2007 recommendation
19 by the worlds leading cancer charity (WCRF) that all new 
cancer patients receive nutrition counselling, it could be argued that research in the role for diet in 
secondary cancer prevention remains current and valid.   
 
That said, in the period between submitting this thesis for examination and addressing reviewer’s 
comments, an important document has been published by the Department of Health in relation to this 
issues. 
 
On December 17, 2008 the Rehabilitation Measures as part of the revised Manual for Cancer Services 
2008 were issued.
128  These measures mandate the establishment of a network cancer rehabilitation 
lead and a network cancer rehabilitation group.  The remit of the cancer rehabilitation team is to: 
1.  conduct a baseline mapping of the current provision of cancer rehabilitation 
2.  develop cancer site specific rehabilitation pathways 
3.  develop a service specification 
4.  conduct a service needs assessment 
5.  develop a training and education strategy from the outcomes of the needs assessment 
 
The above rehabilitation measures apply specifically to four allied health professions; Physiotherapy, 
Occupational Therapy, Speech and Language Therapy and importantly Dietetics. 
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These measures should ensure that future services better meet the needs and expectation of cancer 
patients.  Specifically, if the baseline mapping and subsequent needs assessment process is 
conducted as planned, nutrition education should become, in future part of routine care pathway. 
7.1.2. Patient interest 
As discussed previously little evidence exists to estimate the likely interest in health promotion 
activities for newly diagnosed breast cancer patients.  Inferences can only be drawn from intervention 
studies with outcomes not focused on uptake in health promotion activities.  As the rehabilitation 
measures are introduced, service evaluation will provide this evidence. 
7.1.3. Improving patient health outcomes 
With survival rates from breast cancer continuing to rise to unprecedented levels, the need to look at 
ways to provide health care that addresses the long term needs of this patient group remains as it was 
prior to commencing this study. 
 
Prior to commencing this study, two large scale randomised controlled trials were underway in the US 
to determine if dietary modifications could influence survival rates in postmenopausal women 
diagnosed with breast cancer.  During the course of this study, both those trials published their 
findings.  In the WHEL study, no link between a healthy diet and breast cancer outcomes were found, 
and in the WINS study, the authors report an effect with a low fat diet on recurrence and survival 
however these findings remain controversial in the literature.  Therefore, currently no strong scientific 
evidence exists to show that changing dietary behaviours after diagnosis influences breast cancer 
outcomes.   
 
7.1.4. Summary  
In summary, the implementation of the Rehabilitation Measures for Cancer Services will ensure future 
service provision will address the broader health needs of cancer patients therefore negating the need 
for future research into the level of interest in health promotion programmes in this patient group.  
Providing the implementation of the measures is evaluated as planned, this information will be 
available for future service development initiatives. 
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7.2.  Personal statement 
At times I struggled with the fact that this study failed to meet its aims and objectives.  However the 
many and varied challenges I was presented with during the course of this project and the lessons 
learnt from dealing with those challenges, provided me with an exceptional learning opportunity.   
 
Specifically, I gained valuable experience in; applying for research funding, applying for ethical 
approval, applying for trust approval, setting up a steering group, setting up a research team, 
conflict resolution, communicating with and providing feedback to a wide range of health 
professionals and patients alike and lastly project management skills. 
 
As such I feel satisfied that despite the fact the project failed to achieve its outcomes, the funding 
scheme which was set up to support the development of researchers did achieve its aims and 
objectives and in the words of Henry Ford “ Failure is only the opportunity to begin again more 
intelligently”. 
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Trial 
 
 
 
Publications 
 
Year of 
publication 
 
 
Publication Title 
 
Type of 
dietary 
intervention 
 
Objectives 
 
Primary Outcome 
 
1. 
 
WOMENS INTERVENTION NUTRITION STUDY 
 
Stage I 
 
 
NAS (Nutrition 
Adjuvant Study) 
 
           
   
Trial results 
 
Chlebowski et al
25 
 
 
 
 
1987 
 
 
 
A breast cancer nutrition 
adjuvant study (NAS): protocol 
design and initial patient 
adherence 
 
 
Low fat diet 
 
Reduce dietary fat 
 
Total daily dietary intake of 
fat in grams 
   
As above 
 
Chlebowski et al
26 
 
 
1990 
 
Current Status: Evaluation of 
dietary fat reduction as 
secondary breast cancer 
prevention 
 
 
     
Stage II   
Feasibility study 
 
Chlebowski et al
27 
 
1993 
 
Adherence to dietary fat intake 
reduction therapy for early breast 
cancer 
 
 
Low fat diet 
 
To evaluate the feasibility of 
integrating a program based on 
dietary fat intake reduction into 
adjuvant treatment strategies for 
postmenopausal women 
receiving therapy for early breast 
cancer 
 
Dietary fat reduction to 20% 
of total energy – revised 
during intervention to 15% 
Stage III   
RCT 
 
Chlebowski et al
28 
 
2007 
 
Dietary fat reduction and breast 
cancer outcome: Interim efficacy 
results from the Women's 
Intervention Nutrition Study 
 
Low fat diet  To test the hypothesis that a 
dietary intervention targeting fat 
intake reduction would prolong 
relapse-free survival in women 
with resected breast cancer 
 
Relapse free survival 
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Trial 
 
 
 
Publications 
 
Year of 
publication 
 
 
Publication Title 
 
Type of 
dietary 
intervention 
 
Objectives 
 
Primary Outcome 
 
2. 
 
WOMENS HEALTHY EATING AND LIVING STUDY 
 
 
 
   
Feasibility study 
 
 
Pierce et al
29 
 
1997 
 
Feasibility of a randomized trial of 
a high-vegetable diet to prevent 
breast cancer recurrence 
 
High vegetable, 
reduced fat, and 
increased fibre diet 
 
To examine the feasibility of a 
randomized trial of diet 
intervention involving several 
major changes in the overall 
dietary pattern to reduce 
recurrence of breast cancer 
 
Dietary change 
Dietary adherence 
   
Interim analysis 
on 1010 women 
enrolled  on trial 
 
Rock et al
129 
 
2001 
 
Reduction in fat is not associated 
with weight loss in most women 
after breast cancer diagnosis: 
evidence from a randomized 
controlled trial 
 
High vegetable, 
reduced fat, and 
increased fibre diet 
 
Examine weight change in 
response to diet intervention 
 
 
Weight change 
   
Trial Design 
Paper 
 
Pierce et al
130 
 
2002 
 
A randomized trial of the effect of 
a plant-based dietary pattern on 
additional breast cancer events 
and survival: the Women’s 
Healthy Eating and Living Study 
 
High vegetable, 
reduced fat, and 
increased fibre diet 
   
   
Interim analysis 
of 393 women 
enrolled on trial 
 
 
Rock et a
131l 
 
2004 
 
Plasma triacylglycerol and HDL 
cholesterol concentrations 
confirm self-reported changes in 
carbohydrate and fat intakes in 
women in a diet intervention trial 
 
High vegetable, 
reduced fat, and 
increased fibre diet 
 
To examine the effect of 
increased carbohydrate and 
reduced fat intakes on plasma 
lipids 
 
 
Change in plasma lipid and 
serum insulin concentrations 
 
   
Interim analysis 
of 291 women 
enrolled on trial 
 
Rock et al
132 
 
2004 
 
Effects of a high-fiber, low-fat diet 
intervention on serum 
concentrations of reproductive 
steroid hormones in women with 
a history of breast cancer 
 
High vegetable, 
reduced fat, and 
increased fibre diet 
 
To examine the effects of a high 
vegetable, high-fiber, low-fat diet 
intervention on serum 
concentrations of reproductive 
steroid hormones 
 
 
Change in serum hormone 
and sex hormone binding 
globulin concentrations 
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Trial 
 
 
 
Publications 
 
Year of 
publication 
 
 
Publication Title 
 
Type of 
dietary 
intervention 
 
Objectives 
 
Primary Outcome 
   
Results from 
2970 women 
who had 
completed 1-year 
follow-up and 
had not had a 
breast cancer 
event 
 
 
Pierce et al
133 
 
2004 
 
 
Telephone counselling 
intervention increases intakes of 
micronutrient and phytochemical 
rich vegetables, fruit and fiber in 
breast cancer survivors 
 
High vegetable, 
reduced fat, and 
increased fibre diet 
 
Describe the effectiveness of this 
intervention protocol in achieving 
major changes in the overall 
dietary pattern 
 
 
Change in dietary intake 
Change in plasma carotenoid 
concentrations 
   
Subset of 77 
women enrolled 
on trial 
 
Thomson et al
134 
 
2005 
 
Longitudinal changes in body 
weight and body composition 
among women previously treated 
fro breast cancer consuming a 
high-vegetable, fruit and fiber, 
low-fat diet 
 
High vegetable, 
reduced fat, and 
increased fibre diet 
 
To investigate the association 
between reported changes in 
dietary intake and body weight 
and body composition measures 
 
Change in anthropometric 
and body composition 
measurements over 4 year 
period 
   
Reporting of 
baseline to 
twelve month 
dietary change in 
739 ‘on 
counselling’ 
protocol 
Participants 
(adherers) 
 
Newman et at
135 
 
2005 
 
Achieving substantial changes in 
eating behaviour among women 
previously treated fro breast 
caner – An overview of the 
intervention 
 
High vegetable, 
reduced fat, and 
increased fibre diet 
 
Reporting of baseline to 12-month 
dietary change and achievement 
of select Healthy People 2010 
dietary objectives 
 
 
Change in intake of 
vegetables, vegetable juice, 
fruit, fiber and fat and the 
association between cooking 
classes attended and overall 
dietary adherence 
   
Subset of 202 
women enrolled 
on WHEL 
 
 
Thomson et al
136 
 
2005 
 
 
Diet and Biomarkers of Oxidative 
Damage in Women Previously 
Treated for Breast Cancer 
 
 
High vegetable, 
reduced fat, and 
increased fibre diet 
 
To explore the relationship 
between dietary intake and 
oxidative DNA damage 
 
Effect of diet on oxidative 
damage biomarkers 
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Trial 
 
 
 
Publications 
 
Year of 
publication 
 
 
Publication Title 
 
Type of 
dietary 
intervention 
 
Objectives 
 
Primary Outcome 
 
3.  
 
 
Djuric et al and Jen et al  
   
 
 
 
Djuric et al
31 
 
2002 
 
Combining weight loss 
counselling with the weight 
watchers plan for obese breast 
cancer survivors 
 
Energy restriction 
 
To develop and test individualised 
methods for effective weight loss 
in obese breast cancer survivors 
 
Weight change 
   
 
 
 
Jen et al
32 
 
2004 
 
Improvement of metabolism 
among obese breast cancer 
survivors in differing weight loss 
regimens 
 
 
Energy restriction 
 
To examine the possible 
beneficial effects of three weight 
loss regimens on insulin 
resistance and blood lipid and 
leptin levels in obese breast 
cancer survivors 
 
Change in cholesterol, insulin 
and leptin levels 
 
4. 
 
 
Holm et al and Nordevang et al 
   
 
 
Holm  et al
33 
 
 
1990 
 
Dietary intervention as adjuvant 
therapy in breast cancer patients 
a feasibility study 
 
Low fat diet 
(20-25% of total 
energy) 
  
To evaluate the feasibility of using 
a low fat diet as a component of 
adjuvant therapy for breast 
cancer patients 
 
Change in dietary fat intake 
     
Nordevang et al
34 
 
 
1990 
 
Dietary intervention in breast 
cancer patients: effects on dietary 
habits and nutrient intake 
     
     
Nordevang et al
35 
 
1992 
 
 
Dietary intervention in breast 
cancer patients: effects on food 
choice 
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Trial 
 
 
 
Publications 
 
Year of 
publication 
 
 
Publication Title 
 
Type of 
dietary 
intervention 
 
Objectives 
 
Primary Outcome 
 
5.  
 
BRIDGES 
 
     
Herbert et al
36 
 
2001 
 
Change in Women’s diet and 
body mass following intensive 
intervention for early-stage breast 
cancer 
 
Low fat (20%), high 
fiber and 
micronutrients from 
plant sources 
 
To report on the effect of an 
intensive dietary intervention on 
dietary factors 
 
Change in dietary fat intake 
 
6. 
 
 
de Waard et al 
   
 
 
De Waard et al
37 
 
 
1993 
 
A feasibility study on weight 
reduction in obese 
postmenopausal breast cancer 
patients 
 
Low fat diet 
 
Feasibility study of weight 
reduction in obese 
postmenopausal women 
 
Weight change 
 
7. 
 
BCDIP 
 
     
Kristal et al
86 
 
1997 
 
 
Feasibility of using volunteer 
research staff to deliver and 
evaluate a low-fat dietary 
intervention: the American cancer 
society breast cancer dietary 
intervention project 
 
Low fat diet 
 
 
To examine whether a 
randomized trial using community 
volunteers could recruit study 
participants, deliver and monitor 
the intervention and achieve 
intervention goals 
 
Change in dietary fat intake 
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Study Title or 
Author 
 
 
Group allocation 
 
 
Details of nutrition intervention 
 
Dietary Assessment 
Method 
 
 
Duration of 
diet 
intervention 
 
Duration of 
Study 
 
Dietary 
Assessment 
schedule 
 
 
1.  
 
 
 
WOMENS INTERVENTION NUTRITION STUDY
24-28 
 
 
Stage I 
 
Nutrition 
Adjuvant Study 
 
1. Attention Control 
 
 
2. Intervention 
 
Fortnightly for 1
st 3 months then once a 
month up to one year 
 
Fortnightly for 1
st 3 months then once a 
month up to one year 
 
 
4 day food records 
 
1 year 
 
1 year  
 
0,3,6,12 months 
 
Stage II 
 
 
Feasibility study 
1. Attention Control 
 
 
2. Intervention 
Fortnightly for 1
st 3 months then once a 
month up to one year 
 
Fortnightly for 1
st 3 months then once a 
month up to one year 
 
 
3 unannounced, 24-hr 
dietary recalls 
1 year  1 year  0,3,6,12 months 
 
Stage III 
 
RCT 
 
1.  Control 
 
2. Intervention 
 
   
24 hr diet recalls 
 
2 years 
 
5 years 
 
 
 
2.  
 
 
 
WOMENS HEALTHY EATING AND LIVING STUDY
29 30 
 
 
 
Feasibility study 
 
1. Control 
 
2. Intervention 
 
Not reported 
 
Repeated 24-hr diet 
recall 
 
Not reported 
 
1 year 
 
0,6,12 months 
   
 
RCT 
 
1. Control 
 
2. Intervention 
 
Telephone counselling -  
Cooking classes - monthly 
Print material - monthly 
 
24 hour diet recall 
and FFQ 
   
5 years 
 
0,6,12,24,36,48,72 
months 
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Study Title or 
Author 
 
 
Group allocation 
 
 
Details of nutrition intervention 
 
Dietary Assessment 
Method 
 
 
Duration of 
diet 
intervention 
 
Duration of 
Study 
 
Dietary 
Assessment 
schedule 
 
 
3.  
 
 
 
Djuric et al and Jen et al
31 32 
     
1. Attention Control 
 
 
2. Weight Watchers (WW) 
 
 
 
3. Individualised counselling  
 
 
 
 
 
4. WW and individualised 
counselling 
 
 
 
Written materials on healthy eating 
 
 
Encouraged to attend WW with no other 
diet or exercise instruction 
 
 
Weekly telephone contacts by dietitian for 
1
st 3 months, biweekly for months 3 and 6 
and monthly thereafter.  Plus monthly 
meeting where written information was 
distributed 
 
 
Weekly telephone contacts by dietitian for 
1
st 3 months, biweekly for months 3 and 6 
and monthly thereafter.  Plus encouraged 
to attend WW meetings. 
 
 
3 day food records 
 
1 year 
 
1 year 
 
0,3,6,12 months 
 
 
4.  
 
 
 
Holm et al and Nordevang et al
33-35 
     
1. Control 
 
2. Intervention 
 
 
Individualised dietary counselling to 
reduce fat over 4-6 sessions over two 
months 
 
Diet history interview 
4 day food records 
 
2 months 
 
2 years 
 
0,3,6,9,12 and 24 
months 
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Study Title or 
Author 
 
 
Group allocation 
 
 
Details of nutrition intervention 
 
Dietary Assessment 
Method 
 
 
Duration of 
diet 
intervention 
 
Duration of 
Study 
 
Dietary 
Assessment 
schedule 
 
 
5.  
 
 
 
BRIDGES
36  
   
 
 
1. Control 
 
2. Nutrition Intervention 
 
 
 
 
 
 
3. Stress reduction intervention 
 
Usual care - no intervention 
 
2 x individual sessions, 1
st (60 mins) at 
beginning of program and 2
nd (30 mins) at 
the end of the program and 15 (14 x 150 
mins and 1 5.5 hour) x dietetic led group 
sessions.  Sessions were held weekly. 
 
Equivalent contact time with 
psychologists.  There was no nutrition 
material presented. 
 
7 day diet recall using 
FFQ 
   
1 year 
 
0,4,12 
 
 
6.  
 
 
 
de Waard et al
37  
     
1. Control 
 
2. Intervention 
 
 
Not reported 
 
Not reported 
 
Not reported 
 
1 year 
 
Not reported 
 
 
7.  
 
 
 
BCDIP
38  
   
Kristal et al 
 
 
1. Control 
 
2. Intervention 
 
 
6 x one hour weekly individual sessions 
then monthly 1 hour group sessions x 10 
 
 
4 day food record 
 
1 year 
 
1 year 
 
0,3,6 and 12 months 
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9.2.  CONSORT Checklist  
 
PAPER SECTION 
And topic 
Item  Description 
TITLE & ABSTRACT  1  How participants were allocated to interventions (e.g., "random 
allocation", "randomized", or "randomly assigned"). 
INTRODUCTION 
Background 
2  Scientific background and explanation of rationale. 
METHODS 
Participants 
3  Eligibility criteria for participants and the settings and locations 
where the data were collected. 
Interventions  4  Precise details of the interventions intended for each group and 
how and when they were actually administered. 
Objectives  5  Specific objectives and hypotheses. 
Outcomes  6  Clearly defined primary and secondary outcome measures and, 
when applicable, any methods used to enhance the quality of 
measurements (e.g., multiple observations, training of 
assessors). 
Sample size  7  How sample size was determined and, when applicable, 
explanation of any interim analyses and stopping rules. 
Randomization -- 
Sequence generation 
8  Method used to generate the random allocation sequence, 
including details of any restrictions (e.g., blocking, stratification) 
Randomization -- 
Allocation 
concealment 
9  Method used to implement the random allocation sequence (e.g., 
numbered containers or central telephone), clarifying whether the 
sequence was concealed until interventions were assigned. 
Randomization -- 
Implementation 
10  Who generated the allocation sequence, who enrolled 
participants, and who assigned participants to their groups. 
Blinding (masking)  11  Whether or not participants, those administering the 
interventions, and those assessing the outcomes were blinded to 
group assignment. If done, how the success of blinding was 
evaluated. 
Statistical methods  12  Statistical methods used to compare groups for primary 
outcome(s); Methods for additional analyses, such as subgroup 
analyses and adjusted analyses. 
RESULTS 
Participant flow 
 
13  Flow of participants through each stage (a diagram is strongly 
recommended). Specifically, for each group report the numbers 
of participants randomly assigned, receiving intended treatment, 
completing the study protocol, and analyzed for the primary 
outcome. Describe protocol deviations from study as planned, Chapter Nine: Appendices 
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together with reasons. 
Recruitment  14  Dates defining the periods of recruitment and follow-up. 
Baseline data  15  Baseline demographic and clinical characteristics of each group. 
Numbers analyzed  16  Number of participants (denominator) in each group included in 
each analysis and whether the analysis was by "intention-to-
treat".   State the results in absolute numbers when feasible (e.g., 
10/20, not 50%). 
Outcomes and 
estimation 
17  For each primary and secondary outcome, a summary of results 
for each group, and the estimated effect size and its precision 
(e.g., 95% confidence interval). 
Ancillary analyses  18  Address multiplicity by reporting any other analyses performed, 
including subgroup analyses and adjusted analyses, indicating 
those pre-specified and those exploratory. 
Adverse events  19  All important adverse events or side effects in each intervention 
group. 
DISCUSSION 
Interpretation 
20  Interpretation of the results, taking into account study 
hypotheses, sources of potential bias or imprecision and the 
dangers associated with multiplicity of analyses and outcomes. 
Generalizability  21  Generalizability (external validity) of the trial findings. 
Overall evidence  22  General interpretation of the results in the context of current 
evidence. 
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The Consort E-Flowchart  Aug. 2005 
 
       
 
 
 
 
 
Assessed for eligibility (n=   ) 
Excluded (n=   ) 
 
Not meeting inclusion criteria (n=   
) 
Refused to participate (n=   ) 
Other reasons (n=   ) 
Analyzed (n=    ) 
 
Excluded from analysis (n=    ) 
Give reasons 
Lost to follow-up (n=   ) 
Give reasons 
 
Discontinued intervention (n=    ) 
Give reasons 
Allocated to intervention (n=    ) 
Received allocated intervention (n=    ) 
Did not receive allocated  
intervention (n=   ) 
Give reasons 
Lost to follow-up (n=   ) 
Give reasons 
 
Discontinued intervention (n=   ) 
Give reasons 
Allocated to intervention (n=   ) 
Received allocated intervention (n=    ) 
Did not receive allocated  
intervention (n=   ) 
Give reasons 
Analyzed (n=    ) 
 
Excluded from analysis (n=   ) 
Give reasons 
Allocation 
Analysis 
Follow-Up 
Enrolment 
Is it randomized? Chapter Nine: Appendices 
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9.3.  Recruitment matrix for focus groups 
 
1  Single Person Household, Working, no children, recently diagnosed 
2  Single Person Household, Working, no children, diagnosed 1-3 yrs ago 
3  Single Person Household, Working, no children, diagnosed >5 yrs ago 
4  More than 1 Person Household, working, no children, recently diagnosed 
5  More than 1 Person Household, working, no children, diagnosed 1-3 yrs ago 
6  More than 1 Person Household, working, no children, diagnosed >5 yrs ago 
7  Single Person Household, Working, with children, recently diagnosed 
8  Single Person Household, Working, with children, diagnosed 1-3 yrs ago 
9  Single Person Household, Working, with children, diagnosed >5 yrs ago 
10  More than 1 Person Household, working, with children, recently diagnosed 
11  More than 1 Person Household, working, with children, diagnosed 1-3 yrs ago 
12  More than 1 Person Household, working, with children, diagnosed >5 yrs ago 
13  Single Person Household, Retired, recently diagnosed 
14  Single Person Household, Retired, diagnosed 1-3 yrs ago 
15  Single Person Household, Retired, diagnosed >5 yrs ago 
16  More than 1 Person Household, Retired, recently diagnosed 
17  More than 1 Person Household, Retired, diagnosed 1-3 yrs ago 
18  More than 1 Person Household, Retired, diagnosed >5 yrs ago 
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9.4.  Covering letter for focus groups 
 
Date: 
 
Dear 
 
Re: Study entitled ‘Reshaping Breast Care Services – A Role for Dietitians?’ 
 
I am writing to inform you that our Breast Unit has agreed to take part in a small study to 
identify: 
 
  if Breast Cancer patients would like to have nutrition education as part of their 
standard care pathway  
  if so, what type of programme would they like implemented. 
 
The study will take the form of a focus group, which will be held on (date). 
 
 I am enclosing a copy of the patient information sheet for your information.  However, if 
you have any questions please do not hesitate to contact the lead investigator, Jillian 
Milne. 
 
With kind regards 
 
 
Consultant Breast Surgeon 
 
_________________________________________________________ 
 
Reply slip 
 
Please reply by…………..  A phone call or email will do instead of the reply slip. 
 
To:  Jillian Milne 
  State Registered Dietitian 
  Tel (direct line) 
  Email  
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I will be attending the focus group on   
 
Name ………………………………………………………………………………… 
 
If you are coming to the group, please could you give a contact phone number so that 
Jillian can contact you if necessary.   Please contact Jillian if you have any questions 
about the group or need directions. 
 
Please note: As some participants may still be having treatment for their breast cancer, 
we would be grateful if you would consider others by not attending the meeting if you have 
an acute infection.  If this is the case we would ask that you notify us on the day. Chapter Nine: Appendices 
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9.5.  Patient information sheet 
 
Reshaping Breast Care Services – A Role for Dietitians? 
 
My colleague (Consultant Surgeon) is forwarding this information sheet to you on my 
behalf.  My name is Jillian Milne and I am a State Registered Dietitian.  I have recently 
begun postgraduate studies with the School of Medicine at the University of Southampton 
looking at the care given to Breast Cancer Patients in the NHS.  
 
This letter is to invite you to consider participating in my study.  Before you decide if you 
would like to take part it is important that you understand what your participation may 
involve.  I would therefore be grateful for a few moments of your time to read the following 
information and to discuss it with your family and/or friends if you so wish. 
 
Background 
 
In my previous position as the Research Dietitian with the Winchester and Eastleigh NHS 
Trusts Breast Care Unit, I had the opportunity to meet many breast cancer patients, some 
of whom expressed their concern about the lack of nutrition advice given at the time of 
their diagnosis.  Now that a holistic approach to care is being taken and diet for a general 
healthy lifestyle is an area of interest to Breast Cancer patients, I applied for and have 
received funding from the Department of Health to conduct some research on piloting a 
nutrition education programme for newly diagnosed breast cancer patients.  
 
The study will be conducted in three parts and I am writing to you today to ask if you 
would be interested in taking part in the first stage of the study.  The first stage of the 
project will be conducting group discussions called ‘focus groups’ with around 10-12 
current and past breast cancer patients.  The purpose of these discussions is to get your 
views and opinions on the type of nutrition programme you would like to see in the NHS, 
as ultimately the success of the programme will depend on its acceptance to breast 
cancer patients. 
 
What would participation involve? 
 
The focus group I am inviting you to attend is to be held on (date).  During this time I would like 
you and the other participants to discuss and comment on the type of nutrition programme you 
would like to see offered to breast cancer patients.   
 
We are very interested in your views and want to make sure we capture all the comments made 
during the focus group and for this reason the discussion will be audio taped.  The audio will be 
analysed to draw out the main themes at a later date and this information along with some 
handwritten notes taken during the focus group will be compiled into a report detailing 
recommendations for the development of the nutrition education program to be run in stage two.  
The audio tapes will be stored for 15 years in line with the data protection policy of the 
University of Southampton.  All information from the discussion will be anonymised and 
therefore no personal details will be retained. Chapter Nine: Appendices 
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Will I benefit from the study? 
 
This study will have no direct benefit to you as you have either begun or finished your treatment 
and the programme will be aimed at newly diagnosed breast cancer patients.  However the 
information obtained will help to inform my colleagues and myself as to how we can improve 
things for future patients. 
 
What do I need to do if I decide to take part? 
 
Please return the reply slip to me in the enclosed envelope (retain this copy of the patient 
information sheet for your future reference).  On the day I will then ask you to sign a consent 
form.  This is nothing to be alarmed about.  The consent form gives your permission for me to 
share the information with colleagues outside of (Relevant NHS Trust)  The information that I 
will obtain will not contain any of your personal details; therefore you anonymity will be assured. 
 
What if I decide not to take part? 
 
If you decide not participate in the study you need take no further action.   
 
Who do I contact if I have any further questions? 
 
Please feel free to telephone me on the above number, which is a direct line.  I would be more 
than happy to discuss this study in more detail with you. 
 
Thank you for your time in reading this information sheet. 
 
 
 
 
Jillian Milne 
 Chapter Nine: Appendices 
 
  182 
 
9.6.  Consent form for focus groups 
 
Title of Project: Reshaping Breast Care Services – A Role for Dietitians? 
 
Name of Researcher: Jillian Milne 
                       
  Please initial box 
 
1.  I confirm that I have read and understand the patient information sheet 
dated ............................  (version ............) for the above study and have had the 
opportunity to ask questions. 
 
2.  I understand that my participation is voluntary and that I am free to withdraw at any 
time, without giving any reason, without my medical care or legal rights being 
affected. 
 
3.  I understand that sections of any of my medical notes may be looked at by 
responsible individuals from [hospital/institution] or from regulatory authorities 
where it is relevant to my taking part in research.  I give permission for these 
individuals to have access to my records. 
 
4.  I agree to take part in the above study.                                                        
 
 
   
Name of Patient  Date  Signature 
 
 
   
Name of Person taking consent  Date  Signature 
(if different from researcher) 
 
 
   
Researcher  Date  Signature 
 
 
1 for patient;  1 for researcher;  1 to be kept with hospital notes 
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9.7.  GP letter for focus groups 
 
 
Date 
 
 
Dear Dr ……….. 
 
Re:   Patients Name   ………………………………. 
DOB      ……/……/…… 
 
I are writing to inform you that this lady has agreed to take part in a focus group looking at ways to 
improve current services offered to breast cancer patients.  Please find enclosed a leaflet regarding 
this Study.    
 
…………………………… will be attending a group session on ………………….. at 
…………………………….. 
 
Ethical approval for this Study has been obtained and it is funded by the Department of Health’s - 
National Co-ordinating Centre for Research Capacity Development. 
 
I would be pleased to discuss any aspects of this Study with you should you require any more 
information. 
 
Yours sincerely 
 
 
 
Jillian Milne SRD 
Research Dietitian 
 
Enc – Patient Information Sheet Chapter Nine: Appendices 
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9.8.  Rosenberg Self-Esteem Scale (Rosenberg, 1965) 
 
 
 
 Chapter Nine: Appendices 
 
  185 
 
 
 
 Chapter Nine: Appendices 
 
  186 
 
9.9.  Multidimensional Health Locus of Control Questionnaire 
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9.10. Food Frequency Qestionnaire (HEA3) 
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9.11. Fact-ES Questionnaire (Version 4) 
 
 
 Chapter Nine: Appendices 
 
  195 
 Chapter Nine: Appendices 
 
  196 
 Chapter Nine: Appendices 
 
  197 
 
 
 Chapter Nine: Appendices 
 
  198 
 
9.12. Covering letter for healthy eating programme 
 
 
Date 
 
 
Dear 
 
I am writing to you as our Breast Unit is participating in a research study with the University of Southampton.  The 
study is looking at whether a group healthy eating programme would be of interest for women who have had a recent 
diagnosis of breast cancer.  
 
 
I have enclosed a patient information sheet which provides complete details about the study including the contact 
details of the research team. 
 
 
 
Yours sincerely 
 
 
 
 
CONSULANT BREAST SURGEON 
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9.13.  Patient information sheet for healthy eating programme 
 
 
 
 
Patient information sheet 
Uptake and response to dietary intervention  
in women with breast cancer 
PART 1 
 
You are being invited to take part in a research study to see whether a group “healthy eating” programme would be 
beneficial for newly diagnosed breast cancer patients.  Before you decide whether or not to participate it is important for you 
to understand why the research is being done and what it will involve.  Please take time to read the following information 
carefully and talk to others such as family or friends about the study if you wish. 
 
  Part 1 tells you the purpose of this study and what will happen to you if you take part 
  Part 2 gives you more detailed information about the conduct of the study 
 
Please do not hesitate to ask me if there is anything that is not clear or if you would like more information. Take time to 
decide whether or not you wish to take part. 
 
 
What is the purpose of the study? 
 
In my previous position as the Research Dietitian with the Winchester and Eastleigh NHS Trusts Breast Care Unit, I had the 
opportunity to meet many breast cancer patients, some of whom expressed their concern about the lack of nutrition advice 
given at the time of their diagnosis.   
 
Now that a holistic approach to care is being taken by the NHS and diet for a general healthy lifestyle is an area of interest to 
breast cancer patients, I applied for and subsequently received funding from the Department of Health to conduct research 
into the benefit of a group “healthy eating” programme for newly diagnosed breast cancer patients.    
 
At an individual level, the purpose of the study is to help you improve your diet which in turn could improve your overall 
health and well-being.  At a broader level the study will allow us to identify the demand for a healthy eating programme and 
secondly to identify whether the programme was helpful in improving women’s diets.   The results of this study may be used 
by NHS service development units when planning improvements to cancer services. 
 
Why have I been chosen? 
 
All postmenopausal women at (name of trust) diagnosed with breast cancer during a period of six months starting from 
February 2007 are being invited to participate in the study.   
 
Do I have to take part? 
No.  It is up to you to decide whether or not to take part.  If you do, you should keep this information sheet and before we 
collect any information you will be asked to sign a consent form.   
 
You are still free to withdraw at any time and without giving a reason.  A decision to withdraw at any time, or a decision not to 
take part, will not affect the standard of care you receive. 
 
What will happen to me if I take part? 
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You will be contacted by phone from a nurse in your Breast Unit’s team within the next seven days to see if you are 
interested.  If you are, the nurse from the Breast Unit will arrange to meet with you at your next appointment. At this meeting 
you will be asked to sign the consent form and we will begin to collect information from you which are outlined below. 
 
The study itself will be conducted in two stages.  I have included a diagram which might be helpful to look at when you are 
reading the following section. 
 
Stage One 
 
You will be asked to complete three questionnaires looking at your current diet and other health behaviours which consider 
the reasons for your desire to participate in this study or not.  The questionnaires will take approximately fifteen minutes to 
complete.  Your height and weight will also be measured by the nurse at this time. 
 
Stage Two 
 
To find out if providing “healthy eating” classes is helpful in improving your diet, we need to put people into two groups, half 
the people will attend the group “healthy eating” programme and the other half will receive normal services.  Currently in the 
NHS newly diagnosed breast cancer patients are not offered any nutrition advice as part of their care package.  To try and 
ensure the groups are the same to start with each patient is put into one of the two groups by chance (randomly).  This is 
done by a computer.   At the end of the study the results are compared.  You will have a one in two or a 50% chance of 
being placed in the “healthy eating” programme. 
 
If you are selected to attend the group “healthy eating” classes you will be invited to attend 4 x two-hour small (maximum 12) 
group nutrition education classes held over the course of six months.  We would like you to attend these classes once a 
month however we understand that there may be times during the course of your treatment when you may not be able to 
attend classes.  By giving you six months to complete the four classes this allows some flexibility to pick and choose which 
classes suit you the most.    
 
The classes will be conducted by a State Registered Dietitian.  The classes will be based on the Government’s “Eatwell: 
Your Guide to Healthy eating” programme as currently, we do not know what type of diet will delay or prevent your cancer 
from returning.   We do know however that following a healthy diet can benefit your general health and well-being.  
 
Other topics such as common nutrition problems that occur during cancer treatment and discussions about alternative diets 
and supplements will be addressed.  The classes will be very interactive and will encourage group participation.  They will be 
held during working hours at the Macmillan Centre facilities.  
 
Before you start attending classes, in addition to the three questionnaires you completed in stage one you will be asked to fill 
in one further Quality of Life questionnaire which will take about five minutes to complete.  At the end of the six month study 
period we will ask you to repeat the same measurements taken in both stages one and two so that we can compare the 
results.   
 
After we have collected this information there will be no further follow-up required for this study. 
 
For those women who are not placed into the nutrition education classes at the time of allocation, we will be offering 2 
x half-day “healthy eating” seminars where you will be given all the information outlined above that was taught to the 
“healthy eating” group once the study is over. 
 
Expenses and Payments 
 
We will not be able to offer any reimbursement for travel expenses incurred in attending the group “healthy eating” 
classes.   
 
Will I benefit from the study? 
 
We cannot promise the study will help you, however adopting a healthier diet has been shown to improve general health and 
well-being.   
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The information we collect might help improve the services offered to future Breast Cancer Patients.  
 
What if there is a problem? 
 
Any complaint about the way you have been dealt with during the study will be addressed.  The detailed information on this 
is given in Part 2.  
 
Contact number for complaints is  
Jillian Milne  
Chief Investigator  
Telephone:  023 8079 6539 
 
Will my taking part in the study be kept confidential? 
 
Yes.  All the information about your participation in this study will be kept confidential.  The details are included in Part 2. 
 
Contact Details 
 
Jillian Milne 
Research Fellow 
Institute of Human Nutrition 
Level E (MP893) Centre Block 
Southampton General Hospital 
Tremona Rd 
Southampton 
SO16 6YD 
  
Tel  +44 (0)23 8079 6539 
Fax +44 (0)23 8079 5102 
Mobile 07960 607149 
 
This completes Part 1 of the Information Sheet.  If the information in Part 1 has interested you and you are 
considering participation, please continue to read the additional information in Part 2 before making any decision. 
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PART 2 
 
What will happen if I don’t want to carry on with the study? 
 
You can withdraw from the study at any time; however we will contact you six months after starting the program to ask if you 
would be willing to: 
  
  Complete the end of study questionnaires 
  Have your weight measured 
 
You may accept or decline one or all of these requests without affecting the standard of care you receive. 
 
What if there is a problem 
 
Complaints 
 
If you have a concern about any aspect of this study, you should ask to speak with the researcher who will do her best to 
answer your questions (023 8079 6539). 
If you remain unhappy and wish to complain formally, you can do this through the NHS Complaints Procedure.  Details can 
be obtained from the hospital. 
 
Harm 
 
Participation in the study carries no significant risk of physical or psychological harm.  However if you are harmed due to 
someone’s negligence, you may have grounds for a legal action for compensation against The University of Southampton 
and the University of Southampton NHS Hospitals trust but you may have to pay your legal costs.  The normal National 
Health Service complaints mechanisms will still be available to you. 
 
Will my taking part in this study be kept confidential? 
 
Any information which is collected about you during the course of the research will be kept strictly confidential.  Any personal 
details about you will be kept by the research nurse at the Breast Unit who will give you a unique study number.  All data 
collected by the research team will contain only this study number.  No personal information will be passed onto the research 
team.  
 
The data collected will be used to compare the results between the two groups for measures of dietary patterns, weight and 
quality of life scores.  The data will be held for 30 years and then destroyed securely in accordance with NHS Policy. The 
data will not be used for any future studies.   
 
Involvement of the GP 
 
With your consent, we will notify your GP that you are participating in the study.  
 
What will happen to the results of the research study? 
 
At the end of the study we will write to you outlining the main findings of the study. 
 
The results from this study will also be submitted for publication to relevant medical journals and presented at conferences 
for health professionals. 
 
Participants will not be identified in any report or publication. 
 
Who is organising and funding the research? 
 
The study is funded by the Department of Health’s’ National Co-ordinating Centre for Research Capacity Development.  The 
Researcher, Jillian Milne has received a Researcher Development Award which covers salary costs along with a small 
research budget.  The sponsors of this study, the Southampton University’s Hospital NHS trust and the University of 
Southampton will not receive any money for including you in the study. 
 
Who has reviewed the study? 
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This study was given a favourable ethical opinion by the Southampton & South West Hampshire Research Ethics Committee 
B (REC Reference Number: 06/Q1704/144) 
 
 
Thank you for your time in reading this information sheet. Chapter Nine: Appendices 
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9.14. Consent form for healthy eating programme 
 
Title of Project: Uptake and response to dietary intervention in women with breast cancer 
 
Name of Researcher: Jillian Milne 
                    Please initial box 
 
1.  I confirm that I have read and understand the information sheet dated 11, 
December, 2006 (version 3) for the above study.  I have had the 
opportunity to consider the information, ask questions and have had these 
answered satisfactorily 
 
2.  I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care or 
legal rights being affected 
 
3.  I understand that relevant sections of any of my medical notes and data 
collected during the study may be looked at by responsible individuals from 
the University of Southampton, regulatory authorities or from the NHS trust, 
where it is relevant to my taking part in this research.  I give permission for 
these individuals to have access to my records 
 
4.  I agree to my GP being informed of my participation in the study 
 
 
5.  I agree to take part in the study 
 
 
Name of Patient  Date    Signature 
 
 
 
Name of Person taking consent  Date    Signature 
(if different from researcher) 
 
 
   
Researcher  Date                Signature 
 
When completed, 1 for patient; 1 for researcher site file; 1 (original) to be kept in medical notes Chapter Nine: Appendices 
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9.15. GP Letter for healthy eating programme 
 
Date 
 
 
Dear Dr ……….. 
 
Re:   Patients Name   ………………………………. 
DOB      ……/……/…… 
 
I are writing to inform you that this lady has agreed to take part in a study looking at ways to improve current services 
offered to breast cancer patients.  Please find enclosed a leaflet regarding this Study.    
 
(name of patient) will be attending group sessions at the Macmillan Cancer Support Centre, Southampton General 
Hospital. 
 
Ethical approval for this Study has been obtained and it is funded by the Department of Health’s - National Co-
ordinating Centre for Research Capacity Development. 
 
I would be pleased to discuss any aspects of this Study with you should you require any more information. 
 
Yours sincerely 
 
 
 
Jillian Milne SRD 
Research Dietitian 
02380 798924 
 
Enc – Patient Information SheetChapter Nine: Appendices 
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9.16. Steering Group Member List 
Table 9-3 Invited steering group members 
Name  Organisation  Role 
Mr Mark Mullee  RDSU Southampton University Hospital Trust  Director and Statistician 
Dr Rachel Thompson  Institute of Human Nutrition 
Senior Research Fellow/Public Health 
Nutritionist 
Dr Sian Robinson  Medical Research Council Epidemiology Unit  Senior Research Fellow 
Mr Richard Rainsbury  Winchester and Eastleigh Healthcare Trust  Consultant Breast Surgeon 
Mr David Rew  Southampton Universities Hospital Trust  Consultant Breast Surgeon 
Ms Lorraine Brown  Winchester and Eastleigh Healthcare Trust  Breast Care Nurse 
Professor  William Rosenberg  Wellcome Trust Clinical Research Facility  Director 
Professor  Alan Jackson   Institute of Human Nutrition  Director 
Professor  Martin Wiseman  WCRF (World Cancer Research Fund)  Consultant 
Professor Tony Kendricks  NCCRCD   Chair of the Researcher Development Awards 
Ms Anne Croudass  NCRN (National Cancer Research Network)  Network Lead Nurse 
Ms Pat Dawney  Consumer Research Panel  Consumer Representative 
Ms Fran Williams  MacMillan Cancer Relief  Service Development Manager 
Ms Janice Gabriel  Research Ethics Committee  Committee member 
Professor Lesley Fallowfield  Brighton and Sussex Medical School  Professor in Psycho-Oncology 
Mrs Hilary Warwick  Nutrition and Dietetics  Director 
Dr Deborah Fenlon  Southampton University, School of Nursing and Midwifery  Senior Research Fellow Chapter Nine: Appendices 
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9.17.  Birmingham Clinical Trials Unit Peer Review Report 
 
 
24
th November 2006 
 
Dear Sir 
 
Re: Reshaping Breast Cancer Services – A Role for Dieticians? 
 
This study forms part of a PhD project and aims to understand the factors that influence enrolment 
and  subsequent  participation  in  a  “healthy  eating”  program  for  postmenopausal  women  newly 
diagnosed  with  breast  cancer,  and  then  plans  to  assess  if  a  group  “healthy  eating”  program 
improves diet in these women. 
 
Previous breast cancer research has focused mainly on prevention, with the findings that the risk of 
breast cancer can be reduced by taking regular exercise, adopting a healthy diet, not smoking and 
drinking alcohol in moderation.  The prevention of breast cancer remains a priority, as it still affects 
one in eight women in the United Kingdom.  However, with the number of women now surviving a 
diagnosis of breast cancer having increased in the last ten years, there has been a shift towards 
addressing the needs of cancer survivors (with cancer survivorship labelled a national priority by 
the National Cancer Research Institute).   
 
Whilst the role of nutrition in the primary prevention  of cancer has been the subject of several 
reviews,  the  role  of  lifestyle  changes  in  the  secondary  prevention  of  breast  cancer  remains 
unanswered.  Research shows that women newly diagnosed with breast cancer are interested in 
and do make lifestyle changes, reasoning that if diet can reduce the risk of breast cancer, then diet 
might also reduce the risk of disease recurrence.  However, despite this, currently the National 
Health  Service  does  not  offer  nutrition  advice  to  these  women.    Further,  with  many  women 
overweight or obese at time of diagnosis, any improvement in diet would be of benefit to their 
general health (and reduce the risk of other complications such as diabetes and cardiovascular 
problems). 
 
The randomised controlled trial part of the study compares a group “health eating” program with 
usual care.  The planned intervention is cheap and relatively easy to implement both in the clinic 
and at home by the patient.  Importantly, the results from this part of the study will help inform 
health care providers of the needs and expectations of breast cancer patients.   
 
The primary outcome of the study is diet quality, which will be assessed using the Diet Quality 
Index-Revised (DQI-R), and aims to detect a 10 point improvement in the DQI-R (with 90% power).  
The study plans to recruit 200 patients, which would actually provide statistical power to detect a 
smaller difference (between 5 and 6 points).  However, by recruiting 200 patients, this allows for 
patient drop-out and loss to follow-up, but also the confidence intervals for the primary outcome will 
be tighter and analysis of the secondary outcomes will be more robust. 
 
My  main  criticism  of  the  proposed  study  is  the  possibility  of  contamination  in  those  patients 
randomised to routine care (the control group).  There is the potential for these women to make 
changes to their diet outside the realms of the trial, which could potentially dilute any treatment 
effect.  However, this is a pragmatic study and the authors are aware of this problem, and the trial 
is powered to detect a smaller difference than stated in the protocol. 
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In summary, the proposal is well-written and thought out (they have discussed the project with a 
variety  of  leading  experts  within  the  field),  and  asks  an  interesting  question  (with  an  easy  to 
implement intervention) in an important disease area. 
 
 
Yours faithfully 
 
 
 
 
Natalie Ives 
Senior Statistician, BCTU 
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9.18. Results Study Two  
9.18.1.  Study two - Stage two – Participation 
Due to the small number of women enrolled to participate in the group healthy eating programme, 
insufficient data was generated to enable meaningful statistical analyses to be conducted.  The 
following section instead details the outcomes from each of the proposed protocol sections as 
described in the methods. The reason for this is that each of these sections will form the basis of a 
large part of the following chapter, the discussion,  in order to identify the reasons for the study’s 
failure to meet its aims and objectives. 
9.18.1.1.  Study outcomes 
Study outcomes were not achieved.  The reasons for this are systematically reviewed in Chapter 
Six (Discussion).   
9.18.1.2.  Randomisation 
Randomisation was achieved as planned via telephone utilising the services of the Birmingham 
Clinical Trials Unit. 
9.18.1.3.  Data collection 
Data was not collected as per protocol (see section 5.7.5.2 below for further details). 
9.18.2.  Intervention schedule 
Due to poor recruitment numbers, only one group was formed and subsequently completed the 
group healthy eating programme as per protocol. 
9.18.3.  Quality control  
9.18.3.1.  Screening and recruitment Chapter Nine: Appendices 
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9.18.3.2.  Data 
Significant numbers of missing and incomplete data were found (see tables 5-16 and 5-17).  In total 
of the 105 sets of data that should have been completed, 23 (22%) was missing and all 17 (100%) 
food frequency questionnaires were unable to be analysed due to incomplete data. 
 
 
 
 
Data form  Incomplete  Missing 
Food frequency questionnaire  17/21  4/21 
Multidimensional health locus of control  1/21  4/21 
Self rated diet  0/21  6/21 
Body mass index  0/21  2/21 
Self esteem  0/21  5/21 
 
Table 9-4 Summary of incomplete/missing data at baseline 
 
Data form  Incomplete  Missing 
Food frequency questionnaire  8/10  2/10 
Body mass index  0/10  3/10 
Self esteem  0/10  2/10 
 
Table 9-5 Summary of incomplete/missing data at six-month follow-up 
 
9.18.3.3.  Dietary intervention 
The healthy eating classes were delivered in accordance with the protocol. 
9.18.4.  Study period 
The study was open for recruitment as planned for six months between April 2007 and September 
2007. 
9.18.5.  Data collection 
Data was collected at the correct time periods as per protocol however procedures for data 
collection were violated. Chapter Nine: Appendices 
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9.18.6.  Data analysis 
Due to the small data sets, electronic scanning was not performed.  All completed data collection 
forms were manually entered into SPSS by the CI and as planned, the CI conducted all analyses.Chapter Nine: Appendices 
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1.0  Introduction 
 
Survival rates for breast cancer have improved dramatically over recent years largely due to earlier 
detection and more effective treatments.  Currently over 80% of postmenopausal women 
diagnosed with breast cancer can expect to survive their diagnosis.   
 
Not surprisingly, these women are becoming increasingly interested in how they can improve their 
overall health and well-being.  One area of particular interest patients consistently report in the 
literature is diet, as cancer patients view nutrition as an important part of their cancer therapy.  The 
literature shows that significant numbers of these women make changes to their diets after their 
diagnosis and cite frustration with the lack of support from health care providers in adopting these 
changes. 
 
Currently a unique opportunity exists in the National Health Service to develop health promotion 
activities for breast cancer survivors. With the recent shift in focus from a NHS that does things “to” 
and “for” its patients to one that is “patient led” the foundations had been laid to identify, plan and 
deliver services that better meet the needs and expectations of patients. 
 
This study will pilot a group healthy eating program with newly diagnosed postmenopausal women 
with breast cancer.  The results from this study will help future cancer service development 
initiatives. Procedures Manual 
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2.0  Overall aims 
 
 
Title 
 
Reshaping Breast Care Services – A Role for Dietitians? 
 
 
Overall Aims 
 
1.  To understand the factors that influence enrolment and 
subsequent participation in a “healthy eating” program 
for newly diagnosed postmenopausal women with 
breast cancer. 
 
2.  To assess if a group “healthy eating” program improves 
the diets of newly diagnosed postmenopausal women 
with breast cancer 
 
 
Purpose 
 
 
To inform cancer service development initiatives 
 
Design 
 
This “mixed method” study will be conducted in two stages 
 
Stage 1: Cross-sectional study  
Stage 2: Randomised controlled trial 
 
. 
               
  Procedures Manual 
  217 
2.1 Aims and Objectives – Study One 
 
 
Study 1 – Cross-sectional study 
 
 
Aims  
 
3.  To estimate the proportion of newly diagnosed postmenopausal women with 
breast cancer who will enrol on a group “healthy eating” program 
4.  To understand the factors that influence enrolment in a “healthy eating” 
program 
 
 
Objectives  
 
3.  To invite 400 newly diagnosed postmenopausal women with breast cancer 
to a group “healthy eating” program during the recruitment period of six 
months 
4.  To describe the factors that determine whether or not newly diagnosed 
postmenopausal women with breast cancer enrol on a “healthy eating” 
program 
 
 
Hypothesis 
 
 
50% of newly diagnosed postmenopausal women with breast cancer will enrol in a 
“healthy eating” program 
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a.  Aims and Objectives – Study Two 
 
Study 2 – Randomised Controlled Trial 
Aims  3.  To assess if a group “healthy eating” program improves the diets of newly 
diagnosed postmenopausal women with breast cancer compared with usual care 
4.  To determine the impact of participating in a “healthy eating” program on self 
reported quality of life scores compared with usual care  
5.  To understand the factors that influence participation in a “healthy eating” 
program 
Objectives   4.  To compare change in overall diet quality scores in the “healthy eating” group with 
usual care 
5.  To compare change in weight in the “healthy eating” group with usual care 
6.  To compare self reported quality of life scores in the “healthy eating” group with 
usual care 
7.  To describe the factors that determine whether or not newly diagnosed 
postmenopausal women with breast cancer complete a  “healthy eating” program 
Hypothesis 
 
3.  Difference in change of overall diet quality scores will be 10 points higher for 
women in the “healthy eating” group compared to women in usual care. 
4.  Difference in change in weight over the course of the intervention will be 3 kgs less 
in women enrolled in the “healthy eating” group compared to women in usual care. 
Intervention   A group “healthy eating” program of 4 x 2 hour sessions over a six-month period 
Study Groups  Usual care 
Healthy Eating Group 
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3.0 Participant  
Flow 
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4.0 General information 
 
  All the data collection forms are specially designed to be scanned.  Therefore please DO 
NOT PHOTOCOPY them as the information will not be recognised by the scanning 
computer 
  Only information recorded in the boxes will be picked up by the scanner so please do not 
write information outside these boxes.  If you make a mistake in a box you will have to start 
another form. 
  I can’t stress how important it is that ALL postmenopausal women be invited.  If women are 
missed the study will be deemed invalid.  If you think there is going to be a problem with 
achieving this PLEASE contact Jocelyn Walters and myself ASAP so that we can try and 
sort something out. Procedures Manual 
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5.0 Screening and Recruitment Schedule 
5.1 Screening 
 
Identify all postmenopausal women newly diagnosed with breast cancer.   
 
How you do this is entirely up to you.  Obviously the least time consuming method would be the 
most appropriate.  I believe each trust has a different system for recording new diagnoses.  I would 
suggest you speak with the data manager because numbers of new diagnoses are uploaded to the 
Department of Health on a regular basis so the data manager must get this information from 
somewhere. 
 
  Allocate a study number (1- 200 at Portsmouth and 201- 400 at SUHT) 
  Complete demographic information for data collection sheet 
  Record study number, name and hospital number on a password protected computer file.  
(This will be the only patient identifiable information gathered and is the linking file between 
study numbers and names.  You will be the only one to access this file) 
5.2  Post invitation packs 
 
  ALL postmenopausal women receive an invitation 
  The invitation should be sent out ONE WEEK AFTER DISCHARGE from primary surgery 
  The packs are made up.  The only thing missing is the invitation letter which MUST 
  be printed on BREAST UNIT LETTERHEAD and be SIGNED by THE 
CONSULTANT (MR ROYLE for SUHT and MR WISE for Portsmouth) 
  DO NOT USE HANDWRITING on the envelope.  Please insert the name and address in 
the space provided in the word document which should automatically line up with the 
window on the envelope. 
  The packs are pre numbered.  PLEASE ensure you match up the persons study number 
with the correct envelope 
5.3  Follow-up phone call 
 
  Phone patient a few days after sending the invitation  
  Record phone call in phone log 
  Ask patient if they are interested in joining the study.  If there are any queries that you can’t 
deal with please direct them to me.  My contact details are on the patient information sheet  
  RECORD OUTCOME ON THE DATA COLLECTION FORM Procedures Manual 
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  If they agree to participate in either the one off questionnaires (stage one) or decide to join 
the classes (Stage two) please arrange to meet them at their next appointment which 
should be in a few days (Results clinic)  
  If they decline any participation PLEASE ask them if they would mind letting us know why 
and this information is important when conducting research.  RECORD the reason on the 
DATA COLLECTION FORM 
  FOR ALL PATIENTS please encourage them to complete the optional form in the pack 
asking them to write down their thoughts/feelings about the trial.  There is a pre stamped 
envelope for them to return the form 
5.4 Meeting to consent and collect baseline data 
 
Information to collect at meeting 
 
  Consent form 
  Height and weight 
  Questionnaires 
o  MHLC 
o  FFQ (HEA3) 
o  ROSENBERG SELF ESTEEM  
o  FACT-ES only for those joining the classes 
  Once you have all the data phone the randomisation unit for group allocation 
  Please give all patients randomised a study number card for their wallets.   
  If allocated to the group healthy eating classes, please give patient class schedule 
 
5.5 Six month follow-up 
For those who were allocated to the classes, one month before their six month follow-up is due, 
check patient’s next appointment.  If this coincides approximately to six months, arrange to meet 
them at this appointment to collect follow up data.  If not, please schedule an appointment to collect 
data. 
 
The following data must be collected at this time 
  Treatment order (from medical record) e.g. surgery + chemo + rxt 
  Height and weight 
  Questionnaires 
o  MHLC 
o  FFQ (HEA3) – assessing USUAL diet (before their diagnosis!) 
o  ROSENBERG SELF ESTEEM  Procedures Manual 
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o  FACT-ES  
 
 
THIS DATA MUST BE COLLECTED FOR ALL PATIENTS ALLOCATED TO THE CLASSES 
EVEN IF THEY DIDN’T ATTEND. 
6.0 Record keeping 
 
6.1 Patient – study number linking file 
Please keep a password protected file linking patient identifiable data (name, hospital number) with 
the allocated study number.  This file will be the ONLY record as I will only receive numbered 
information.  It is really important this is kept up to date. 
 
6.2 Study file  
 
This file will be handed over to me at the end of the study so it MUST NOT have patient identifiable 
data on it.  The excel file has been set up and sent to you electronically.    The fields are as follows: 
 
Study Number 
Date letter dispatched 
Date of phone call 
No to any involvement 
Yes to stage one only 
Yes to stage two 
Date of consent and baseline data collection 
Treatment order 
Date for six – month follow up  
 
 
Please keep this record up to date 